<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugRecordsOutput><serviceExecutionTime>635</serviceExecutionTime><Drug id="9000"><DrugName>onabotulinumtoxinA</DrugName><DrugNamesKey><Name id="43070423">Botox</Name></DrugNamesKey><DrugSynonyms><Name><Value>botulinum toxin type A</Value></Name><Name><Value>onabotulinumtoxinA</Value></Name><Name><Value>Botox</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>onaclostox</Value></Name><Name><Value>Botox-A</Value></Name><Name><Value>Botox Injection 100</Value></Name><Name><Value>BTX-A</Value></Name><Name><Value>GSK-1358820</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>Botox X</Value></Name><Name><Value>AGN-151607</Value><Types><Type>Research Code</Type></Types></Name></DrugSynonyms><CompanyOriginator id="23191">Oculinum</CompanyOriginator><CompaniesPrimary><Company id="28355">GlaxoSmithKline plc</Company><Company id="14042">Allergan Inc</Company><Company id="1088700">Allergan plc</Company></CompaniesPrimary><CompaniesSecondary><Company id="15587">Daewoong Pharmaceutical Co Ltd</Company><Company id="23191">Oculinum</Company></CompaniesSecondary><CrossReferences><SourceEntity id="9000" type="Drug"><TargetEntity id="168612" type="siDrug">OnabotulinumtoxinA</TargetEntity></SourceEntity><SourceEntity id="1088700" type="Company"><TargetEntity id="5040050523" type="organizationId">Allergan plc</TargetEntity></SourceEntity><SourceEntity id="14042" type="Company"><TargetEntity id="5000014741" type="organizationId">Allergan Inc</TargetEntity></SourceEntity><SourceEntity id="15587" type="Company"><TargetEntity id="4295882473" type="organizationId">Daewoong Pharma</TargetEntity></SourceEntity><SourceEntity id="23191" type="Company"><TargetEntity id="5035523786" type="organizationId">Oculinum</TargetEntity></SourceEntity><SourceEntity id="28355" type="Company"><TargetEntity id="4295895781" type="organizationId">GlaxoSmithKline PLC</TargetEntity></SourceEntity><SourceEntity id="1107" type="ciIndication"><TargetEntity id="10039085" type="MEDDRA"></TargetEntity><TargetEntity id="-600684678" type="omicsDisease"></TargetEntity><TargetEntity id="298" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="1241" type="ciIndication"><TargetEntity id="10051482" type="MEDDRA"></TargetEntity><TargetEntity id="D011470" type="MeSH"></TargetEntity><TargetEntity id="-1410482198" type="omicsDisease"></TargetEntity><TargetEntity id="362" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="1274" type="ciIndication"><TargetEntity id="F52.4" type="ICD10"></TargetEntity><TargetEntity id="302.75" type="ICD9"></TargetEntity><TargetEntity id="10036596" type="MEDDRA"></TargetEntity><TargetEntity id="-2110563963" type="omicsDisease"></TargetEntity><TargetEntity id="366" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="1295" type="ciIndication"><TargetEntity id="10029223" type="MEDDRA"></TargetEntity><TargetEntity id="D009437" type="MeSH"></TargetEntity><TargetEntity id="-533466818" type="omicsDisease"></TargetEntity><TargetEntity id="14" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="148" type="ciIndication"><TargetEntity id="R51" type="ICD10"></TargetEntity><TargetEntity id="784.0" type="ICD9"></TargetEntity><TargetEntity id="10019211" type="MEDDRA"></TargetEntity><TargetEntity id="D006261" type="MeSH"></TargetEntity><TargetEntity id="-843303252" type="omicsDisease"></TargetEntity><TargetEntity id="25" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="1542" type="ciIndication"><TargetEntity id="10003658" type="MEDDRA"></TargetEntity><TargetEntity id="D001281" type="MeSH"></TargetEntity><TargetEntity id="-1073626038" type="omicsDisease"></TargetEntity><TargetEntity id="194" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="1790" type="ciIndication"><TargetEntity id="N48.6" type="ICD10"></TargetEntity><TargetEntity id="10034765" type="MEDDRA"></TargetEntity><TargetEntity id="D010411" type="MeSH"></TargetEntity><TargetEntity id="-1005988670" type="omicsDisease"></TargetEntity><TargetEntity id="1779" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="20" type="ciIndication"><TargetEntity id="10033371" type="MEDDRA"></TargetEntity><TargetEntity id="D010146" type="MeSH"></TargetEntity><TargetEntity id="-1585850437" type="omicsDisease"></TargetEntity><TargetEntity id="1" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="210" type="ciIndication"><TargetEntity id="G43" type="ICD10"></TargetEntity><TargetEntity id="10027599" type="MEDDRA"></TargetEntity><TargetEntity id="D008881" type="MeSH"></TargetEntity><TargetEntity id="-672899670" type="omicsDisease"></TargetEntity><TargetEntity id="27" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="217" type="ciIndication"><TargetEntity id="10033799" type="MEDDRA"></TargetEntity><TargetEntity id="D010243" type="MeSH"></TargetEntity><TargetEntity id="-874006602" type="omicsDisease"></TargetEntity><TargetEntity id="1875" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="2225" type="ciIndication"><TargetEntity id="R61" type="ICD10"></TargetEntity><TargetEntity id="10020642" type="MEDDRA"></TargetEntity><TargetEntity id="D006945" type="MeSH"></TargetEntity><TargetEntity id="-982941024" type="omicsDisease"></TargetEntity><TargetEntity id="1230" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="2231" type="ciIndication"><TargetEntity id="10061402" type="MEDDRA"></TargetEntity><TargetEntity id="D014623" type="MeSH"></TargetEntity></SourceEntity><SourceEntity id="2239" type="ciIndication"><TargetEntity id="G24.5" type="ICD10"></TargetEntity><TargetEntity id="333.81" type="ICD9"></TargetEntity><TargetEntity id="10005159" type="MEDDRA"></TargetEntity><TargetEntity id="D001764" type="MeSH"></TargetEntity><TargetEntity id="-835604233" type="omicsDisease"></TargetEntity><TargetEntity id="759" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="2376" type="ciIndication"><TargetEntity id="N32.81" type="ICD10"></TargetEntity><TargetEntity id="D053201" type="MeSH"></TargetEntity><TargetEntity id="-745956714" type="omicsDisease"></TargetEntity><TargetEntity id="358" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="245" type="ciIndication"><TargetEntity id="10031161" type="MEDDRA"></TargetEntity><TargetEntity id="D010003" type="MeSH"></TargetEntity><TargetEntity id="-478836143" type="omicsDisease"></TargetEntity><TargetEntity id="747" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="2481" type="ciIndication"><TargetEntity id="10042159" type="MEDDRA"></TargetEntity><TargetEntity id="D013285" type="MeSH"></TargetEntity><TargetEntity id="-1449503512" type="omicsDisease"></TargetEntity><TargetEntity id="3125" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="2521" type="ciIndication"><TargetEntity id="10020880" type="MEDDRA"></TargetEntity><TargetEntity id="D006984" type="MeSH"></TargetEntity><TargetEntity id="-97171024" type="omicsDisease"></TargetEntity><TargetEntity id="3418" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="2696" type="ciIndication"><TargetEntity id="R49.0" type="ICD10"></TargetEntity><TargetEntity id="10013952" type="MEDDRA"></TargetEntity><TargetEntity id="D055154" type="MeSH"></TargetEntity><TargetEntity id="-233143630" type="omicsDisease"></TargetEntity><TargetEntity id="3316" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="2934" type="ciIndication"><TargetEntity id="10043220" type="MEDDRA"></TargetEntity><TargetEntity id="D013706" type="MeSH"></TargetEntity><TargetEntity id="210581" type="ORPHANET"></TargetEntity><TargetEntity id="-1443697481" type="omicsDisease"></TargetEntity><TargetEntity id="2296" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="2967" type="ciIndication"><TargetEntity id="10004161" type="MEDDRA"></TargetEntity><TargetEntity id="D049970" type="MeSH"></TargetEntity><TargetEntity id="-1337914071" type="omicsDisease"></TargetEntity><TargetEntity id="1688" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="358" type="ciIndication"><TargetEntity id="M62.83" type="ICD10"></TargetEntity><TargetEntity id="10028334" type="MEDDRA"></TargetEntity><TargetEntity id="D013035" type="MeSH"></TargetEntity><TargetEntity id="-323136046" type="omicsDisease"></TargetEntity><TargetEntity id="154" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="478" type="ciIndication"><TargetEntity id="I73.0" type="ICD10"></TargetEntity><TargetEntity id="10037912" type="MEDDRA"></TargetEntity><TargetEntity id="D011928" type="MeSH"></TargetEntity><TargetEntity id="-140562337" type="omicsDisease"></TargetEntity><TargetEntity id="263" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="4898" type="ciIndication"><TargetEntity id="F33" type="ICD10"></TargetEntity><TargetEntity id="10012378" type="MEDDRA"></TargetEntity><TargetEntity id="-1357758656" type="omicsDisease"></TargetEntity><TargetEntity id="54" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="589" type="ciIndication"><TargetEntity id="G24" type="ICD10"></TargetEntity><TargetEntity id="10013983" type="MEDDRA"></TargetEntity><TargetEntity id="D004421" type="MeSH"></TargetEntity><TargetEntity id="-277209898" type="omicsDisease"></TargetEntity><TargetEntity id="125" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="913" type="ciIndication"><TargetEntity id="10028335" type="MEDDRA"></TargetEntity><TargetEntity id="D009122" type="MeSH"></TargetEntity><TargetEntity id="-702772965" type="omicsDisease"></TargetEntity><TargetEntity id="175" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="PTGT-09910" type="ciTarget"><TargetEntity id="807250" type="siTarget">SRC kinase signaling inhibitor 1</TargetEntity><TargetEntity id="-98374089" type="omicsTarget"></TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="L">Launched</PhaseHighest><PhaseHighestDetailed><FirstLaunched>Blepharospasm - US - Dec-1989</FirstLaunched><FirstLaunched>Strabismus - US - Dec-1989</FirstLaunched></PhaseHighestDetailed><RegulatoryDesignations><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><RegulatoryDesignation id="11">Priority Review</RegulatoryDesignation></RegulatoryDesignations><IndicationsPrimary><Indication id="1107">Allergic rhinitis</Indication><Indication id="1542">Atrial fibrillation</Indication><Indication id="1790">Penile induration</Indication><Indication id="20">Pain</Indication><Indication id="210">Migraine</Indication><Indication id="2225">Hyperhidrosis</Indication><Indication id="2239">Blepharospasm</Indication><Indication id="2376">Overactive bladder</Indication><Indication id="2481">Strabismus</Indication><Indication id="2521">Hypertrophy</Indication><Indication id="2696">Dysphonia</Indication><Indication id="2934">Temporomandibular joint syndrome</Indication><Indication id="358">Muscle spasm</Indication><Indication id="4898">Major depressive disorder</Indication><Indication id="564">Cervical dystonia</Indication><Indication id="913">Muscle hypertonia</Indication></IndicationsPrimary><IndicationsSecondary><Indication id="1241">Prostate hyperplasia</Indication><Indication id="1274">Premature ejaculation</Indication><Indication id="1295">Neuropathic pain</Indication><Indication id="148">Headache</Indication><Indication id="217">Paralysis</Indication><Indication id="2231">Vagina disease</Indication><Indication id="245">Osteoarthritis</Indication><Indication id="2967">Thyroid associated ophthalmopathy</Indication><Indication id="376">Gastric motility disorder</Indication><Indication id="478">Raynauds disease</Indication><Indication id="589">Dystonia</Indication><Indication id="689">Esophageal function disorder</Indication></IndicationsSecondary><ActionsPrimary><Action id="55100">p130Cas associated protein inhibitor</Action><Action id="162">Acetylcholine receptor antagonist</Action></ActionsPrimary><ActionsSecondary><Action id="2941">Antidepressant</Action><Action id="2946">Analgesic</Action><Action id="449">Antiarrhythmic agent</Action><Action id="450">Neuromuscular blocking agent</Action></ActionsSecondary><Technologies><Technology id="651">Intramuscular formulation</Technology><Technology id="749">Drying</Technology><Technology id="761">Biological therapeutic</Technology><Technology id="80">Peptide</Technology><Technology id="851">Intradermal formulation</Technology><Technology id="93">Toxin</Technology><Technology id="898">Formulation powder</Technology></Technologies><EphmraCodes><Ephmra><Code>G4C</Code><Name>BPH (benign prostatic hypertrophy) products </Name></Ephmra><Ephmra><Code>M3A</Code><Name>MUSCLE RELAXANTS, PERIPHERALLY ACTING</Name></Ephmra><Ephmra><Code>C1B</Code><Name>ANTI-ARRHYTHMICS</Name></Ephmra><Ephmra><Code>N2C</Code><Name>ANTI-MIGRAINE PREPARATIONS</Name></Ephmra><Ephmra><Code>N6A</Code><Name>ANTI-DEPRESSANTS AND MOOD STABILISERS</Name></Ephmra><Ephmra><Code>N2</Code><Name>ANALGESICS</Name></Ephmra></EphmraCodes><LastModificationDate>2019-06-26T05:41:01.000Z</LastModificationDate><ChangeDateLast>2019-06-26T00:00:00.000Z</ChangeDateLast><AddedDate>1996-02-16T00:00:00.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;Originally developed by &lt;ulink linkID="23191" linkType="Company"&gt;Oculinum&lt;/ulink&gt;  and launched by &lt;ulink linkID="1088700" linkType="Company"&gt;Allergan Plc&lt;/ulink&gt; (following Actavis' acquisition of &lt;ulink linkID="14042" linkType="Company"&gt;Allergan Inc&lt;/ulink&gt; and subsequent name change), onabotulinumtoxinA (botulinum toxin type A; Botox; Botox-A; AGN-151607) is an injectable, purified neurotoxin complex produced by Clostridium botulinum [&lt;ulink linkID="1201421" linkType="Reference"&gt;1201421&lt;/ulink&gt;], [&lt;ulink linkID="1642310" linkType="Reference"&gt;1642310&lt;/ulink&gt;], [&lt;ulink linkID="1670060" linkType="Reference"&gt;1670060&lt;/ulink&gt;]. The product is indicated in the US and EU for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency and frequency in adults who have had an inadequate response to or are intolerant of an anticholinergic medication;  treatment of urinary incontinence due to detrusor overactivity associated with a neurologic condition, e.g. spinal cord injury (SCI) or multiple sclerosis (MS), in adults who have had an inadequate response to or are intolerant of an anticholinergic medication; prophylaxis of headaches in adults with chronic migraine; and, the treatment of severe axillary hyperhidrosis that is inadequately managed by topical agents in adults [&lt;ulink linkID="1140098" linkType="Reference"&gt;1140098&lt;/ulink&gt;], [&lt;ulink linkID="2051504" linkType="Reference"&gt;2051504&lt;/ulink&gt;]. In the US, the drug is additionally indicated for the treatment of upper and lower limb spasticity in adults, including spasmodic dysphonia; treatment of cervical dystonia in adult patients, to reduce the severity of abnormal head position and neck pain; treatment of blepharospasm associated with dystonia in patients &amp;gt;/= 12 years of age; for the treatment of strabismus in patients &amp;gt;/= 12 years of age; and, for the treatment of pediatric patients (2 to 17 years of age) with upper limb spasticity  [&lt;ulink linkID="1140098" linkType="Reference"&gt;1140098&lt;/ulink&gt;].  In the EU, the product is additionally indicated for treatment of focal spasticity, including: dynamic equinus foot deformity due to spasticity in ambulant pediatric cerebral palsy patients, two years of age or older; wrist and hand disability due to upper limb spasticity associated with stroke in adults; ankle disability due to lower limb spasticity associated with stroke in adults; and, symptomatic relief of blepharospasm, hemifacial spasm and idiopathic cervical dystonia (spasmodic torticollis)  [&lt;ulink linkID="2051504" linkType="Reference"&gt;2051504&lt;/ulink&gt;]. In Japan, the product is indicated for blepharospasm; unilateral facial spasm; spasmodic torticollis; upper limb spasm; lower limb spasm; cusp accompanied by lower limb spasticity in children aged two years and older; primary axillary hyperhidrosis; strabismus; and, spasticity vocal disorders [&lt;ulink linkID="1977973" linkType="Reference"&gt;1977973&lt;/ulink&gt;].   &lt;/para&gt;&lt;para&gt;In 1989, the FDA approved onabotulinumtoxinA for strabismus and blepharospasm; the drug was presumed to have been launched shortly thereafter  [&lt;ulink linkID="989200" linkType="Reference"&gt;989200&lt;/ulink&gt;]. In 1992, European approval for blepharospams was granted, and the drug was presumed to have been launched shortly after [&lt;ulink linkID="1085385" linkType="Reference"&gt;1085385&lt;/ulink&gt;]; by May 2014, the drug had been approved for strabismus in France [&lt;ulink linkID="1649035" linkType="Reference"&gt;1649035&lt;/ulink&gt;]. In 1997, Japanese approval for blepharospasm was granted; the drug was presumed to have been launched  that year [&lt;ulink linkID="372009" linkType="Reference"&gt;372009&lt;/ulink&gt;]; in June 2015, Japanese approval was granted for  strabismus [&lt;ulink linkID="1677140" linkType="Reference"&gt;1677140&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In July 1993, European approval for cervical dystonia began [&lt;ulink linkID="1445020" linkType="Reference"&gt;1445020&lt;/ulink&gt;]. In December 2000, onabotulinumtoxinA was approved for cervical dystonia in the US  [&lt;ulink linkID="562127" linkType="Reference"&gt;562127&lt;/ulink&gt;].  In 2001, onabotulinumtoxinA was launched for cervical dystonia in Japan [&lt;ulink linkID="457501" linkType="Reference"&gt;457501&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By June 2000, onabotulinumtoxinA was licensed for hemifacial spasm in Japan [&lt;ulink linkID="372009" linkType="Reference"&gt;372009&lt;/ulink&gt;]; in February 2009, the drug was launched in Japan for talipes equinis-associated leg spasms in cerebral palsy patients over the age of two years [&lt;ulink linkID="994690" linkType="Reference"&gt;994690&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By September 2001, onabotulinumtoxinA had been approved in the UK for hyperhidrosis [&lt;ulink linkID="422204" linkType="Reference"&gt;422204&lt;/ulink&gt;]; in 2Q03, the drug was appproved in Europe for hyperhidrosis [&lt;ulink linkID="498678" linkType="Reference"&gt;498678&lt;/ulink&gt;]. In July 2004, US approval for hyperhidrosis was granted  [&lt;ulink linkID="549794" linkType="Reference"&gt;549794&lt;/ulink&gt;]. In January 2013, licensee &lt;ulink linkID="28355" linkType="Company"&gt;GlaxoSmithKline&lt;/ulink&gt; launched the drug in Japan for that indication [&lt;ulink linkID="1357361" linkType="Reference"&gt;1357361&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;By April 2002, European approval had been granted for spasticity [&lt;ulink linkID="457501" linkType="Reference"&gt;457501&lt;/ulink&gt;]. In March 2010, onabotulinumtoxinA was approved in the US for the treatment of spasticity in the flexor muscles of the elbow, wrist and fingers [&lt;ulink linkID="1080788" linkType="Reference"&gt;1080788&lt;/ulink&gt;], [&lt;ulink linkID="1081190" linkType="Reference"&gt;1081190&lt;/ulink&gt;]; in April 2015, the FDA approved a label expansion for upper limb spasticity to include the addition of two thumb muscles: flexor pollicis longus and adductor pollicis [&lt;ulink linkID="1652361" linkType="Reference"&gt;1652361&lt;/ulink&gt;]; in January 2016, the FDA approved onabotulinumtoxinA for lower limb spasticity in adults [&lt;ulink linkID="1729043" linkType="Reference"&gt;1729043&lt;/ulink&gt;].  In June 2018, the US FDA approved a sBLA for the treatment of pediatric patients (2 to 17 years of age) with upper limb spasticity   [&lt;ulink linkID="2166888" linkType="Reference"&gt;2166888&lt;/ulink&gt;]; in March 2019, the US FDA accepted for review an sBLA  to expand the indication for the treatment of pediatric patients 2 years of age and older with lower limb spasticity, with a target PDUFA date in 4Q19  [&lt;ulink linkID="2126949" linkType="Reference"&gt;2126949&lt;/ulink&gt;]. In October 2010, Japanese approval was granted for upper and lower limb spasticity [&lt;ulink linkID="1146735" linkType="Reference"&gt;1146735&lt;/ulink&gt;]. In May 2018, the product was approved for the treatment of spasmodic dysphonia in Japan [&lt;ulink linkID="2037706" linkType="Reference"&gt;2037706&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In July 2010, European approvals began for for headache prophylaxis in adults with chronic migraine [&lt;ulink linkID="1115291" linkType="Reference"&gt;1115291&lt;/ulink&gt;], [&lt;ulink linkID="1146735" linkType="Reference"&gt;1146735&lt;/ulink&gt;]. In October 2010, the product was approved in the US for chronic migraine [&lt;ulink linkID="1140062" linkType="Reference"&gt;1140062&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In August 2011, the FDA approved the product for neurogenic OAB  in patients with neurologic conditions such as spinal cord injury and multiple sclerosis [&lt;ulink linkID="1217387" linkType="Reference"&gt;1217387&lt;/ulink&gt;]; in January 2013, the FDA approved onabotulinumtoxinA for the treatment of idiopathic OAB and symptoms of urge urinary incontinence, urgency and frequency [&lt;ulink linkID="1358320" linkType="Reference"&gt;1358320&lt;/ulink&gt;]. By February 2012, the drug had been approved in a number of European countries for OAB [&lt;ulink linkID="1267857" linkType="Reference"&gt;1267857&lt;/ulink&gt;], [&lt;ulink linkID="1366306" linkType="Reference"&gt;1366306&lt;/ulink&gt;]; by the end of 2013, onabotulinumtoxinA had been approved for idiopathic OAB in certain European countries [&lt;ulink linkID="1494584" linkType="Reference"&gt;1494584&lt;/ulink&gt;], [&lt;ulink linkID="1530302" linkType="Reference"&gt;1530302&lt;/ulink&gt;]. By August 2016, phase III trials in OAB had been inititated in Japan, at that time, completion was expected in November 2018 [&lt;ulink linkID="1765575" linkType="Reference"&gt;1765575&lt;/ulink&gt;], [&lt;ulink linkID="2058475" linkType="Reference"&gt;2058475&lt;/ulink&gt;]. In October 2016, a further phase III trial began in in Japanese patients with neurogenic detrusor overactivity with urinary incontinence [&lt;ulink linkID="1785344" linkType="Reference"&gt;1785344&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Development is ongoing in other indications.  In January 2014, a phase II study for bilateral masseter muscle hypertrophy was initiated; in Novermber 2017, the trial completed [&lt;ulink linkID="1509907" linkType="Reference"&gt;1509907&lt;/ulink&gt;]; in March 2019, clinical data were presented [&lt;ulink linkID="2126230" linkType="Reference"&gt;2126230&lt;/ulink&gt;]. In April 2014, a phase II study for major depressive disorder was initiated [&lt;ulink linkID="1550953" linkType="Reference"&gt;1550953&lt;/ulink&gt;]; in April 2017, data were reported, and a phase III program for major depressive disorder was planned [&lt;ulink linkID="1915978" linkType="Reference"&gt;1915978&lt;/ulink&gt;]. In June 2009, a phase II study for Peyronies disease was initiated; in November 2016, the study was recruiting participants [&lt;ulink linkID="1697385" linkType="Reference"&gt;1697385&lt;/ulink&gt;]. In March 2019, a phase II study was initiated for prevention of post operative atrial fibrillation (POAF) [&lt;ulink linkID="2106734" linkType="Reference"&gt;2106734&lt;/ulink&gt;]. By November 2015, an optimized formulation, Botox X, was in phase I clinical trials for spasticity [&lt;ulink linkID="1724426" linkType="Reference"&gt;1724426&lt;/ulink&gt;]. By August 2016, Botox was in development for an undisclosed urological indication [&lt;ulink linkID="1786116" linkType="Reference"&gt;1786116&lt;/ulink&gt;].  In August 2018, Allergan was investigating the drug for the potential treatment of allergic rhinitis [&lt;ulink linkID="2061434" linkType="Reference"&gt;2061434&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Development in other indications was also previously undertaken, including gastric motility disorder, esophageal function disorder, paralysis and  pain  [&lt;ulink linkID="175740" linkType="Reference"&gt;175740&lt;/ulink&gt;], [&lt;ulink linkID="365728" linkType="Reference"&gt;365728&lt;/ulink&gt;], [&lt;ulink linkID="369389" linkType="Reference"&gt;369389&lt;/ulink&gt;], [&lt;ulink linkID="370087" linkType="Reference"&gt;370087&lt;/ulink&gt;], [&lt;ulink linkID="562127" linkType="Reference"&gt;562127&lt;/ulink&gt;]; however, no development has been reported in any of these indications.  In February 2006, phase  II trials in benign prostatic hyperplasia  were also underway [&lt;ulink linkID="649262" linkType="Reference"&gt;649262&lt;/ulink&gt;]; development in BPH was ongoing in March 2011 [&lt;ulink linkID="1172325" linkType="Reference"&gt;1172325&lt;/ulink&gt;]; however development had been discontinued by March 2013 [&lt;ulink linkID="1391329" linkType="Reference"&gt;1391329&lt;/ulink&gt;]. In August 2010, a phase I trial in primary vaginismus was initiated; in December 2012, the trial was completed, and no further development has been reported [&lt;ulink linkID="1201025" linkType="Reference"&gt;1201025&lt;/ulink&gt;].   In January 2011, a study in patients with thyroid-associated ophthalmopathy was planned; however, in February 2012, the trial was withdrawn prior to enrollment due to lack of funding [&lt;ulink linkID="1254956" linkType="Reference"&gt;1254956&lt;/ulink&gt;].  In January 2012, a phase I/II trial in patients with osteoarthritis pain began [&lt;ulink linkID="1552552" linkType="Reference"&gt;1552552&lt;/ulink&gt;]; in September 2014, a further phase II trial had been initiated in that setting [&lt;ulink linkID="1632449" linkType="Reference"&gt;1632449&lt;/ulink&gt;]; in February 2015, development of osteoarthritis pain was ongoing [&lt;ulink linkID="1641366" linkType="Reference"&gt;1641366&lt;/ulink&gt;]; no development has since been reported.  In August 2013, a phase II trial for premature ejaculation was initiated [&lt;ulink linkID="1467285" linkType="Reference"&gt;1467285&lt;/ulink&gt;]; in February 2015, development of that indication was ongoing [&lt;ulink linkID="1641366" linkType="Reference"&gt;1641366&lt;/ulink&gt;]; however, in March 2017, this indication was no longer listed on the Allergan pipeline and was presumed to have been discontinued [&lt;ulink linkID="1912826" linkType="Reference"&gt;1912826&lt;/ulink&gt;]. In December 2013, a phase II trial for allodynic-type neuropathic pain was initiated;  in April 2015, the trial was ongoing. However, by October 2015, the trial had been terminated following negative data from  patients with spinal cord injury [&lt;ulink linkID="1468290" linkType="Reference"&gt;1468290&lt;/ulink&gt;]. In January 2015, a phase III trial for  Raynaud's syndrome was initiated; the trial completed in December 2016 [&lt;ulink linkID="1629968" linkType="Reference"&gt;1629968&lt;/ulink&gt;]; no development has since been reported.&lt;/para&gt;&lt;para&gt;OnabotulinumtoxinA is also marketed widely for cosmetic use to remove glabellar lines, under the trade names Botox Cosmetic, Vistabel and Botox Vista; the cosmetic indications are not covered in this record.&lt;/para&gt;&lt;/Summary&gt;</value></Summary><PatentsAndGenerics><displayLabel>Patents and Generics</displayLabel><value>&lt;PatentsAndGenerics&gt;&lt;para&gt;In February 2014, Allergan noted that onabotulinumtoxinA was covered by 100 issued US and European use and process patents covering various indications, including the treatment of chronic migraine, overactive bladder and hyperhydrosis [&lt;ulink linkID="1530302" linkType="Reference"&gt;1530302&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In February 2018, &lt;ulink linkID="18439" linkType="Company"&gt;Mylan&lt;/ulink&gt; and &lt;ulink linkID="1014924" linkType="Company"&gt;Revance Therapeutics&lt;/ulink&gt; signed a global agreement to develop and commercialize a biosimilar to onabotulinumtoxinA [&lt;ulink linkID="2009132" linkType="Reference"&gt;2009132&lt;/ulink&gt;].&lt;/para&gt;&lt;/PatentsAndGenerics&gt;</value></PatentsAndGenerics><Regulatory><displayLabel>Regulatory</displayLabel><value>&lt;Regulatory&gt;&lt;para&gt;&lt;subtitle&gt;The US&lt;/subtitle&gt;&lt;subtitle&gt;Idiopathic overactive bladder&lt;/subtitle&gt;In March 2012, an sBLA was submitted in the US for the treatment of idiopathic OAB [&lt;ulink linkID="1275598" linkType="Reference"&gt;1275598&lt;/ulink&gt;]. In January 2013, the FDA approved onabotulinumtoxinA for the treatment of idiopathic OAB and symptoms of urge urinary incontinence, urgency and frequency,  in adult patients who have not responded to or  are intolerant of an anticholinergic medication [&lt;ulink linkID="1358320" linkType="Reference"&gt;1358320&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Neurogenic overactive bladder&lt;/subtitle&gt;By September 2010, an sBLA for neurogenic OAB had been filed  [&lt;ulink linkID="1143621" linkType="Reference"&gt;1143621&lt;/ulink&gt;]. In August 2011, the FDA approved the drug for neurogenic OAB  [&lt;ulink linkID="1217387" linkType="Reference"&gt;1217387&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Migraine&lt;/subtitle&gt;By September 2009, Allergan had filed an sBLA for migraine [&lt;ulink linkID="1052917" linkType="Reference"&gt;1052917&lt;/ulink&gt;]. By July 2010, the FDA had requested additional data before the BLA could be approved and the PDUFA date had been extended 3 months [&lt;ulink linkID="1120818" linkType="Reference"&gt;1120818&lt;/ulink&gt;]. In October 2010, the FDA approved the drug for the prophylactic treatment of headaches in adults with chronic migraine [&lt;ulink linkID="1140062" linkType="Reference"&gt;1140062&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Spasticity&lt;/subtitle&gt;In October 2008, Allergan filed an sBLA with the FDA for post-stroke upper limb spasticity. The application was granted Priority Review [&lt;ulink linkID="996519" linkType="Reference"&gt;996519&lt;/ulink&gt;]. In May 2009, Allergan was issued a Complete Response letter from the FDA, requesting updates to product safety, labelling and verification of underlying patient source documentation  [&lt;ulink linkID="1012823" linkType="Reference"&gt;1012823&lt;/ulink&gt;]. The information had been submitted by September 2009 [&lt;ulink linkID="1052917" linkType="Reference"&gt;1052917&lt;/ulink&gt;]. In March 2010, the FDA granted approval for the treatment of spasticity in the flexor muscles of the elbow, wrist and fingers in adults [&lt;ulink linkID="1080788" linkType="Reference"&gt;1080788&lt;/ulink&gt;], [&lt;ulink linkID="1081190" linkType="Reference"&gt;1081190&lt;/ulink&gt;]. In April 2015, the FDA approved a label expansion for upper limb spasticity to include the addition of two thumb muscles: flexor pollicis longus and adductor pollicis; label expansion also included increasing the maximum dose from 360 to 400 units for the treatment of upper limb spasticity [&lt;ulink linkID="1652361" linkType="Reference"&gt;1652361&lt;/ulink&gt;]. In August 2015, the FDA accepted for review the resubmission of an sBLA for the treatment of adults with lower limb (involving ankle and toe muscles) spasticity in adults. At that time, a 6-month review period was assigned and the PDUFA date was expected in 1Q16 [&lt;ulink linkID="1688074" linkType="Reference"&gt;1688074&lt;/ulink&gt;]. In January 2016, the FDA approved onabotulinumtoxinA for lower limb spasticity in adults [&lt;ulink linkID="1729043" linkType="Reference"&gt;1729043&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2019, the US FDA accepted a sBLA  to expand the indication for the treatment of pediatric patients 2 years of age and older with upper and lower limb spasticity. The upper limb spasticity indication was accepted with Priority Review, and the target PDUFA date was set for 2Q19. The lower limb spasticity indication was accepted under standard review timelines, with a target PDUFA date set for 4Q19  [&lt;ulink linkID="2126949" linkType="Reference"&gt;2126949&lt;/ulink&gt;]. In June 2018, the US FDA approved the sBLA for the treatment of pediatric patients (2 to 17 years of age) with upper limb spasticity; at that time, a decision regarding  lower limb spasiticy approval was still expected in 4Q19  [&lt;ulink linkID="2166888" linkType="Reference"&gt;2166888&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Hyperhidrosis&lt;/subtitle&gt;By July 2003, Allergan had filed a BLA with the FDA for the use of onabotulinumtoxinA for hyperhidrosis in the US  [&lt;ulink linkID="498678" linkType="Reference"&gt;498678&lt;/ulink&gt;], [&lt;ulink linkID="510085" linkType="Reference"&gt;510085&lt;/ulink&gt;]; in July 2004, FDA approval was received for the treatment of severe primary axillary hyperhidrosis that is inadequately managed with topical agents [&lt;ulink linkID="549794" linkType="Reference"&gt;549794&lt;/ulink&gt;], [&lt;ulink linkID="551268" linkType="Reference"&gt;551268&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Cervical dystonia&lt;/subtitle&gt;In 1999, a supplemental application for the treatment of cervical dystonia was filed in the US [&lt;ulink linkID="365728" linkType="Reference"&gt;365728&lt;/ulink&gt;]. In December 2000, onabotulinumtoxinA was approved by the FDA for that  indication  [&lt;ulink linkID="394727" linkType="Reference"&gt;394727&lt;/ulink&gt;], [&lt;ulink linkID="394728" linkType="Reference"&gt;394728&lt;/ulink&gt;]. It had received Orphan Drug status for this indication in 1986 [&lt;ulink linkID="366468" linkType="Reference"&gt;366468&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Blepharospasm&lt;/subtitle&gt;In 1989, the FDA approved onabotulinumtoxinA for blepharospasm; the drug was presumed to have been launched shortly thereafter  [&lt;ulink linkID="989200" linkType="Reference"&gt;989200&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Strabismus&lt;/subtitle&gt;In 1989, the FDA approved onabotulinumtoxinA for the treatment of strabismus associated with dystonia  [&lt;ulink linkID="989200" linkType="Reference"&gt;989200&lt;/ulink&gt;].  &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Europe&lt;/subtitle&gt;&lt;subtitle&gt;Strabismus&lt;/subtitle&gt;By May 2014, the drug had been approved for strabismus in France [&lt;ulink linkID="1649035" linkType="Reference"&gt;1649035&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Idiopathic overactive bladder&lt;/subtitle&gt;In March 2012, a filing was submitted in Europe for idiopathic OAB [&lt;ulink linkID="1275598" linkType="Reference"&gt;1275598&lt;/ulink&gt;]. In December 2012, onabotulinumtoxinA was granted a positive opinion from the Irish Medicines Board for idiopathic OAB with symptoms of urinary incontinence, urgency and frequency in adult patients [&lt;ulink linkID="1366082" linkType="Reference"&gt;1366082&lt;/ulink&gt;]. By the end of 2013, onabotulinumtoxinA had been approved for idiopathic OAB in  certain European countries   [&lt;ulink linkID="1494584" linkType="Reference"&gt;1494584&lt;/ulink&gt;], [&lt;ulink linkID="1530302" linkType="Reference"&gt;1530302&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By December 2013, the drug had been approved for idiopathic OAB in Switzerland [&lt;ulink linkID="1530302" linkType="Reference"&gt;1530302&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Neurogenic overactive bladder&lt;/subtitle&gt;In June 2011, onabotulinumtoxinA was granted a positive opinion from the French license committee, for use in urinary incontinence associated with neurogenic detrusor overactivity, not controlled with an anticholinergic treatment, in subjects with spinal cord injury or multiple sclerosis who are able to use a urinary catheter [&lt;ulink linkID="1212203" linkType="Reference"&gt;1212203&lt;/ulink&gt;]. In August 2011, onabotulinumtoxinA was granted a positive opinion from the Irish Medicines Board, the reference member state in the MRP, for use in the management of urinary incontinence associated with neurogenic detrusor overactivity in patients with spinal cord injury or multiple sclerosis who are willing and able to use a catheter to empty their bladder. By that time, filings had also been made under the MRP in Austria, Belgium, Denmark, Finland, Germany, Greece, Iceland, Italy, Luxembourg, Norway, Portugal, Spain and Sweden [&lt;ulink linkID="1213289" linkType="Reference"&gt;1213289&lt;/ulink&gt;]. By February 2012, the drug had been approved in a number of European countries for OAB [&lt;ulink linkID="1267857" linkType="Reference"&gt;1267857&lt;/ulink&gt;],  [&lt;ulink linkID="1366306" linkType="Reference"&gt;1366306&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Migraine&lt;/subtitle&gt;In 4Q09, the drug was filed for approval for migraine in a number of European countries  [&lt;ulink linkID="1073300" linkType="Reference"&gt;1073300&lt;/ulink&gt;]. In July 2010, onabotulinumtoxinA was approved for headache prophylaxis in adults who have chronic migraine  in the UK, with other European approvals following [&lt;ulink linkID="1115291" linkType="Reference"&gt;1115291&lt;/ulink&gt;], [&lt;ulink linkID="1146735" linkType="Reference"&gt;1146735&lt;/ulink&gt;]. By May 2011, the company had filed for approval for chronic migraine with the EMA [&lt;ulink linkID="1197962" linkType="Reference"&gt;1197962&lt;/ulink&gt;]; by March 2014, the drug had been approved for chronic migraine throughout the European Economic Area [&lt;ulink linkID="1530302" linkType="Reference"&gt;1530302&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Spasticity&lt;/subtitle&gt;By October 2001, onabotulinumtoxinA had been granted a positive opinion by the EU for focal spasticity of the wrist and hand in adult post-stroke patients [&lt;ulink linkID="425413" linkType="Reference"&gt;425413&lt;/ulink&gt;]. By April 2002, approval had been granted in a number of European countries for spasticity [&lt;ulink linkID="457501" linkType="Reference"&gt;457501&lt;/ulink&gt;]; by February 2003, the  drug had been approved for that indication  accross the EU  [&lt;ulink linkID="870659" linkType="Reference"&gt;870659&lt;/ulink&gt;].  . &lt;/para&gt;&lt;para&gt;By May 2014, OnabotulinumtoxinA had received positive opinion from the Irish Medicines Board, the reference member state in the MRP, for the treatment of focal spasticity of the ankle in adult post stroke patients [&lt;ulink linkID="1554162" linkType="Reference"&gt;1554162&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In Feburary 2014, the drug was aproved in the UK for upper and lower limb spasticity in adults who have had a stroke [&lt;ulink linkID="1532620" linkType="Reference"&gt;1532620&lt;/ulink&gt;]. By February 2015, the product had been approved for the treatment of lower limb spasticity in all major Western European markets [&lt;ulink linkID="1641366" linkType="Reference"&gt;1641366&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Hyperhidrosis&lt;/subtitle&gt;By July 2000, a phase III study to support a 4Q00 MAA filing in the EU evaluating onabotulinumtoxinA for the treatment of hyperhidrosis had been completed [&lt;ulink linkID="376356" linkType="Reference"&gt;376356&lt;/ulink&gt;], [&lt;ulink linkID="420751" linkType="Reference"&gt;420751&lt;/ulink&gt;].  By September 2001, onabotulinumtoxinA had been approved in the UK for the management of severe hyperhidrosis of the axillae that does not respond to topical treatment with antiperspirants or antihidrotics [&lt;ulink linkID="422204" linkType="Reference"&gt;422204&lt;/ulink&gt;]; in 2Q03, the drug was appproved in Europe for hyperhidrosis [&lt;ulink linkID="498678" linkType="Reference"&gt;498678&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Cervical dystonia&lt;/subtitle&gt;In July 1993, European approval for cervical dystonia began, in the Czech Republic [&lt;ulink linkID="1445020" linkType="Reference"&gt;1445020&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Blepharospasm&lt;/subtitle&gt;In 1992, European approval for blepharospams was granted, and the drug was presumed to have been launched shortly after [&lt;ulink linkID="1085385" linkType="Reference"&gt;1085385&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Japan&lt;/subtitle&gt;&lt;subtitle&gt;Spasmodic dysphonia&lt;/subtitle&gt;By June 2017, a filing had been submitted in Japan for spasmodic dysphonia [&lt;ulink linkID="1941435" linkType="Reference"&gt;1941435&lt;/ulink&gt;]. In April 2018, the Ministry of Health, Labor and Welfare's 1st Committee on New Drugs PAFSC recommended the approval of botulinum toxin type A for spasmodic dysphonia [&lt;ulink linkID="2031220" linkType="Reference"&gt;2031220&lt;/ulink&gt;]. In May 2018, the product was approved for the treatment of spasmodic dysphonia [&lt;ulink linkID="2037706" linkType="Reference"&gt;2037706&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Strabismus&lt;/subtitle&gt;In July 2014,  GSK filed an application for approval of  onabotulinumtoxinA  injection 50 and 100 units for strabismus [&lt;ulink linkID="1649035" linkType="Reference"&gt;1649035&lt;/ulink&gt;]. In May 2015, the Japanese MHLW's PAFSC was scheduled to meet in June 2015 to discuss the filing for strabismus [&lt;ulink linkID="1663003" linkType="Reference"&gt;1663003&lt;/ulink&gt;]. In June 2015, approval was granted in Japan for the treatment of strabismus [&lt;ulink linkID="1677140" linkType="Reference"&gt;1677140&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Hyperhidrosis&lt;/subtitle&gt;In December 2011, GSK filed for Japanese approval for axillary hyperhidrosis [&lt;ulink linkID="1253898" linkType="Reference"&gt;1253898&lt;/ulink&gt;]. In October 2012, the Pharmaceutical Affairs and Food Sanitation Council's First Committee on Drugs was to review the application on October 26, 2012 [&lt;ulink linkID="1332260" linkType="Reference"&gt;1332260&lt;/ulink&gt;]; later that month, the Committee recommended approval of the drug [&lt;ulink linkID="1338425" linkType="Reference"&gt;1338425&lt;/ulink&gt;]. In November 2012, approval was granted in Japan for severe axillary hyperhidrosis [&lt;ulink linkID="1342871" linkType="Reference"&gt;1342871&lt;/ulink&gt;]; in January 2013 the drug was launched in Japan for this indication [&lt;ulink linkID="1357361" linkType="Reference"&gt;1357361&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Spasticity&lt;/subtitle&gt;In October 2010, onabotulinumtoxinA was approved in Japan for upper and lower limb spasticity [&lt;ulink linkID="1146735" linkType="Reference"&gt;1146735&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Cervical dystonia&lt;/subtitle&gt;In 2001, onabotulinumtoxinA was launched for cervical dystonia in Japan  [&lt;ulink linkID="457501" linkType="Reference"&gt;457501&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Spasms&lt;/subtitle&gt;By June 2000, onabotulinumtoxinA was licensed for hemifacial spasm in Japan  [&lt;ulink linkID="372009" linkType="Reference"&gt;372009&lt;/ulink&gt;]. By July 2008, GSK had filed an sNDA in Japan for juvenile cerebral palsy [&lt;ulink linkID="929710" linkType="Reference"&gt;929710&lt;/ulink&gt;]. In February 2009, the sNDA was approved and the drug was launched in Japan for talipes equinis-associated leg spasms in cerebral palsy patients over the age of two years [&lt;ulink linkID="994690" linkType="Reference"&gt;994690&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Blepharospasm&lt;/subtitle&gt;In 1997, Japanese approval for blepharospasm was granted, having previously been granted Orphan Drug status for that indication; the drug was presumed to have been launched  that year [&lt;ulink linkID="372009" linkType="Reference"&gt;372009&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;China&lt;/subtitle&gt;&lt;subtitle&gt;Spasticity&lt;/subtitle&gt;By October 2005, the drug had been approved in China for hemifacial spasm  and blepharospasm [&lt;ulink linkID="626580" linkType="Reference"&gt;626580&lt;/ulink&gt;]. In October 2006, the drug was launched in China for hemifacial spasm  and blepharospasm [&lt;ulink linkID="1290656" linkType="Reference"&gt;1290656&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Rest of the world&lt;/subtitle&gt;&lt;subtitle&gt;Canada&lt;/subtitle&gt;&lt;subtitle&gt;Strabismus&lt;/subtitle&gt;By May 2014, the drug was approved for strabismus in Canada [&lt;ulink linkID="1649035" linkType="Reference"&gt;1649035&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Overactive bladder&lt;/subtitle&gt;In December 2011, Health Canada approved the drug as a treatment of urinary incontinence due to neurogenic detrusor overactivity resulting from neurogenic bladder associated with multiple sclerosis or subcervical spinal cord injury in adults [&lt;ulink linkID="1259743" linkType="Reference"&gt;1259743&lt;/ulink&gt;]. By October 2013, the product had been approved in Canada for OAB  [&lt;ulink linkID="1494584" linkType="Reference"&gt;1494584&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;During 2Q12, Allergan submitted an application with Health Canada seeking approval for the use of the drug as a treatment of OAB with symptoms of urinary incontinence, urgency, and frequency, in adult patients who have an inadequate response to or are intolerant of an anticholinergic medication [&lt;ulink linkID="1312675" linkType="Reference"&gt;1312675&lt;/ulink&gt;]. By December 2013, the drug had been approved for idiopathic OAB in Canada [&lt;ulink linkID="1530302" linkType="Reference"&gt;1530302&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Migraine&lt;/subtitle&gt;By February 2010, Allergan had filed for approval for chronic migraine in Canada [&lt;ulink linkID="1073300" linkType="Reference"&gt;1073300&lt;/ulink&gt;]. In November 2011, Health Canada approved approved the drug as a prophylactic treatment for headaches in adult patients with chronic migraine [&lt;ulink linkID="1259743" linkType="Reference"&gt;1259743&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Hyperhidrosis&lt;/subtitle&gt;By October 2001, the drug had  been approved for  hyperhidrosis in Canada [&lt;ulink linkID="426726" linkType="Reference"&gt;426726&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Spasticity&lt;/subtitle&gt;By December 1999, onabotulinumtoxinA had been approved for the treatment of lower-limb spasticity in Canada; it was presumed to have been launched shortly after [&lt;ulink linkID="365728" linkType="Reference"&gt;365728&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Cervical dystonia&lt;/subtitle&gt;By December 1999, onabotulinumtoxinA had been approved for cervical dystonia in Canada [&lt;ulink linkID="365728" linkType="Reference"&gt;365728&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Latin America&lt;/subtitle&gt;&lt;subtitle&gt;Migraine&lt;/subtitle&gt;By November 2010, regulatory filings had  been submitted in Brazil [&lt;ulink linkID="1146735" linkType="Reference"&gt;1146735&lt;/ulink&gt;].  In 1Q11, approval was granted in Brazil [&lt;ulink linkID="1197962" linkType="Reference"&gt;1197962&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In 1Q11, approval was granted in Chile [&lt;ulink linkID="1197962" linkType="Reference"&gt;1197962&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By August 2012, approval had been granted in Costa Rica for chronic migraine [&lt;ulink linkID="1313331" linkType="Reference"&gt;1313331&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Overactive bladder&lt;/subtitle&gt;By February 2009, onabotulinumtoxinA had been approved in Mexico for the treatment of neurogenic OAB [&lt;ulink linkID="981764" linkType="Reference"&gt;981764&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By February 2009, onabotulinumtoxinA had been approved in Brazil for the treatment of neurogenic OAB [&lt;ulink linkID="981764" linkType="Reference"&gt;981764&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By August 2012, the product had been approved in Panama for neurogenic OAB  [&lt;ulink linkID="1313331" linkType="Reference"&gt;1313331&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By February 2013, the product had been approved  in Argentina for  neurogenic OAB [&lt;ulink linkID="1366306" linkType="Reference"&gt;1366306&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In July 2013, the drug was approved for  OAB in Chile [&lt;ulink linkID="1461069" linkType="Reference"&gt;1461069&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By July 2014, the product had been approved in Ecuador for OAB [&lt;ulink linkID="1579469" linkType="Reference"&gt;1579469&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Middle East and Africa&lt;/subtitle&gt;&lt;subtitle&gt;Overactive bladder&lt;/subtitle&gt;By August 2012, the product had been approved in Egypt for neurogenic OAB [&lt;ulink linkID="1313331" linkType="Reference"&gt;1313331&lt;/ulink&gt;]. By December 2013, the drug had been approved for idiopathic OAB in Egypt [&lt;ulink linkID="1530302" linkType="Reference"&gt;1530302&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By August 2012, the product had been approved in Jordan for neurogenic OAB [&lt;ulink linkID="1313331" linkType="Reference"&gt;1313331&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By February 2013, the product had been approved  in Saudi Arabia for  neurogenic OAB [&lt;ulink linkID="1366306" linkType="Reference"&gt;1366306&lt;/ulink&gt;]. By December 2013, the drug had been approved for idiopathic OAB in Saudi Arabia [&lt;ulink linkID="1530302" linkType="Reference"&gt;1530302&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By February 2013, the product had been approved  in Kuwait for  neurogenic OAB [&lt;ulink linkID="1366306" linkType="Reference"&gt;1366306&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By October 2013, the product had been approved in Qatar for OAB   [&lt;ulink linkID="1494584" linkType="Reference"&gt;1494584&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In July 2013, the drug was approved for neurogenic OAB in  Morocco  [&lt;ulink linkID="1461069" linkType="Reference"&gt;1461069&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In July 2013, the drug was approved for OAB in Oman [&lt;ulink linkID="1461069" linkType="Reference"&gt;1461069&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By December 2013, the drug had been approved for idiopathic OAB in Israel [&lt;ulink linkID="1530302" linkType="Reference"&gt;1530302&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Migraine&lt;/subtitle&gt;By August 2012, approval had been granted in Bahrain for chronic migraine [&lt;ulink linkID="1313331" linkType="Reference"&gt;1313331&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By August 2012, approval had been granted in Kuwait for chronic migraine [&lt;ulink linkID="1313331" linkType="Reference"&gt;1313331&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By August 2012, approval had been granted in Jordan for chronic migraine [&lt;ulink linkID="1313331" linkType="Reference"&gt;1313331&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Commonwealth of Independent states&lt;/subtitle&gt;&lt;subtitle&gt;Overactive bladder&lt;/subtitle&gt;By February 2013, the product had been approved  in Russia, for  neurogenic OAB [&lt;ulink linkID="1366306" linkType="Reference"&gt;1366306&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Migraine&lt;/subtitle&gt;By February 2013, the product had been approved for chronic migraine in Russia [&lt;ulink linkID="1366306" linkType="Reference"&gt;1366306&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;South Asia&lt;/subtitle&gt;&lt;subtitle&gt;Overactive bladder&lt;/subtitle&gt;In July 2013, the drug was approved for OAB India  [&lt;ulink linkID="1461069" linkType="Reference"&gt;1461069&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Migraine&lt;/subtitle&gt;In August 2011, the product was approved in India for the treatment of chronic migraine  [&lt;ulink linkID="1214548" linkType="Reference"&gt;1214548&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Asia Pacific&lt;/subtitle&gt;&lt;subtitle&gt;Spasmodic dysphonia&lt;/subtitle&gt;By May 2018,  the product had been approved for the treatment of spasmodic dysphonia in Australia, and was presumed to be launched   [&lt;ulink linkID="2037706" linkType="Reference"&gt;2037706&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Strabismus&lt;/subtitle&gt;By May 2014, the drug was approved for strabismus in Australia [&lt;ulink linkID="1649035" linkType="Reference"&gt;1649035&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Overactive bladder&lt;/subtitle&gt; By August 2012, the product had been approved in Philippines for neurogenic OAB [&lt;ulink linkID="1313331" linkType="Reference"&gt;1313331&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt; By October 2013, the product had been approved in Korea for OAB  [&lt;ulink linkID="1494584" linkType="Reference"&gt;1494584&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By October 2013, the product had been approved in Taiwan for neurogenic OAB [&lt;ulink linkID="1494584" linkType="Reference"&gt;1494584&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In July 2013, the drug was approved for neurogenic OAB in Singapore [&lt;ulink linkID="1461069" linkType="Reference"&gt;1461069&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In July 2013, the drug was approved for neurogenic OAB in Australia [&lt;ulink linkID="1461069" linkType="Reference"&gt;1461069&lt;/ulink&gt;]. By December 2013, the drug had been approved for idiopathic OAB in Australia [&lt;ulink linkID="1530302" linkType="Reference"&gt;1530302&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In July 2013, the drug was approved for OAB in New Zealand [&lt;ulink linkID="1461069" linkType="Reference"&gt;1461069&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By December 2013, the drug had been approved for idiopathic OAB in Hong Kong [&lt;ulink linkID="1530302" linkType="Reference"&gt;1530302&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Migraine&lt;/subtitle&gt;By November 2010, regulatory filings had also been submitted in Australia [&lt;ulink linkID="1146735" linkType="Reference"&gt;1146735&lt;/ulink&gt;].  In 1Q11, approval was granted in Australia [&lt;ulink linkID="1197962" linkType="Reference"&gt;1197962&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By November 2010, regulatory filings had also been submitted in New Zealand [&lt;ulink linkID="1146735" linkType="Reference"&gt;1146735&lt;/ulink&gt;]. By June 2018, approval had been granted for  the prophylaxis of headaches in adults with chronic migraine  [&lt;ulink linkID="2058447" linkType="Reference"&gt;2058447&lt;/ulink&gt;].  &lt;/para&gt;&lt;para&gt;In 1Q11, approval was granted in Hong Kong [&lt;ulink linkID="1197962" linkType="Reference"&gt;1197962&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In 1Q11, approval was granted in Korea [&lt;ulink linkID="1197962" linkType="Reference"&gt;1197962&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Spasticity&lt;/subtitle&gt;By July 2008, the Australian regulatory authorities had expanded the approval of onabotulinumtoxinA to include upper-limb spasticity in juvenile cerebral palsy; approval for the treatment of lower-limb spasticity in cerebral palsy patients was granted in 1998 [&lt;ulink linkID="929710" linkType="Reference"&gt;929710&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In June 2008, the drug was approved for post-stroke upper limb spasticity in South Korea  [&lt;ulink linkID="996519" linkType="Reference"&gt;996519&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Hyperhidrosis&lt;/subtitle&gt;During 2001, onabotulinumtoxinA also received approval for hyperhidrosis in Australia [&lt;ulink linkID="457501" linkType="Reference"&gt;457501&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;During 2001, onabotulinumtoxinA also received approval for hyperhidrosis in New Zealand [&lt;ulink linkID="457501" linkType="Reference"&gt;457501&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2008, the drug was approved for primary axillary hyperhidrosis in South Korea  [&lt;ulink linkID="996519" linkType="Reference"&gt;996519&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;SAFETY INFORMATION&lt;/subtitle&gt;In February 2008, the FDA began reviewing reports of serious adverse events  following the use of botulinum toxins, particularly for the management of juvenile cerebral palsy. Adverse events, including respiratory failure and death, were linked to overdose of the product [&lt;ulink linkID="875383" linkType="Reference"&gt;875383&lt;/ulink&gt;]. Health Canada announced it was undertaking a similar safety review at that time [&lt;ulink linkID="878896" linkType="Reference"&gt;878896&lt;/ulink&gt;]; in January 2009, Health Canada informed healthcare professionals that the labelling information would now include the risk of the toxin spreading to other distant parts of the body [&lt;ulink linkID="978542" linkType="Reference"&gt;978542&lt;/ulink&gt;]. In April 2009, the FDA mandated a boxed warning and risk evaluation and management strategy for all botulinum-based products after reports of the effects of the toxin spreading to areas beyond the injection site [&lt;ulink linkID="1005283" linkType="Reference"&gt;1005283&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;POSTMARKETING STUDIESSpasticity&lt;/subtitle&gt;In April 2018, one year interim results were presented from an international, real-world, prospective, observational, multicenter registry study (&lt;ulink linkID="152839" linkType="Protocol"&gt;NCT01930786&lt;/ulink&gt;, ASPIRE)  of onabotulinumtoxinA in adult spasticity patients (n = 731) were presented at the 70th AAN Annual Meeting in Los Angeles, CA. Disability Assessment Scale revealed that onabotulinumtoxinA treatment showed a significant improvement in stroke, multiple sclerosis and cerebral palsy and did not show any improvement in traumatic brain injury and spinal cord injury. Most of the patients and clinicians expressed satisfaction that spasticity was managed by the most recent onabotulinumtoxinA treatment [&lt;ulink linkID="2026042" linkType="Reference"&gt;2026042&lt;/ulink&gt;]. Further clinical data were presented at the same conference. The most commonly treated upper limb presentation observed was clenched fist (71%; primary objective); and most commonly injected muscle to treat clenched fist noted was flexor digitorum superficialis. The most commonly treated lower limb presentation observed was equinovarus foot (53%); and most commonly injected muscle to treat equinovarus foot noted was gastrocnemius. In the overall population (n = 731), majority of patients and clinicians expressed satisfaction that the most recent onabotulinumtoxinA therapy helped their upper and lower limb spasticity. OF 731 patients, adverse events (AEs; 559 events) reported in 211 patients; in that 23 AEs were considered as treatment related (n = 17). Most common treatment-related AE reported was muscular weakness (0.8%). Serious AEs were reported in 75 patients (136 events) [&lt;ulink linkID="2026178" linkType="Reference"&gt;2026178&lt;/ulink&gt;]. In May 2019, further data of 730 patients were presented at the 71st AAN Annual Meeting in Philadelphia, PA. The most commonly treated lower limb presentation observed was equinovarus foot (59%); and most commonly injected muscle to treat equinovarus foot noted was gastrocnemius (79%). In the overall population, majority of patients and clinicians expressed satisfaction that the most recent onabotulinumtoxinA therapy helped manage spasticity and had sustained benefit of treatment. Of 530 safety evaluable patients, adverse events (AEs; 643 events) were reported in 197 patients; of whom 21 AEs in 18 patients were considered as treatment related [&lt;ulink linkID="2143087" linkType="Reference"&gt;2143087&lt;/ulink&gt;].  Further data were presented at the same conference. The most commonly treated upper limb presentation observed was clenched fist (52%); and most commonly injected muscle to treat equinovarus foot noted was Flexor digitorum superficialis (86%). In the overall population, majority of patients and clinicians expressed satisfaction that the most recent onabotulinumtoxinA therapy helped manage spasticity and had sustained benefit of treatment. Of 484 safety evaluable patients, adverse events (AEs; 563 events) were reported in 179 patients; of whom 15 AEs in 14 patients were considered as treatment related [&lt;ulink linkID="2143146" linkType="Reference"&gt;2143146&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Migraine​&lt;/subtitle&gt;In May 2015, clinical data about a multicenter (approximately 40 US sites), randomized, open-label, parallel-group, post-authorization, prospective study (&lt;ulink linkID="204639" linkType="Protocol"&gt;NCT02191579&lt;/ulink&gt;; GMA-US-NEU-0206; FORWARD) in patients (expected n = 400) were presented at the 17th International Headache Society Congress in Valencia, Spain. Patients would be randomized to receive onabotulinumtoxinA (155 units, q12w) or topiramate (50 to 100 mg/day, po tablets) for &amp;lt;/= 36 weeks. Patients who discontinue topiramate would receive onabotulinumtoxinA (155 units) not earlier than 12 weeks and up to 36 weeks. The primary endpoint was the percentage of patients with a &amp;gt;/= 50% responder rate at week 32. As of January 2015, 25 sites had been initiated, 12 sites were enrolling and 13 patients were randomized [&lt;ulink linkID="1682578" linkType="Reference"&gt;1682578&lt;/ulink&gt;]. In June 2018, further data were presented at 4th EAN Congress in Lisbon, Portugal. Compared to baseline, onabotulinumtoxinA demonstrated significantly higher proportion of patients with &amp;gt;/= 50% reduction in headache frequency versus topiramate (40.0 versus 12.0%, respectively; and adjusted odd ratio, 4.9, p &amp;lt; 0.001). Significant change in headache day frequency, HIT-6 scores, and &amp;gt;/= 70% responder rate (p &amp;lt; 0.001) (secondary endpoints) [&lt;ulink linkID="2061853" linkType="Reference"&gt;2061853&lt;/ulink&gt;]. In May 2019, exploratory analysis data were presented at 71st AAN Annual Meeting in Philadelphia, PA. From week-16 to end of the study, 52.5, 43.4 and 22.5% of patients who switched from topiramate to onabotulinumtoxinA reported &amp;gt;/= 30, 50 and 70% response (reductions in headache days/28 days) at weeks 29 to 32, weeks 17 to 20 and weeks 37 to 40, respectively   [&lt;ulink linkID="2142996" linkType="Reference"&gt;2142996&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In May 2015, clinical data were presented from two long-term, multicenter, open-label (COMPEL, NCT01516892) and double-blind (PREEMPT, NCT00156910 and NCT00168428) studies in 1401 patients at the 17th International Headache Society Congress in Valencia, Spain. Patients received onabotulinumtoxinA (155 units, q12w) for 24 weeks. In COMPEL and PREEMPT studies, reductions in headache days (primary endpoint; -7.6 versus -8.4 days, respectively); change in moderate/severe headache days (secondary endpoint; -6.7 versus -7.7 days, respectively) and headache impact test 6 scores (-5.4 versus -4.8 points, respectively) showed improvements at week 24 [&lt;ulink linkID="1682577" linkType="Reference"&gt;1682577&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In May 2015, interim analysis results were presented from a prospective, observational, multinational (UK, Germany, Spain and Sweden), European post-authorization study (&lt;ulink linkID="80773" linkType="Protocol"&gt;NCT01432379&lt;/ulink&gt;) in 1160 patients at the 17th International Headache Society Congress in Valencia, Spain. Patients received onabotulinumtoxinA and the majority of patients (78%) received 150 to 200 total dose units of onabotulinumtoxinA. Treatment-related adverse events (TRAEs), discontinuations due to TRAEs and serious TRAEs (worsening migraine) were reported in 227, 33 and 1 patient, respectively [&lt;ulink linkID="1682576" linkType="Reference"&gt;1682576&lt;/ulink&gt;]. In April 2016, further clinical data were presented at the 68th AAN Annual Meeting in Vancouver, Canada. There were no unexpected TRAEs reported. Treatment-related dysphagia was reported by three patients [&lt;ulink linkID="1753325" linkType="Reference"&gt;1753325&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2015, interim analysis data were presented from a long-term, multicenter, open-label study (COMPEL; &lt;ulink linkID="84306" linkType="Protocol"&gt;NCT01516892&lt;/ulink&gt;)  in 691 adult chronic migraine patients at the 67th AAN Annual Meeting in Washington DC. Patients  received 155 U of onabotulinumtoxinA q12w. Significant improvements in headache impact test (-5 point change) and migraine disability assessment questionnaire (-36 point change) scores from baseline and moderate improvements in generalized anxiety disorder assessment and patient health questionnaire scores were observed. Neck pain (3%) were the most frequently reported treatment-related adverse events [&lt;ulink linkID="1651660" linkType="Reference"&gt;1651660&lt;/ulink&gt;]. In May 2015, similar data were presented at the 34th APS Annual Scientific Meeting in Palm Springs, CA [&lt;ulink linkID="1659944" linkType="Reference"&gt;1659944&lt;/ulink&gt;]. In April 2017, further clinical data were presented at the 69th AAN Annual Meeting in Boston, MA. The mean change from baseline in headache days (primary efficacy measure) were - 7.4, - 9.2, - 9.8 and - 10.7 at week-24, 60, 84 and 108, respectively; significant reduction was observed in number of headache days per month (p &amp;lt; 0.0001) by week-108. At week-48, 96 and 108, the mean change from baseline in migraine specific quality of life questionnaire were 18.6, 19.1 and 18.4 (role function preventive), 23.7, 26.4 and 26.1 (role function restrictive), 24.3, 26.6 and 26 (emotional function), respectively [&lt;ulink linkID="1920058" linkType="Reference"&gt;1920058&lt;/ulink&gt;]. In June 2017, further data were presented at the 3rd EAN Congress in Amsterdam, the Netherlands. Significant improvement in the mean Pittsburgh Sleep Quality Index scores was observed by 108 weeks of treatment; mean change from baseline at week 24, 60, 84 and 108 was -1.2, -1.5, -1.7 and -1.9, respectively (all p &amp;lt; 0.0001 compared with baseline). Similar results were observed for mean Fatigue Severity Scale scores; mean change from baseline at week 24, 60, 84 and 108 was -4.0, -4.3, -5.2 and -5.8, respectively (all p &amp;lt; 0.0001 compared with baseline) [&lt;ulink linkID="1950815" linkType="Reference"&gt;1950815&lt;/ulink&gt;]. Further data were presented at the same conference. At all time-points (week 24, 60, 84 and 108), patients in headache everyday and allodynia subgroups exhibited a significant improvement (decrease) in mean Migraine Disability Assessment Questionnaire score. By week 108, the number of patients who responded to question of extremely satisfied or satisfied and would continue using onabotulinumtoxinA was  86.8 and 82.6% of patients with and without headache everyday at baseline, respectively (n = 68 and 302, respectively); and 84.0 and 83.6% of patients with and without allodynia at baseline, respectively (n = 156 and 214, respectively). Treatment-related deaths did not occur [&lt;ulink linkID="1950824" linkType="Reference"&gt;1950824&lt;/ulink&gt;]. In September 2017, further clinical data were presented at the 18th IHC Congress in Vancouver, Canada. Neck pain, eyelid ptosis, musculoskeletal stiffness, injection-site pain and headache were the most common AEs reported in 2.7, 1.8, 1.4, 1.3 and 1.3% of patients, respectively, after the first cycle of treatment, and these were reduced to 0.2, 0, 0.2, 0 and  0.5%, respectively, after the last cycle. Serious AEs and treatment related AEs were reported in 75 and 131 patients, respectively. OnabotulinumtoxinA was well tolerated  [&lt;ulink linkID="1970126" linkType="Reference"&gt;1970126&lt;/ulink&gt;]. Further clinical data were presented at the same conference. In patients with and without headache every day groups, onabotulinumtoxinA treatment showed significant reduction in 28-day headache frequency. Relative to baseline, the mean 28-day headache day frequency at week 60 was -7.9 and -10.7 and at week 108 was -10.5 and -12, respectively in patients with and without and headache every day [&lt;ulink linkID="1970124" linkType="Reference"&gt;1970124&lt;/ulink&gt;]. Further clinical data were presented at the same conference. In patients with and without allodynia subgroups, treatment with onabotulinumtoxinA exhibited significant reduction in 28-day headache frequency relative to baseline; the mean reduction at week 60 was -9.9 and -10.3, and at week 108 was -10.8 and -12.5, respectively. At week 60 and 108, patients with and without allodynia exhibited a significant improvement (decrease) in mean MIDAS score; -48.6 and -38.9 at week 60 (p &amp;lt; 0.05) and -53.0 and -37.7 at week 108, respectively [&lt;ulink linkID="1970123" linkType="Reference"&gt;1970123&lt;/ulink&gt;]. Further clinical data were presented at the same conference. At week 108, headache day frequency was significantly decreased from baseline mean of 22 to 11.3 days (p &amp;lt; 0.0001). At week 12, 24, 48, 72 and 108, the mean Generalized Anxiety Disorder Assessment (GAD-7) score was significantly reduced by -1.4, -1.9, -2.0, -2.8, and -2 (p &amp;lt; 0.0001 for all), respectively, when compared to baseline mean GAD-7 score of 6.3; decrease in anxiety symptoms (GAD-7 score &amp;gt;/= 5)  by 41, 35.1, 34.8, 28 and 26.3%, respectively,  compared to baseline of 53%; mean Patient Health Questionnaire (PHQ-9) score was significantly decreased by -2.5, -3.4, -3.4, -4.2 and -4.5 (p &amp;lt; 0.0001 for all), respectively, from baseline score of 9.2. Symptoms of depression (PHQ-9 score &amp;gt;/= 5) were significantly decreased at week 12 (57.8%), 24 (49.6%), 48 (50.4%), 72 (40.2%) and 108 (33%) from baseline (73%) [&lt;ulink linkID="1970133" linkType="Reference"&gt;1970133&lt;/ulink&gt;]. In June 2018, further clinical data from  639 patients who used acute pain medication were presented at the 4th EAN Congress in Lisbon, Portugal. The effect of onabotulinumtoxinA on reduction in headache days (-11.4 versus -12.5 days) and MIDAS scores (-41.8 versus -48.7) in patients with and without medication overuse was similar (p &amp;lt; 0.001) [&lt;ulink linkID="2061820" linkType="Reference"&gt;2061820&lt;/ulink&gt;]. Further clinical data were presented at the same conference.  A total of 83.7 and 60.3% of headache frequency responders and non-responders, respectively, experienced a reduction of &amp;gt;/= 1 Severity Category in PHQ-9; and 86.0 and 71.4%, respectively, experienced a reduction of &amp;gt;/= 1 Severity Category in GAD-7 [&lt;ulink linkID="2061838" linkType="Reference"&gt;2061838&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Overactive bladder&lt;/subtitle&gt;In March 2019, data from female pateints enrolled in a randomized, double-blind, placebo-controlled phase IV trial (&lt;ulink linkID="288178" linkType="Protocol"&gt;NCT03052764&lt;/ulink&gt;) of an alternative 10-injection regimen of onabotulinumtoxinA to assess safety and efficacy, as well as incidence of clean intermittent catheterization (CIC) requirement, in adult patients with OAB and urinary incontinence were presented at the 2019 International EAU Meeting in Barcelona, Spain. The alternative paradigm was shown to significantly reduce urinary incontinence, with least square mean reductions from baseline in urinary incontinence and and urgent urinary continennce episodes/day of -3.07 and -2.76, respectively, for treated patients (n = 73) versus -0.15 and -0.05, respectively, for placebo (n = 39). Decreases in episodes/day of 100 and &amp;gt;/=50% at week 12 were reported in 14.3 and 52.9% of treated patients versus 2.7 and 18.9% of patients in the placebo group. Significant improvements in I-QOL score from baseline was also reported versus placebo for the onabotulinumtoxinA treated group. No female patient required CIC in the first 12 weeks (versus 5.2% in previous trials using the standard 20-injection regimen) and no new safety signal were reported [&lt;ulink linkID="2128576" linkType="Reference"&gt;2128576&lt;/ulink&gt;], [&lt;ulink linkID="2130725" linkType="Reference"&gt;2130725&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In August 2018, results   from a pooled post hoc analysis of three randomized, placebo-controlled, multicenter trials and a randomized phase IV post marketing study  of onabotulinumtoxinA 100U based on baseline OAB duration and BMI in OAB patients with urinary incontinence were presented at 48th Annual Meeting of the International Continence Society in Philadelphia, PA. Patients were stratified by baseline OAB duration (&amp;lt; 2 (n = 279), 2 to 5 (n = 641), and &amp;gt; 5 years (n = 505)) and BMI (&amp;lt; 25 (n = 317), 25 to &amp;lt; 30 (n = 454), 30 to &amp;lt; 40 (n = 502), and &amp;gt;/= 40 (n = 153) kg/m2). In the &amp;lt; 2, 2 to 5 and &amp;gt; 5 years of baseline OAB duration, &amp;lt; 25, 25 to &amp;lt; 30, 30 to &amp;lt; 40 and &amp;gt;/= 40 kg/m2 baseline BMI groups, mean change in UI episodes from baseline to week 12 was -3.3, -2.9, -3.4, -2.8, -2.8, -3.4 and -4.2; the percentage of patients attaining 100% reduction in UI episodes/day at week 12 was 38.7, 27.9, 27.9, 32.5, 31.1, 29.9 and 22.9% and the percentage of patients attaining &amp;gt;/= 50% reduction in UI episodes/day at week 12 was 72.4, 62.9, 66.9, 66.9, 65.6, 65.1 and 70.6%, respectively  [&lt;ulink linkID="2114958" linkType="Reference"&gt;2114958&lt;/ulink&gt;]. At the same conference further results were presented. Proportions of patients who attained a 100% reduction in UI episodes/day were similar between those treated with onabotulinumtoxinA for a first or second time (37.4 versus 33%, respectively) in treatment 2.  Proportions of patients who attained a &amp;gt;/= 50% reduction in UI episodes/day were also similar between patients treated with onabotulinumtoxinA for a first or second time (79.4 versus 69.3%). There were no unexpected safety signals in the first 12 weeks of either treatment cycle, and urinary tract infection was the most common adverse event (AE) reported. Clean intermittent catheterization (CIC) rates for urinary retention in the 12 weeks following the first treatment were 6.3 and 0% in onabotulinumtoxinA- and placebo-treated patients, respectively [&lt;ulink linkID="2114955" linkType="Reference"&gt;2114955&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2014, an open-label, randomized, parallel assigned, safety and efficacy phase IV trial (&lt;ulink linkID="216648" linkType="Protocol"&gt;NCT02297100&lt;/ulink&gt;, IRB00026734) was initiated in the US in patients (expected n = 40) with interstitial cystitis. At that time, the trial was expected to be completed in August 2015 [&lt;ulink linkID="1623706" linkType="Reference"&gt;1623706&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Hyperhidrosis&lt;/subtitle&gt;By February 2010, Allergan was conducting a phase IV trial of onabotulinumtoxinA in the treatment of palmar hyperhidrosis, as part of its commitments to the FDA for approval in axillary hyperhidrosis [&lt;ulink linkID="1085385" linkType="Reference"&gt;1085385&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In July 2005, results from a 3-year, open-label study in axillary hyperhidrosis were reported, showing that onabotulinumtoxinA was safe and effective. The study enrolled 193 patients who had participated in a previous trial. Repeat injections were given when the effect of the previous injection had worn off and patients reported that their sweating was barely tolerable (3 or 4 on HDSS scale). After two and three treatments, 81 and 78% of patients reported at least a 2-grade improvement in HDSS score, respectively. In addition, 9 to 20% of patients reported occupational dissatisfaction and limitation, compared to 66 to 72% of patients prior to treatment. The number of patients who reported feeling "emotionally damaged or injured" was reduced by 50%. Patients reported significantly less limitation in interpersonal and social situations [&lt;ulink linkID="613500" linkType="Reference"&gt;613500&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Cervical dystonia&lt;/subtitle&gt;In April 2018, real-world data from a multicenter, prospective, observational study (&lt;ulink linkID="89803" linkType="Protocol"&gt;NCT01655862&lt;/ulink&gt;, POSTURe) of onabotulinumtoxinA in cervical dystonia (CD) patients were presented  at the 70th AAN Annual Meeting in Los Angeles, CA. Patients (n = 61) received &amp;gt;/= 1 onabotulinumtoxinA at the physician’s discretion (maximum of nine treatment sessions). When compared to baseline, onabotulinumtoxinA treatment significantly reduced Pain Numeric Rating Scale score (reduction of neck pain with a mean value of 2.1 versus 4.6, respectively; p &amp;lt; 0.001) and also reduced the Hospital Anxiety (7.1 versus 4.8, respectively) and Depression (4.2 versus 2.8, respectively) score (p &amp;lt; 0.01 for both). The average Cervical Dystonia Impact Profile (CDIP-58) scores across all subscales (including Head/Neck Symptoms, Pain/Discomfort, Sleep, Upper Limb Activities, Walking, Annoyance, Mood, and Psychosocial Functioning)  and conceptual domain (symptoms, daily activities and psychosocial sequelae) were significantly reduced by onabotulinumtoxinA when compared to baseline (all p &amp;lt; 0.001) [&lt;ulink linkID="2026104" linkType="Reference"&gt;2026104&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In May 2001, a phase IV trial comparing onabotulinumtoxinA to Elan's botulinum toxin product &lt;ulink linkID="7819" linkType="Drug"&gt;Myobloc&lt;/ulink&gt; in cervical dystonia was ongoing. Results were expected from mid-2002 [&lt;ulink linkID="420751" linkType="Reference"&gt;420751&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;By March 2006, a phase IV study (&lt;ulink linkID="13009" linkType="Protocol"&gt;NCT00241215&lt;/ulink&gt;; UCLA#03-03-061-03A), initiated in June 2003 in the US in patients (expected n = 150), was ongoing in its investigation of the efficacy of onabotulinumtoxinA in myofascial pain of the neck and shoulders [&lt;ulink linkID="757321" linkType="Reference"&gt;757321&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regulatory&gt;</value></Regulatory><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;&lt;subtitle&gt;Atrial Fibrillation&lt;/subtitle&gt;In December 2018, a multi-center, randomized, double-blind, placebo-controlled, parallel group, dose-ranging, phase II study (&lt;ulink linkID="363971" linkType="Protocol"&gt;NCT03779841&lt;/ulink&gt;; Eudra 2017-004399-68; 1925-201-008) was planned in the US, to begin in January 2019, to evaluate the efficacy and safety of botulinum toxin type A (AGN-151607) injections into the epicardial fat pads, foci of ganglionic plexi, to prevent post-operative atrial fibrillation (POAF) in patients (expected n = 330) undergoing open-chest cardiac surgery. The primary endpoint was to measure the percentage of patients with at least 1 continuous atrial fibrillation (AF) episode &amp;gt;/= 30 seconds during the first 30 days post-surgery. At that time, the trial was expected to complete in February 2021. In March 2019, the trial was initiated in the US [&lt;ulink linkID="2106734" linkType="Reference"&gt;2106734&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Pain&lt;/subtitle&gt;In March 2019, an IND application presumably for pain was filed in China [&lt;ulink linkID="2124883" linkType="Reference"&gt;2124883&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In July 2017, a randomized, parallel assigned, phase III trial (&lt;ulink linkID="305800" linkType="Protocol"&gt;NCT03223298&lt;/ulink&gt;; 1607017383) was planned 	in September 2017, to assess comparison of botulinum toxin versus placebo injections to temporalis and masseter muscles in patients (expected n = 110) with myofascial pain disorder. At that time, the trial was expected to complete in May 2020 [&lt;ulink linkID="1956040" linkType="Reference"&gt;1956040&lt;/ulink&gt;]; in August 2018, the trial was initiated [&lt;ulink linkID="1956040" linkType="Reference"&gt;1956040&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Spasticity&lt;/subtitle&gt;&lt;subtitle&gt;Phase III&lt;/subtitle&gt;In  April 2016, clinical data from a multicenter, double-blind, placebo-controlled, phase III study (REFLEX) which evaluated the efficacy of onabotulinumtoxin A in patients (n = 468) with post-stroke lower-limb spasticity (PSLLS) were presented at the 68th AAN Annual Meeting in Vancouver, Canada. Patients were randomized to onabotulinumtoxin A (300 to 400 U; injection of muscles) or placebo for 12 weeks. In the intent-to-treat populations, onabotulinumtoxin A significantly improved mean ankle modified Ashworth scale (MAS) change (primary endpoint) from baseline compared with placebo (-0.81 versus -0.61; at average of weeks 4 and 6) and also physician-assessed clinical global impression of change (CGI; 0.86 versus 0.65, respectively. Overall, onabotulinumtoxin A injections were safe and effective in reducing ankle spasticity in patients with PSLLS [&lt;ulink linkID="1755144" linkType="Reference"&gt;1755144&lt;/ulink&gt;]. Further clinical data were presented at the same conference. Improvements in CGI scores, MAS scores observed during the double-blind phase were further enhanced with repeated treatments. For onabotulinumtoxin A versus placebo groups, physician- and patient-assessed Goal Attainment Scale (active and passive) scores and percent of responders (69.1 versus 68.5% and 74.1 and 71.5%, respectively at week 12) improved with each subsequent treatment [&lt;ulink linkID="1755131" linkType="Reference"&gt;1755131&lt;/ulink&gt;]. Similar data were presented at the same conference [&lt;ulink linkID="1753658" linkType="Reference"&gt;1753658&lt;/ulink&gt;]. In June 2016, further data were presented at the 20th International PDMD Congress in Berlin, Germany. Regardless of the time since stroke, significant improvement in ankle MAS (–0.98 versus –0.52) and CGI (0.80 versus 0.38) was observed with additional injections into flexor digitorum longus and flexor hallucis longus muscles versus placebo. OnabotulinumtoxinA 300 to 400 U was well tolerated with no new safety findings [&lt;ulink linkID="1780949" linkType="Reference"&gt;1780949&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In  April 2015, clinical data  were presented from a post hoc-analysis that included 11 double-blind, placebo-controlled and 7 open-label, completed studies  in 1342 patients  at the 67th AAN Annual Meeting in Washington DC. Overall adverse event (AE) profile was consistent without changes in AE or serious AEs profiles with increasing doses in a patient subset that received four consecutive doses of onabotulinumtoxinA &amp;gt;/= 400 U [&lt;ulink linkID="1651930" linkType="Reference"&gt;1651930&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2015, data were reported from two randomized, multicenter, double-blind, placebo-controlled studies evaluating the efficacy and safety of onabotulinumtoxinA in patients with upper limb spasticity. In the first study in 170 patients with upper limb spasticity, patients received a single treatment of onabotulinumtoxinA or placebo into thumb flexor muscles, showing a significant median change from baseline to week 6 in thumb flexor tone measured by the modified Ashworth Scale of 1 for onabotulinumtoxinA versus 0 for placebo. In the second trial in 109 patients with upper limb spasticity, patients received a single treatment with lower dose (30 units) or higher dose (40 units) of onabotulinumtoxinA or placebo into thumb flexor muscles, showing significant reduction in thumb flexor muscle tone on the modified Ashworth Scale of 0.5 for onabotulinumtoxinA versus 0 [&lt;ulink linkID="1652361" linkType="Reference"&gt;1652361&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2013, pooled data from eight studies were presented at the 65th AAN Annual Meeting in San Diego, CA. OnabotulinumtoxinA therapy was safe and well tolerated in patients with lower limb spasticity [&lt;ulink linkID="1389400" linkType="Reference"&gt;1389400&lt;/ulink&gt;]. In August 2015, it was noted that positive results were obtained from a double-blind, placebo-controlled study involving 468 patients with lower limb spasticity [&lt;ulink linkID="1688074" linkType="Reference"&gt;1688074&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2007, a placebo-controlled, randomized, double-blind,  phase III trial (&lt;ulink linkID="8122" linkType="Protocol"&gt;NCT00460564&lt;/ulink&gt;; BTX108509) was initiated in subjects (expected n = 105) with post-stroke upper limb spasticity in Japan. The subjects were to receive a double blind treatment period followed by an open label period. The primary endpoint was a change in Modified Ashworth Scale (MAS) wrist score [&lt;ulink linkID="799585" linkType="Reference"&gt;799585&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2007, a placebo-controlled, randomized, double-blind,  phase III trial (&lt;ulink linkID="8130" linkType="Protocol"&gt;NCT00460655&lt;/ulink&gt;; BTX108512) was initiated in subjects (expected n = 105) with equinus deformity associated with post-stroke lower limb spasticity in Japan. The trial was to involve a double blind treatment period followed by an open label period. The primary endpoint was a change in MAS ankle score [&lt;ulink linkID="799597" linkType="Reference"&gt;799597&lt;/ulink&gt;].  In March 2013, data from the 120-patient study were presented at the 65th AAN Annual Meeting in San Diego, CA. OnabotulinumtoxinA therapy was found to be associated with greater reductions in modified AS ankle score and improvements in physician global assessment of response than placebo; significant differences were seen at weeks at 4, 6 and 8 [&lt;ulink linkID="1389399" linkType="Reference"&gt;1389399&lt;/ulink&gt;]. In  April 2015,  further data were presented at the 67th AAN Annual Meeting in Washington DC. The mean change in modified ashworth scale (MAS) was superior for onabotulinumtoxinA (‐0.8 compared with ‐0.6 for placebo), including MAS at weeks 2, 4, and 6. More onabotulinumtoxinA‐treated patients achieved a &amp;gt;/= 1 grade decrease in MAS OnabotulinumtoxinA treatment was associated with improvement mean clinical global impression (CGI) of change and CGI at weeks 2, 4, and 6 [&lt;ulink linkID="1652864" linkType="Reference"&gt;1652864&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 2006, final US data were presented at the joint annual meeting of the American College of Rehabilitation Medicine and the American Society for Neurorehabilitation in Boston, MA. Results indicated muscle tone was markedly decreased in 279 stroke patients with wrist, hand or elbow spasticity six months or more after their stroke. The effect was apparent after 6 weeks and the improvement was maintained throughout the 1-year study. Before treatment with onabotulinumtoxinA, 57% of patients classified themselves as having between moderately to extremely limited mobility and walking ability due to impaired arm function; after treatment, 46 to 49% of these patients reported improvement in this regard. Improvements in patients' work activities and in quality-of-life parameters for both patients and caregivers were also observed [&lt;ulink linkID="728088" linkType="Reference"&gt;728088&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In early 2004, US phase III and Japanese phase I/II trials were ongoing for adult spasticity [&lt;ulink linkID="372009" linkType="Reference"&gt;372009&lt;/ulink&gt;], [&lt;ulink linkID="536695" linkType="Reference"&gt;536695&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase II&lt;/subtitle&gt;By November 2005, phase II trial results had demonstrated that onabotulinumtoxinA improved muscle tone and functional disability in patients with spasticity of the upper limbs following a stroke [&lt;ulink linkID="631185" linkType="Reference"&gt;631185&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 2003, an international, double blind, parallel assignment, placebo control, randomized, safety phase II trial (&lt;ulink linkID="49023" linkType="Protocol"&gt;NCT00076687&lt;/ulink&gt;; 191622-057) was initiated in post-upper limb stroke subjects (expected n = 150) with reduced lung function. The subjects were to receive placebo or onabotulinumtoxinA (240 or 360 U) injection on day 1, week 12, week 18. The primary endpoint was to establish forced expiratory volume and forced vital capacity. The study was expected to be completed in December 2009 and was still recruiting in December 2008 [&lt;ulink linkID="990471" linkType="Reference"&gt;990471&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By April 2002, phase II trials for adult spasticity were underway in Japan and phase III trials for this indication were ongoing in the US [&lt;ulink linkID="457501" linkType="Reference"&gt;457501&lt;/ulink&gt;]; these studies were ongoing in early 2004 [&lt;ulink linkID="562127" linkType="Reference"&gt;562127&lt;/ulink&gt;]. In October 2005,  were released showing that the drug improved muscle tone and functional disability in patients with post-stroke spasticity of the upper limbs [&lt;ulink linkID="631185" linkType="Reference"&gt;631185&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase I&lt;/subtitle&gt;By November 2015, an optimized formulation, Botox X, was in phase I clinical trials for spasicisty [&lt;ulink linkID="1724426" linkType="Reference"&gt;1724426&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Cervical dystonia&lt;/subtitle&gt;In July 2008, a randomized, double-blind, safety and efficay, parallel-assigned,  phase II trial (&lt;ulink linkID="14131" linkType="Protocol"&gt;NCT00564681&lt;/ulink&gt;; 191622-090) was  initiated in patients with cervical dystonia, in the US, Canada, India, Singapore, Phillipines, Taiwan, Thailand, South Africa and Europe. In December 2009, the trial was completed. In December 2012, data were reported demonstrating changes from baseline in observed total Toronto Western spasmodic torticollis rating scale (TWSTRS) score at week 4 of treatment cycle 1 of -10.3, -13.6 and -5.6 for onabotulinumtoxinA, onabotulinumtoxinA  formulation 2 and placebo, respectively [&lt;ulink linkID="1727125" linkType="Reference"&gt;1727125&lt;/ulink&gt;].  &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Other studies&lt;/subtitle&gt;In September 2007, a prospective, non-randomized, observational, multicentre trial (MOBILITY; &lt;ulink linkID="105086" linkType="Protocol"&gt;NCT00535938&lt;/ulink&gt;; AGN/MMC B00705) was initiated in patients (n = 1383) receiving Botox. The study was completed during August 2013 [&lt;ulink linkID="1527484" linkType="Reference"&gt;1527484&lt;/ulink&gt;]. In February 2014,  interim results were presented from the  MOBILITY study at the 2014 International Stroke Conference in San Diego, CA. A total of 333 patients were included in the interim analysis. When compared with the maintenance patients, the SF-D scores were lower among onabotulinumtoxinA-naive patients. At subsequent visits 1 and 2, improvements in SF-D scores from baseline were observed in both naive and maintenance patients [&lt;ulink linkID="1526340" linkType="Reference"&gt;1526340&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In October 2002, an open label, prospective, multicentric, randomized trial (&lt;ulink linkID="174706" linkType="Protocol"&gt;NCT00199589&lt;/ulink&gt;; I01014) was initiated in France to evaluate efficacy of Botox in stroke patients (expected n = 46) with equinovarus foot. In December 2007, the trial was completed [&lt;ulink linkID="1545053" linkType="Reference"&gt;1545053&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Hyperhidrosis&lt;/subtitle&gt;By December 2011, a trial had been completed in Japan in patients with hyperhidrosis [&lt;ulink linkID="1448708" linkType="Reference"&gt;1448708&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In February 2004, clinical data on onabotulinumtoxinA were presented at the 62nd American Academy of Dermatology meeting in Washington, DC. A total of 322 patients were randomized to receive 50 or 75 units of injectable onabotulinumtoxinA or placebo. Four weeks after one treatment with  onabotulinumtoxinA, 75% of each onabotulinumtoxinA cohort and 25% of the placebo group achieved at least two grades of improvement in Hyperhidrosis Disease Severity Scale (HDSS) scoring. A total of 43% of the onabotulinumtoxinA group and 12% of the placebo group required only one treatment for the year of the study. Among patents requiring a second injection, 85% of the 50 unit group, 74% of the 75 unit group and 27% of the placebo group reported two grades improvement. Median duration of response for the 50 and 75 unit and the placebo groups were 197, 205 and 96 days, respectively. After a second treatment, the median duration of response was 182, 159 and 63 days, respectively. Four weeks after the first treatment, mean gravimetric sweat production was significantly decreased in both onabotulinumtoxinA groups by 82 and 87% compared to 33% in the placebo group. Four weeks after the second treatment, sweat production was decreased by 87, 81 and 24%, respectively. Four weeks after the first treatment, patients in the onabotulinumtoxinA groups reported significantly greater quality-of-life improvements for all categories compared to those in the placebo group [&lt;ulink linkID="524648" linkType="Reference"&gt;524648&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2001, clinical data on onabotulinumtoxinA were presented at the 59th American Academy of Dermatology meeting in Washington DC. In a study designed to evaluate the safety and efficacy of intradermal administration of onabotulinumtoxinA compared to placebo for the treatment of bilateral primary axillary hyperhidrosis, 320 patients, aged 18 to 75, were enrolled in a multicenter, randomized, placebo-controlled study. Patients were randomized to receive either 50 U/axilla Botox or a placebo, and were evaluated at baseline and at 1, 4, 8, 12 and 16 weeks post treatment. At week 4, 93.8% of patients treated with onabotulinumtoxinA were responders (&amp;gt; 50% reduction in sweat production) compared with 35.9% of the placebo group. The mean percentage reduction in sweat production at week 4 was 83.5% in the onabotulinumtoxinA group compared with 20.8% in the placebo group [&lt;ulink linkID="408851" linkType="Reference"&gt;408851&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Cervical dystonia&lt;/subtitle&gt;In May 2014, clinical data were presented from the open-label, multicenter, observational prospective registry study (CD PROBE) at the 66th AAN Annual Meeting in Philadelphia, PA. According to the clinical global impression of change, the percentages of patients who exhibited very much improved, much improved and minimally improved CD were  29, 45.1 and 20.9%, respectively, during final visit. According to the patient global impression of change, the percentages of patients who exhibited very much improved, much improved and minimally improved CD were  25.7, 38.7 and 27.2%, respectively, during final visit [&lt;ulink linkID="1544843" linkType="Reference"&gt;1544843&lt;/ulink&gt;]. Later that month, safety data were presented at the same conference [&lt;ulink linkID="1545109" linkType="Reference"&gt;1545109&lt;/ulink&gt;]. In June 2014, clinical data were presented at the 18th International Congress of Parkinson's Disease and Movement Disorders in Stockholm, Sweden. In 407 patients who had completed all Cervical Dystonia Impact Profile-58 assessments, marked reductions from baseline were observed in subscale scores for head and neck, pain and discomfort, upper limb activities, walking, sleep, annoyance, mood and psychological  subscales [&lt;ulink linkID="1575367" linkType="Reference"&gt;1575367&lt;/ulink&gt;]. ​In April 2015, further results were presented at the 67th AAN Annual Meeting in Washington DC. Overall, 88.7 to 90.2% of patients consistently reported experience of neck pain or discomfort due to CD before onabotulinumtoxinA therapy. During the first 2 weeks following onabotulinumtoxinA therapy, significantly greater percentage of patients reported pain relief at final visit (78.9%) when compared to phone interview 1 (69.1%). There were significant decreases in baseline mean pain subscale of the Toronto Western Spasmodic Torticollis Rating Scale, Pain Numeric Rating Scale score and Pain and Discomfort subscales of the CD Impact Profile-58 scores at the final visits [&lt;ulink linkID="1651927" linkType="Reference"&gt;1651927&lt;/ulink&gt;]. In June 2015, further clinical data were presented at the 19th International PDMD Congress in San Diego, CA. Overall, onabotulinumtoxinA significantly decreased  CD symptoms, disability and severity, and improved quality of life without any new safety signals in a real-world treatment setting in subjects naive to botulinum toxin at baseline [&lt;ulink linkID="1677012" linkType="Reference"&gt;1677012&lt;/ulink&gt;]. In April 2017, further clinical data (&lt;ulink linkID="44709" linkType="Protocol"&gt;NCT00836017&lt;/ulink&gt;) were presented at the 69th AAN Annual Meeting in Boston, MA. At final visit (93.7 and 35%, respectively), significant improvement in the Patient Global Impression of Change (PGIC, p &amp;lt;  0.0001) and Clinical Global Impression of Change (CGIC, p &amp;lt;  0.0001) was reported compared with the first post treatment assessment (83 and 91.2%, respectively). The point reduction in Toronto western spasmodic torticollis rating scale score that correlated to very much improved, much improved or better and minimally improved in PGIC were 11, 9 and 8, respectively, and that observed on CGIC were 10, 8 and 7, respectively [&lt;ulink linkID="1920190" linkType="Reference"&gt;1920190&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 1999, data presented at the Basic and Therapeutic Aspects of Botulinum and Tetanus Toxins meeting in Orlando, FL, indicated that onabotulinumtoxinA was very effective in the treatment of cervical dystonia. Results from a multicenter trial demonstrated that onabotulinumtoxinA provided a significant, sustained benefit in comparison to placebo for the treatment of cervical dystonia as measured by head position, pain and disability assessments [&lt;ulink linkID="347888" linkType="Reference"&gt;347888&lt;/ulink&gt;]. Additional data indicated that patients suffering from chronic pain may obtain relief with injections of onabotulinumtoxinA, which produced prolonged muscle relaxation in a dose-dependent manner and was easily targeted to affected muscles. Of patients with myofascial pain in the back and extremities who received onabotulinumtoxinA injection over a 2-year period, 70% reported 15.5 to 54.5% pain relief lasting on average 2.5 to 3.6 months; 10% were free of pain at 1-year of follow up [&lt;ulink linkID="347961" linkType="Reference"&gt;347961&lt;/ulink&gt;].  &lt;/para&gt;&lt;para&gt;Dystonias are neuromuscular disorders characterized by involuntary spasms or contractions. Injected directly into a spastic muscle, onabotulinumtoxinA inhibits the release of acetylcholine, resulting in the inhibition, or relaxation, of muscle overactivity [&lt;ulink linkID="175740" linkType="Reference"&gt;175740&lt;/ulink&gt;], [&lt;ulink linkID="322285" linkType="Reference"&gt;322285&lt;/ulink&gt;]. Clinical effects of onabotulinumtoxinA are usually observed within 1 week of injection. The typical duration of symptomatic relief averages 12.5 weeks [&lt;ulink linkID="343345" linkType="Reference"&gt;343345&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Vaginismus&lt;/subtitle&gt;In August 2010, a phase I, non-randomized, single-group assignment, open-label, safety and efficacy trial (&lt;ulink linkID="81490" linkType="Protocol"&gt;NCT01352546&lt;/ulink&gt;; BTX-PV-01) evaluating onabotulinumtoxinA plus  &lt;ulink linkID="48945" linkType="Drug"&gt;bupivacaine&lt;/ulink&gt; injections and progressive dilation under anesthesia began in patients (expected n = 30) in the US with primary vaginismus. The primary endpoint was transition from the use of vaginal dilators to pain free intercourse, or to be able to continue using the number 5 or 6 of 6 dilators in the absence of a partner. In December 2012, the trial was completed  [&lt;ulink linkID="1201025" linkType="Reference"&gt;1201025&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;POST MARKETING STUDY OVERACTIVE BLADDER&lt;/subtitle&gt;In May 2017, pooled data from two randomized, placebo-controlled phase III studies and from a post marketing study were presented at the AUA Annual Meeting 2017 in Boston, MA. Patients (n = 1177) who were treated with onabotulinumtoxin-A (100 U) in treatment 1 and placebo patients who received open-label onabotulinumtoxin-A in treatment-2 were grouped by age (&amp;lt; 40, 40 to 49, 50 to 59, 60 to 69 and &amp;gt;/= 70 years). In the &amp;lt; 40 years group, the clean intermittent catheterization were found to be lowest (1.1%) with duration of 3 days after onabotulinumtoxin-A treatment and slight increase with age was reported (3.2, 5.3, 5.3 and 7.2% in 40 to 49, 50 to 59, 60 to 69 and &amp;gt;/= 70 years groups, respectively). In all groups a robust treatment response including substantial reductions in urinary incontinence (UI)/episodes (-2.4, -2.6, -3.1, -3.6 and -2.9 in &amp;lt; 40 , 40 to 49, 50 to 59, 60 to 69 and &amp;gt;/= 70 years, respectively) and % change in UI (- 60.8, - 50.4, - 62.4, -64.4 and -46.8% in &amp;lt; 40 , 40 to 49, 50 to 59, 60 to 69 and &amp;gt;/= 70 years, respectively) [&lt;ulink linkID="1931206" linkType="Reference"&gt;1931206&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Neurogenic overactive bladder&lt;/subtitle&gt;&lt;subtitle&gt;Phase III&lt;/subtitle&gt;In March 2017, post-hoc analysis was presented at the 32nd Annual EAU Congress in London, UK, of two phase III (&lt;ulink linkID="57014" linkType="Protocol"&gt;NCT00910520&lt;/ulink&gt; and &lt;ulink linkID="95150" linkType="Protocol"&gt;NCT00910845&lt;/ulink&gt;) and one post-marketing trial (&lt;ulink linkID="104569" linkType="Protocol"&gt;NCT01767519&lt;/ulink&gt;) of OBA in patients with OAB to assess the incidence of clean intermittent catheterization (CIC), as well as efficacy and quality-of-life outcomes in various age groups of patients. The rate of CIC was low and within acceptable levels across all age groups at 1.1, 3.2, 5.3, 5.3 and 7.2% in patients aged &amp;lt; 40, 40 to 49, 50 to 59, 60 to 69 and &amp;gt;/= 70, respectively. The mean duration of CIC and mean change in post-void residual urine volume from baseline in the age groups were 3, 44, 88, 78 and 86 days, and 7.7, 14.1, 20.5, 29.7 and 36.5 ml, respectively. OBA treatment also demonstrated efficacy across all age groups [&lt;ulink linkID="1910259" linkType="Reference"&gt;1910259&lt;/ulink&gt;], [&lt;ulink linkID="1911583" linkType="Reference"&gt;1911583&lt;/ulink&gt;]. In May 2017, further clinical data from 1177 patients were presented at the AUA Annual Meeting 2017 in Boston, MA. Patients who were treated with onabotulinumtoxin-A (100 U) in treatment 1 and placebo patients who received open-label onabotulinumtoxin-A in treatment-2 were grouped by age (&amp;lt; 40, 40 to 49, 50 to 59, 60 to 69 and &amp;gt;/= 70 years). In all groups a robust treatment response including substantial reductions in urinary incontinence (UI)/episodes (-2.4, -2.6, -3.1, -3.6 and -2.9 in &amp;lt; 40 , 40 to 49, 50 to 59, 60 to 69 and &amp;gt;/= 70 years, respectively) and % change in UI (- 60.8, - 50.4, - 62.4, -64.4 and -46.8% in &amp;lt; 40 , 40 to 49, 50 to 59, 60 to 69 and &amp;gt;/= 70 years, respectively) [&lt;ulink linkID="1931206" linkType="Reference"&gt;1931206&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 2016, a randomized, double-blind, phase III study (&lt;ulink linkID="267054" linkType="Protocol"&gt;NCT02849418&lt;/ulink&gt;; 204948) to evaluate the efficacy and safety of GSK-1358820 (botulinum toxin type A) in Japanese patients (expected n = 30) with urinary incontinence due to neurogenic detrusor overactivity. The primary endpoint was change from baseline in the daily average number of urinary incontinence episodes at week 6. In April 2017, the study was expected to complete in August 2018 [&lt;ulink linkID="1785344" linkType="Reference"&gt;1785344&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 2015, results from a multicenter, 3.5-year extension study of two phase III trials were presented at the 2015 American Urogynecologic Society Meeting in Seattle, WA. The trial assessed long-term therapy with  onabotulinumtoxinA in female patients (n = 749) with OAB symptoms. A total of 53% of patients completed the trial, and a reduction in urinary incontinence was demonstrated. At week 12, both co-primary endpoints were met, which showed  that the mean reductions from baseline in urinary incontinence episodes/day were consistent among discrete subgroups of female patients who received 1 to 6 treatments. Additionally, a high proportion of patients reporting improvement or great improvement on the Treatment Benefit scale was also observed in the discrete subgroups across all treatments [&lt;ulink linkID="1703603" linkType="Reference"&gt;1703603&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In May 2015, clinical data were presented from a 3-year, prospective, randomized, double-blind, placebo-controlled, multi-center, extension phase III study, at the 110th AUA Annual Meeting in New Orleans, LA. Patients (n = 122) received onabotulinumtoxinA 2000 U only. At years 1, 2, 3 and 4, urinary retention rate was observed in 23, 7, 2 and 3 patients, respectively and urinary tract infection was reported in 39, 28, 24 and 22 patients, respectively [&lt;ulink linkID="1659738" linkType="Reference"&gt;1659738&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In May 2015, final results were presented a multicenter, three-year, extension study in 543 patients at the 110th AUA Annual Meeting in New Orleans, LA. Patients  received multiple intradetrusor onabotulinumtoxinA (100 U) treatments for up to 3.5 years. At week 12, mean reductions in  urinary incontinence episodes/day (co-primary endpoint) after each treatment were consistent in all subgroups, irrespective of the number of treatments needed. No changes were observed in safety profile observed over time [&lt;ulink linkID="1660945" linkType="Reference"&gt;1660945&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2015, clinical data were presneted  from two 24-week, randomized, double-blind, placebo-controlled, phase III trials (NCT00910845 and NCT00910520) and a long-term extension trial (NCT00915525) in 829 patients  with overactive bladder at the 30th EAU Annual Congress in Madrid, Spain. The most commonly reported adverse events included urinary tract infections and urinary retention and no evidence of increasing rates after repeat treatment were reported. Repeated onabotulinumtoxinA treatment consistently reduced the number of urgency episodes per day at week 12 [&lt;ulink linkID="1641236" linkType="Reference"&gt;1641236&lt;/ulink&gt;]. In May 2016, further clinical data were presented at the AUA Annual Meeting 2016 in San Diego, CA. Improvements in Incontinence-quality of life scores were consistently 2 to 3 times MID with most patients achieving/exceeding the MID after onabotulinumtoxinA treatments 1 to 6. New safety signals were not reported [&lt;ulink linkID="1757227" linkType="Reference"&gt;1757227&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2014, data from a large, multicenter extension study of two phase III studies (NCT00311376 or NCT00461292) were presented at the 29th Annual EAU Meeting in Stockholm, Sweden. The number of urinary incontinence (UI) episodes/day was consistently reduced with onabotulinumtoxinA.At week 6, volume/void was consistently increased after onabotulinumtoxinA treatment. Similar results were observed with 300U onabotulinumtoxinA [&lt;ulink linkID="1541981" linkType="Reference"&gt;1541981&lt;/ulink&gt;].  In September 2014,  data from the extension study (&lt;ulink linkID="101741" linkType="Protocol"&gt;NCT00876447&lt;/ulink&gt;) were presented at the Sixth ACTRIMS-ECTRIMS Joint Triennial Congress in Boston, MA, USA. The mean reductions from baseline were -3.6, -3.8, -3.9, -3.9 and -3.9 after treatment with onabotulinumtoxinA, at week 6. The proportion of patients achieving complete continence at week 6 following treatment, ranged from 45.2 to 61.9% with onabotulinumtoxinA. The effects of both the dose groups were similar. Urinary tract infections, urinary retention, nephrolithiasis and dysuria were the adverse events observed in both the treatment groups [&lt;ulink linkID="1589397" linkType="Reference"&gt;1589397&lt;/ulink&gt;]. In October 2014, similar data were presented at the 44th ICS Annual Meeting in Rio de Janeiro, Brazil [&lt;ulink linkID="1613937" linkType="Reference"&gt;1613937&lt;/ulink&gt;]. In March 2015, further clinical data were  presented at the 30th EAU Annual Congress in Madrid, Spain. Overall, 43 and 83 and 17% of patients experienced 100, &amp;gt;/= 50 and &amp;lt; 50% UI reduction after onabotulinumtoxinA treatment. All subsequent linumtoxinA treatments resulted in consistent improvements in I-QOL total scores that were 2 to 3 times greater than the minimally important difference and consistently high proportions of I-QOL responders  [&lt;ulink linkID="1641209" linkType="Reference"&gt;1641209&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2014, data  from two phase III pivotal trials and one three-year, multicenter, extension study in 3088 patients with overactive bladder syndrome and urinary incontinence were presented at the 29th Annual EAU Meeting in Stockholm, Sweden. At week 12 post-treatment, the mean change in daily urgency episodes was -3.3 and -1.23 for onabotulinumtoxinA and placebo, respectively.   In patients with &amp;gt;/= 50% reduction in urgency episodes, consistently greater improvements in king’s health questionnaire  domain scores were observed when compared with patients with &amp;lt; 50% reduction in urgency episodes [&lt;ulink linkID="1541584" linkType="Reference"&gt;1541584&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In  August 2013, data from  pooled analysis of two phase III, double-blind, placebo-controlled, randomized studies were presented at the 43rd ICS Annual Scientific Meeting in Barcelona, Spain. Clinically meaningful improvements in mean overall total incontinence health-related quality of life (QOL) scores were observed from baseline in both multiple sclerosis and spinal cord injury subpopulation. During treatment cycles 1 and 2, the increased incontinence QOL score were 26.2 and 29.9, respectively [&lt;ulink linkID="1465492" linkType="Reference"&gt;1465492&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In May 2012, clinical data were presented at the Annual Meeting of the American Urological Association, in Atlanta, GA. In an interim analysis of the long-term extension phase of  two phase III studies, urinary incontinence episodes were significantly reduced by 22.7, 23.3, 23.1, 25.3 and 31.9 in patients receiving the toxin (300U) in treatment cycles one to five. The majority of patients achieved at least 50% reduction from baseline in UI episodes and there were consistent increases in the mean volume per void at week 6 in each treatment cycle. The drug was safe and well tolerated [&lt;ulink linkID="1286942" linkType="Reference"&gt;1286942&lt;/ulink&gt;]. Further data, it is presuemd from this extension study were reported  at the 108th Annual AUA Meeting in San Diego, CA. Repeated treatment resulted in consistent efficacy without new safety signals. Up to 7 injections of onabotulinumtoxinA were administered, resulting in consistent reductions in urge incontinence episodes across all injections. Voided volume also increased after onabotulinumtoxinA injection. Time to a request for a further dose was maintained at a median of 9.5 months with the 200-IU dose [&lt;ulink linkID="1414174" linkType="Reference"&gt;1414174&lt;/ulink&gt;], [&lt;ulink linkID="1417601" linkType="Reference"&gt;1417601&lt;/ulink&gt;]. In August 2013,   further data (&lt;ulink linkID="57672" linkType="Protocol"&gt;NCT00915525&lt;/ulink&gt;) were presented at the 43rd ICS Annual Scientific Meeting in Barcelona, Spain. At week 12, the proportions of patients with &amp;gt;/= 50% reduction in UI episodes/day were 68.2, 68.5, 65.2, 54.8 and 58.3% during treatment cycles 1, 2, 3, 4 and 5, respectively.  During treatment cycles 1, 2, 3, 4 and 5, the respective percentages of patients who exceeded the minimal important difference (MID) 3 of a &amp;gt;/=10-point increase in incontinence quality of life total summary scores from baseline were 68.9, 73.2, 71.4, 61.9 and 62.9% [&lt;ulink linkID="1471035" linkType="Reference"&gt;1471035&lt;/ulink&gt;]. In October 2013, interim data from a cohort multiple sclerosis patients with urinary incontinence (UI) due to neurogenic detrusor overactivity (n = 230) were presented at the 29th ECTRIMS Congress in Copenhagen, Denmark. After five cycles of therapy, the mean UI episodes were reduced by 4.3 and 4.7 in the 200- and 300-U groups, respectively. After the first cycle, de novo clean intermittent catheterization rates were found to be higher which decreased thereafter. The 200-U dose was determined to be the recommended dose [&lt;ulink linkID="1482373" linkType="Reference"&gt;1482373&lt;/ulink&gt;]. In May 2014, further data were presented at the 109th AUA Meeting in Orlando, FL. At week 12, the numbers of urinary incontinence (UI) episodes/day were consistently decreased by onabotulinumtoxinA. I-QOL total summary score, and KHQ RL and SL domain score improvements were maintained across all onabotulinumtoxinA treatment cycles. For I-QOL and KHQ this corresponded to a &amp;gt;/= 2.5-fold and a &amp;gt;/= 3-fold change over minimally important differences. The median time to request for retreatment was 24.0, 31.6, 27.9, 24.3 and 23.9 weeks for cycles 1, 2, 3, 4 and 5, respectively. The duration of effect for onabotulinumtoxinA was considered to be consistent. No change in adverse events profile was observed over time for repeated onabotulinumtoxinA treatment. In treatment cycles 1 to 5 of onabotulinumtoxinA (1000 U), clear intermittent catheterization was required by 4.6, 4.0, 4.3, 4.6 and 2.9% of patients [&lt;ulink linkID="1555003" linkType="Reference"&gt;1555003&lt;/ulink&gt;], [&lt;ulink linkID="1558848" linkType="Reference"&gt;1558848&lt;/ulink&gt;]. In October 2015, further clinical data were presented at the 45th annual meeting of the International Continence Society in Montreal, Canada. A consistent response with repeat treatment was seen in the overall population; at week 12 following onabotulinumtoxin A 100 U treatment, mean decreases of urinary incontinence (UI) episodes/day from baseline were -3.3, -3.6, -3.8, -3.5, -3.3, and -3.1 UI episodes/day for treatments 1 to 6, respectively. Overall, long-term onabotulinumtoxin A demonstrated consistent and sustained improvements in UI in patients with OAB, with a median duration of effect &amp;gt; 6 months in about two-thirds of patients and &amp;gt; 12 months in almost one-third of patients. Onabotulinumtoxin A was well tolerated, with no new safety signals [&lt;ulink linkID="1724107" linkType="Reference"&gt;1724107&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In August 2011, data from the phase III DIGNITY program , which consisted of two pivotal trials (&lt;ulink linkID="43778" linkType="Protocol"&gt;NCT00461292&lt;/ulink&gt; and &lt;ulink linkID="43776" linkType="Protocol"&gt;NCT00311376&lt;/ulink&gt;) were reported at the ICS 2011 meeting in Glasgow, UK. The program included approximately 700 patients with spinal cord injury or multiple sclerosis who were not adequately managed with at least one anticholinergic therapy. Treatment with onabotulinumtoxinA (200 or 300 units) was effective after 2 weeks and lasted for approximately 8 to 10 months. Patients treated with 200 units experienced a reduction in wetting episodes/week by week 6 of 21.3, compared with a reduction of 10.5 episodes/week for the placebo group. A total of 37% of patients treated with 200 units were completely dry throughout week 6, compared with 9% of patients receiving placebo. In addition, patients treated with onabotulinumtoxinA experienced improvements in quality of life [&lt;ulink linkID="1220988" linkType="Reference"&gt;1220988&lt;/ulink&gt;], [&lt;ulink linkID="1220989" linkType="Reference"&gt;1220989&lt;/ulink&gt;], [&lt;ulink linkID="1213289" linkType="Reference"&gt;1213289&lt;/ulink&gt;]. In February 2012, data from two pivotal trials (191622-515; 191622-516) were presented at the 27th European Association of Urology Meeting in Paris, France. At week 6, in anticholinergic users and non-users, reductions in mean weekly urinary incontinence (UI) episodes were -20.3 and -22.5 in the onabotulinumtoxinA 200-unit group, and -21 and -21.7 in the onabotulinumtoxinA 300-unit group, respectively (primary endpoint). Reduction in UI episodes &amp;gt;/=50% were achieved by similar percentage of patients in the onabotulinumtoxinA 200- and 300-unit groups at week 6 regardless of anticholinergic use. Compared with placebo, significant increases in maximum cystometric capacity and a significant decrease in maximum detrusor pressure during first intradetrusor contraction were observed in both the onabotulinumtoxinA groups at week 6 regardless of anticholinergic use. In the placebo, onabotulinumtoxinA 200 and 300-unit groups, the median time to patient request for re-treatment was 14, 38 and 42 weeks, respectively, in anticholinergic users, and 13, 38 and 36 weeks, respectively, in non-users. OnabotulinumtoxinA was well tolerated at both doses, regardless of anticholinergic use [&lt;ulink linkID="1270395" linkType="Reference"&gt;1270395&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By March 2009, onabotulinumtoxinA was listed as being in phase III trials for neurogenic OAB [&lt;ulink linkID="989200" linkType="Reference"&gt;989200&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In May 2007, a double-blind, parallel assignment, randomized safety and efficacy phase III trial (&lt;ulink linkID="43778" linkType="Protocol"&gt;NCT00461292&lt;/ulink&gt;; 191622-516) was initiated in subjects (expected n = 261) with neurogenic OAB in the US. The subjects were to receive an injection into detrusor of either placebo or onabotulinumtoxinA (200 or 300 U) on day 1, followed by onabotulinumtoxinA (200 or 300 U) at &amp;gt; 12 weeks intervals. The primary endpoint was to establish the number of urinary incontinence episodes. The study was expected to be completed in September 2010 and was still recruiting in December 2008. The study completed in September 2010 [&lt;ulink linkID="990412" linkType="Reference"&gt;990412&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In August 2006, a double-blind, placebo-controlled, parallel assignment, randomized safety and efficacy phase III trial (NCT00311376l; 191622-515) was initiated in subjects (expected n = 405) with neurogenic OAB in the US. The subjects were to receive placebo or onabotulinumtoxinA (200 or 300 U) followed by onabotulinumtoxinA (200 or 300 U) at &amp;gt; 12 weeks intervals. The primary endpoint was to establish the number of urinary incontinence (UI) episodes. The study was expected to be completed in September 2010 and was still recruiting in September 2008 [&lt;ulink linkID="990453" linkType="Reference"&gt;990453&lt;/ulink&gt;]. In May 2011, data from this phase III trial were presented at the 106th AUA meeting in Washington DC. From the 413 enrolled patients, UI episodes were significantly reduced in the 200 U and 300 U groups, compared with the placebo group. Both doses of onabotulinumtoxinA were well tolerated [&lt;ulink linkID="1190098" linkType="Reference"&gt;1190098&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By August 2006, phase III trials had been initiated [&lt;ulink linkID="869019" linkType="Reference"&gt;869019&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase II&lt;/subtitle&gt;In December 2007, a double-blind, efficacy, parallel assignment, placebo-controlled randomized phase II trial (&lt;ulink linkID="43779" linkType="Protocol"&gt;NCT00575016&lt;/ulink&gt;; 191622-518) was initiated in subjects (expected n = 160) with neurogenic OAB in Serbia. The subjects were to receive injections into the detrusor of either placebo or onabotulinumtoxinA (50, 100 or 200 U) on day 1 followed by onabotulinumtoxinA (200 U) at &amp;gt; 12 weeks intervals. The primary endpoint was to establish the number of urinary incontinence episodes. The study was expected to be completed in June 2010 and was still recruiting in November 2008 [&lt;ulink linkID="990398" linkType="Reference"&gt;990398&lt;/ulink&gt;]. Results were reported in August/September 2011at the ICS 2011 meeting in Glasgow, UK. A significant linear dose response in decrease from baseline in weekly UI episodes was observed; consistent high decrease from baseline was observed in the onabotulinumtoxinA 200U dose group. At week 6, the proportion of dry patients was highest in the 200 U dose group. In both the 100 and 200 U dose groups [&lt;ulink linkID="1220974" linkType="Reference"&gt;1220974&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2005, a randomized, double-blind, placebo-controlled, parallel assignment, phase II trial (&lt;ulink linkID="7090" linkType="Protocol"&gt;NCT00168454&lt;/ulink&gt;; 191622-077) was initiated in subjects (expected n = 270) with  OAB in the US. The subjects were to receive one of five doses of iv onabotulinumtoxinA (50, 100, 150, 200 or  300 U) or placebo, injected into the detrusor muscle of the bladder on day 1. The primary endpoint was the number of incontinence episodes    over a 12-week  period. The study was still recruiting in December 2007 and completion was expected in December 2008 [&lt;ulink linkID="869018" linkType="Reference"&gt;869018&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In May 2005, clinical data on onabotulinumtoxinA were presented at the 2005 American Urological Association annual meeting in San Antonio, TX. The 26-week, double-blind, parallel-group study was conducted at eight centers in Belgium, France and Switzerland. A total of 59 patients with neurogenic OAB and incontinence secondary to spinal cord injury or multiple sclerosis were randomized to receive either onabotulinumtoxinA (200 U and 300 U) or placebo. Mean reductions in daily episodes of urinary incontinence ranged from 32 to 54% and 42 to 58% in the 200 U and 300 U groups, respectively. This effect was absent in placebo-treated patients. OnabotulinumtoxinA was safe and well tolerated [&lt;ulink linkID="603641" linkType="Reference"&gt;603641&lt;/ulink&gt;]. In January 2005, similar results were published [&lt;ulink linkID="610840" linkType="Reference"&gt;610840&lt;/ulink&gt;], [&lt;ulink linkID="610837" linkType="Reference"&gt;610837&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In early 2004, an IND filing was planned for OAB [&lt;ulink linkID="562127" linkType="Reference"&gt;562127&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Idiopathic overactive bladder&lt;/subtitle&gt;&lt;subtitle&gt;Phase III&lt;/subtitle&gt;In August 2018, parallel-assignment, double-blind, randomized, phase III trial (&lt;ulink linkID="264967" linkType="Protocol"&gt;NCT02820844&lt;/ulink&gt;; 204947) was initiated in Japan to assess onabotulinumtoxinA in patients with OAB (expected n = 250). The primary endpoint was change from baseline in the daily average number of urinary incontinence episodes at week 12. The trial was expected to complete in November 2018 [&lt;ulink linkID="2058475" linkType="Reference"&gt;2058475&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In May 2016, a phase III trial in OAB was initiated in Japan [&lt;ulink linkID="1765575" linkType="Reference"&gt;1765575&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2016, data from a multicenter, double-blind study (&lt;ulink linkID="87530" linkType="Protocol"&gt;NCT01600716&lt;/ulink&gt;) for the treatment of urinary incontinence  due to neurogenic detrusor overactivity in patients (n = 144) with non-catheterising multiple sclerosis were presented at the 31st EAU Congress in Munich, Germany. Patients were randomized (1:1) to receive nabotulinumtoxinA (100 U) or placebo as 30 intradetrusor injections (each 1 ml) by cystoscopy. The mean change from baseline in daily UI episodes at weeks 2, 6 and 12 were -1.2 and -2.9 UI episodes/day, -1.1 and -3.3 UI episodes/day, -1.1 and -2.8 UI episodes/day for onabotulinumtoxinA and placebo groups, respectively. At weeks 2, 6 and 12, onabotulinumtoxinA significantly reduced UI episodes compared with placebo. At week 6, the proportion of patients who achieved &amp;gt;/= 50% and 100% reduction in UI episodes were 80.3 and 35.9%, 53 and 10.3% in onabotulinumtoxinA and placebo groups, respectively [&lt;ulink linkID="1743872" linkType="Reference"&gt;1743872&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2016, clinical data from a multicenter, randomized, double-blind, placebo-controlled, phase IIIb study (&lt;ulink linkID="104569" linkType="Protocol"&gt;NCT01767519&lt;/ulink&gt;) which evaluated the efficacy and safety of onabotulinumtoxin A (Botox) or solifenacin in solifenacin-naïve patients (n = 356) with idiopathic overactive bladder and urinary incontinence (UI) were presented at the 31st EAU Congress in Munich, Germany. Patients were randomized (2: 2: 1) to onabotulinumtoxin A 100U/placebo, solifenacin 5/10 mg/placebo injection or double-blind placebo. At week 12, both drugs significantly reduced daily UI episodes compared with placebo. Significantly higher proportion of patients treated with both drugs achieved 100 and &amp;gt;/= 50% reductions in daily UI episodes compared with placebo [&lt;ulink linkID="1743889" linkType="Reference"&gt;1743889&lt;/ulink&gt;]. In May 2016, further clinical data were presented at the AUA Annual Meeting 2016 in San Diego, CA. Percent reductions in UI episodes from baseline was significantly greater with onabotulinumtoxinA compared solifenacin or placebo. UI episodes reductions were 100% in 33.8, 24.5 and 11.7% of onabotulinumtoxinA-, solifenacin- and placebo-treated patients in treatment-1, respectively, while 43.2, 37.6 and 41.9% of onabotulinumtoxinA/onabotulinumtoxinA-, solifenacin /onabotulinumtoxinA- and placebo/onabotulinumtoxinA-treated patients in treatment-2, respectively. Discontinuations due to lack of efficacy and adverse events were low [&lt;ulink linkID="1757206" linkType="Reference"&gt;1757206&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In May 2015, final results were presented a multicenter, three-year, extension study in 543 patients at the 110th AUA Annual Meeting in New Orleans, LA. Patients  received multiple intradetrusor onabotulinumtoxinA (100 U) treatments for up to 3.5 years. At week 12, mean reductions in  urinary incontinence episodes/day (co-primary endpoint) after each treatment were consistent in all subgroups, irrespective of the number of treatments needed. No changes were observed in safety profile observed over time [&lt;ulink linkID="1660945" linkType="Reference"&gt;1660945&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2015, clinical data were presneted  from two 24-week, randomized, double-blind, placebo-controlled, phase III trials (NCT00910845 and NCT00910520) and a long-term extension trial (NCT00915525) in 829 patients  with overactive bladder at the 30th EAU Annual Congress in Madrid, Spain. The most commonly reported adverse events included urinary tract infections and urinary retention and no evidence of increasing rates after repeat treatment were reported. Repeated onabotulinumtoxinA treatment consistently reduced the number of urgency episodes per day at week 12 [&lt;ulink linkID="1641236" linkType="Reference"&gt;1641236&lt;/ulink&gt;]. In May 2016, further clinical data were presented at the AUA Annual Meeting 2016 in San Diego, CA. Improvements in Incontinence-quality of life scores were consistently 2 to 3 times MID with most patients achieving/exceeding the MID after onabotulinumtoxinA treatments 1 to 6. New safety signals were not reported [&lt;ulink linkID="1757227" linkType="Reference"&gt;1757227&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In May 2014,  data from a 3-year long-term extension study  to the already completed two phase III studies,  were presented at the 109th AUA Meeting in Orlando, FL. A total 0f 338 patients weere included. The median duration of the effect of onabotulinumtoxinA (200U) was 36.2 weeks. Reductions in urinary incontinence (UI; -3.2 to -4.1 episodes/day), and the proportions of patients with &amp;gt;/= 50 (83 to 91%) and 100% (28 to 56%) reductions in UI, were consistent over four years. Incontinence quality-of-life total scores increased consistently. Efficacy results in the 300U onabotulinumtoxinA groups were similar [&lt;ulink linkID="1555190" linkType="Reference"&gt;1555190&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In August 2013,  pre-planned pooled data from two phase III, randomized, double-blind, placebo-controlled studies  (&lt;ulink linkID="95150" linkType="Protocol"&gt;NCT00910845&lt;/ulink&gt; and &lt;ulink linkID="57014" linkType="Protocol"&gt;NCT00910520&lt;/ulink&gt;)  were presented at the 43rd ICS Annual Scientific Meeting in Barcelona, Spain. In the intent-to-treat population (n = 1105), the reductions in mean number of daily UI episodes from baseline to week 12  and the proportion of patients achieving a positive response on the treatment benefit scale (co-primary endpoints) were significantly greater in the onabotulinumtoxinA arm versus the placebo arm. A significant increase in the volume voided/micturition was observed with onabotulinumtoxinA  versus placebo  [&lt;ulink linkID="1465493" linkType="Reference"&gt;1465493&lt;/ulink&gt;]. In April 2014, further data were presented at the 29th Annual EAU Meeting in Stockholm, Sweden.  Improvements in incontinence quality of life  total score and king's health questionnaire domain scores of role limitations, social limitations, physical limitations, and incontinence impact were also similar with onabotulinumtoxinA, regardless of clean intermittent catheterization use and urinary tract infection  status [&lt;ulink linkID="1541604" linkType="Reference"&gt;1541604&lt;/ulink&gt;]. In May 2014, further data were presented at the 109th AUA Meeting in Orlando, FL. At week 12, onabotulinumtoxinA showed significantly greater reduction in UI episodes/day in patients &amp;lt; 65 and &amp;gt;/= 65 years of age, when compared with placebo. A positive response on treatment benefit scale was shown by a significantly higher proportion of patients in the onabotulinumtoxinA group. The proportion of patients with post-void residual &amp;gt;/= 200 ml and those using clean intermittent catheterization was greater in the onabotulinumtoxinA group. A positive treatment benefit scale (TBS) response was seen in 61.7 and 28% of the patients who did not use clean intermittent catheterization (CIC), in the onabotulinumtoxinA and placebo groups, respectively. In patients, who initiated CIC within the first 12 weeks of onabotulinumtoxinA treatment, a positive TBS response was seen in 62.9% of the patients. A greater reduction in daily urinary continence episodes was seen with onabotulinumtoxinA treatment when compared with placebo; regardless of urinary tract infection (UTI) status, the treatment effect was similar  [&lt;ulink linkID="1555184" linkType="Reference"&gt;1555184&lt;/ulink&gt;], [&lt;ulink linkID="1563947" linkType="Reference"&gt;1563947&lt;/ulink&gt;]. In October 2014, similar data were presented at the  44th ICS Annual Meeting in Rio de Janeiro, Brazil [&lt;ulink linkID="1613931" linkType="Reference"&gt;1613931&lt;/ulink&gt;]. In March 2015, further clinical data were  presented at the  30th EAU Annual Congress in Madrid, Spain. Overall, 60.5 and 27.1% of patients receiving onabotulinumtoxinA achieved &amp;gt;/= 50 and 100% reduction in daily urinary incontinence episodes, respectively, when compared with 31.0 and 8.4% placebo recipients, respectively [&lt;ulink linkID="1641235" linkType="Reference"&gt;1641235&lt;/ulink&gt;]. In October 2015, further clinical data were presented at the 45th annual meeting of the International Continence Society in Montreal, Canada. Onabotulinumtoxin A demonstrated significantly greater decreases in nocturia episodes/night (-0.88 versus -0.52 for placebo), &amp;gt;/= 1 nocturia episode(s)/night (51.1 versus 36.4% for placebo) and &amp;gt;/= 33% reduction in nocturia episodes/night (46.5 versus 31.8% for placebo). Overall, onabotulinumtoxin A treatment significantly reduced nocturnal voids and resulted in clinically meaningful quality of life improvements in OAB patients with nocturia and was well-tolerated with an acceptable safety profile [&lt;ulink linkID="1724106" linkType="Reference"&gt;1724106&lt;/ulink&gt;]. Further pooled clinical data from the post hoc pooled analysis were presented at the same conference. For the &amp;lt;/= 2, &amp;gt; 2 to &amp;lt;/= 5 and &amp;gt; 5 baseline urinary incontinence (UI) subgroups, onabotulinumtoxin A resulted in significantly greater reductions in UI versus placebo (-0.7 versus +0.1, -1.9 versus -0.7 and -4.5 versus -1.5 episodes/day) and 100% UI reduction (41.4 versus 20.2%; 31.2 versus 9.2% and 17.5 versus 3.3% in the &amp;lt;/= 2, &amp;gt; 2 to &amp;lt;/= 5 and &amp;gt; 5 UI subgroups). . Improvements in incontinence-quality of life total score with onabotulinumtoxin A were consistently 1.5 to 2 times the minimally important difference and significantly greater compared with placebo in all subgroups (19.4 versus 7.8 for &amp;lt;/= 2; 24.4 versus 6.6 for &amp;gt; 2 to &amp;lt;/= 5 and 22.0 versus 6.1 for &amp;gt; 5 UI subgroups. Overall, onabotulinumtoxin A significantly improves UI and QOL in OAB patients regardless of incontinence severity at baseline [&lt;ulink linkID="1724108" linkType="Reference"&gt;1724108&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In May  2013, meta analyses of two phase III studies were presented at the 38th Annual IUGA Meeting in Dublin, Ireland. Overall, treatment with onabotulinumtoxinA results in gains in the quality of life of women with idiopathic overactive bladder [&lt;ulink linkID="1433034" linkType="Reference"&gt;1433034&lt;/ulink&gt;], [&lt;ulink linkID="1433067" linkType="Reference"&gt;1433067&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2013, clinical data were presented at the 28th Annual EAU Meeting in Milan, Italy. In a phase III randomized, double-blind, placebo-controlled trial (&lt;ulink linkID="57014" linkType="Protocol"&gt;NCT00910520&lt;/ulink&gt;), patients (n = 548) with idiopatic overactive bladder received onabotulinumtoxinA (100 U) or placebo. The toxin was associated with a significantly greater improvements in the health-related quality of life compared with placebo. It was also assiciated with greater benefit over placebo across all domain scores, including role limitations, social limitations, physical limitations, personal relationships, emotions, sleep/energy, severity/coping measures, general health perception and incontinence impact [&lt;ulink linkID="1392825" linkType="Reference"&gt;1392825&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In March 2012, topline data from two phase III studies for idiopathic OAB were reported. OnabotulinumtoxinA significantly reduced urinary incontinence episodes in patients with urinary incontinence that had not been adequately treated by an anticholinergic therapy, compared with placebo. In addition, onabotulinumtoxinA patients reported an improvement in quality of life [&lt;ulink linkID="1275598" linkType="Reference"&gt;1275598&lt;/ulink&gt;]. In October 2012, clinical data were presented at the 42nd ICS Annual Scientific Meeting in Beijing, China. OnabotulinumtoxinA was associated with reductions in micturition frequency, urgency frequency and nocturia. There was also a progressive increase in the voided volume per micturition, to a maximum increase of 43% [&lt;ulink linkID="1333093" linkType="Reference"&gt;1333093&lt;/ulink&gt;], [&lt;ulink linkID="1333196" linkType="Reference"&gt;1333196&lt;/ulink&gt;]. Further data from the two phase III studies were reported in January 2013. In both studies, a &amp;gt;/= 50% reduction in   the frequency of daily urinary incontinence episodes from baseline  was observed at week 12 for onabotulinumtoxin-treated patients compared with placebo. In addition, in the two studies, 22.9 and 31.4% of onabotulinumtoxin-treated patients achieved complete continence, compared with 6.5 and 10.3% of placebo-treated patients at week 12  [&lt;ulink linkID="1358320" linkType="Reference"&gt;1358320&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase II&lt;/subtitle&gt;In October 2017, a multicenter, randomized, double-blind, placebo-controlled, single-treatment, 2-stage,  parallel assigned, dose-finding, phase II trial (&lt;ulink linkID="317280" linkType="Protocol"&gt;NCT03320850&lt;/ulink&gt;; APOLLO; 1839-201-021) was initiated in the US, in patients (n = 335) with overactive bladder and urinary incontinence, to assess the safety and efficacy of intravesical onabotulinumtoxinA. At that time, the trial was expected to complete in March 2020 [&lt;ulink linkID="1984376" linkType="Reference"&gt;1984376&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By March 2009, onabotulinumtoxinA was listed as being in phase II trials for idiopathic OAB [&lt;ulink linkID="989200" linkType="Reference"&gt;989200&lt;/ulink&gt;]. In June 2009, data on onabotulinumtoxinA were published. In stage 1 of the study, subjects (n =  22) were randomized to receive  onabotulinumtoxinA or placebo. OnabotulinumtoxinA significantly reduced urge urinary incontinence due to overactive bladder at 6 weeks. At that time, stage 2 of the study was ongoing [&lt;ulink linkID="1044728" linkType="Reference"&gt;1044728&lt;/ulink&gt;]. Recruitment was ongoing in February 2010 [&lt;ulink linkID="1073300" linkType="Reference"&gt;1073300&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In May 2007, results from a randomized, double-blind study evaluating onabotulinumtoxinA as a treatment for idiopathic detrusor overactivity (IDO) in patients with symptoms of OAB were announced; the data were to be published in June 2007. Patients (n = 34) received either onabotulinumtoxinA 200 U or placebo and were assessed at weeks 4 and 12 post-injection; the study was unblinded at week 12 and onabotulinumtoxinA patients were monitored until week 24. At 4 weeks onabotulinumtoxinA increased maximum cystometric capacity (MCC), a measure of urinary bladder capacity, by approximately 72% and at 12 weeks by approximately 45%, compared to baseline; placebo decreased MCC by 15% at both time points [&lt;ulink linkID="794828" linkType="Reference"&gt;794828&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Osteoarthritis pain&lt;/subtitle&gt;In September 2014, a randomized, double-blind, placebo-controlled, phase II trial (&lt;ulink linkID="209503" linkType="Protocol"&gt;NCT02230956&lt;/ulink&gt;; 191622-145; 2014-001076-58) began in the US, Denmark and Czechia to assess the efficacy and safety of two single intra-articular injections of onabotulinumtoxinA in patients (expected n = 160) with knee osteoarthritis. The primary endpoint was the change from baseline in the 7-day average daily pain score using an 11-point scale. The trial was completed in March 2016. In April 2017, data were reported  from 158 patients who completed the study.  The changes from baseline in the 7-day average daily pain score using an 11-point scale were -1.68, -2.07 and -1.98 for onabotulinumtoxinA 400 U, onabotulinumtoxinA 200U and placebo, respectively [&lt;ulink linkID="1632449" linkType="Reference"&gt;1632449&lt;/ulink&gt;]. In May 2018, these data  were published. Additional data showed that  the reductions in the daily average pain scores were sustained throughout the follow-up for 24 weeks post-treatment, with no significant differences between the onabotulinumtoxinA and placebo groups [&lt;ulink linkID="2089553" linkType="Reference"&gt;2089553&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In January 2012, a phase I/II, randomized, double-blind, parallel-group, placebo-controlled trial (&lt;ulink linkID="84335" linkType="Protocol"&gt;NCT01518257&lt;/ulink&gt;; 191622-102) began in Denmark to evaluate the efficacy and safety of onabotulinumtoxinA in patients (n = 121) osteoarthritis knee pain. The primary endpoint was the change from baseline in daily worst pain score. In January 2013, the trial was completed. In August 2014, data were reported. The mean changes from baseline in the average daily worst pain intensity score at week 4, 8 and 12 using an 11-point scale were -1.8, -2.2 and -2.2 versus -1.8, -2.3 and -2.5 for onabotulinumtoxinA 200U and placebo, respectively [&lt;ulink linkID="1552552" linkType="Reference"&gt;1552552&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Pain&lt;/subtitle&gt;In May 2005, a randomized, double-blind, active control, parallel assignment, phase III trial (&lt;ulink linkID="13023" linkType="Protocol"&gt;NCT00496964&lt;/ulink&gt;; PT_PMR_3700) was initiated in subjects (expected n = 20) with patellofemoral pain in the US. The subjects were to receive either a placebo injection or a onabotulinumtoxinA injection into the vastus lateralis muscle. The primary endpoint was to establish whether injection of onabotulinumtoxinA reduced knee pain. In July 2007, the study was still recruiting [&lt;ulink linkID="812645" linkType="Reference"&gt;812645&lt;/ulink&gt;]. However this trial had been terminated by June 2009 due to insufficient recruitment [&lt;ulink linkID="1022126" linkType="Reference"&gt;1022126&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In July 2004, a phase III trial (&lt;ulink linkID="12946" linkType="Protocol"&gt;NCT00211718&lt;/ulink&gt;) in shoulder joint pain was initiated. Expected enrollment was 40, and the trial was expected to complete in June 2007 [&lt;ulink linkID="1022128" linkType="Reference"&gt;1022128&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In 1999, a phase III trial was initiated in the US and Europe for the treatment of back pain [&lt;ulink linkID="376356" linkType="Reference"&gt;376356&lt;/ulink&gt;] [&lt;ulink linkID="365728" linkType="Reference"&gt;365728&lt;/ulink&gt;]. Preliminary analysis of two phase III studies of onabotulinumtoxinA in back pain showed that the product did not achieve the prospectively defined benefit. By 2Q00, an additional study was ongoing in this area [&lt;ulink linkID="376356" linkType="Reference"&gt;376356&lt;/ulink&gt;], and by July 2002, onabotulinumtoxinA was in phase III trials for lower back pain [&lt;ulink linkID="462767" linkType="Reference"&gt;462767&lt;/ulink&gt;].  However, no further development has been reported in back pain.&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Pain and muscle spasm&lt;/subtitle&gt;In a clinical study discussed at the 51st Annual Meeting of the American Society of Anesthesiologists in 2000, onabotulinumtoxinA (100 U) was used to treat 9 of 19 patients with myoneural syndrome and/or lumbar radiculitis. Over a 1-year study period, the control group worsened, whilst the treated group experienced less pain and muscle spasm, as well as a greater range of motion [&lt;ulink linkID="387628" linkType="Reference"&gt;387628&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Non-migraine headaches&lt;/subtitle&gt;By early 2000, an IND had been filed in the US and several European countries for the treatment of chronic tension-type headache. Enrollment was expected to begin during 2000 [&lt;ulink linkID="322285" linkType="Reference"&gt;322285&lt;/ulink&gt;], [&lt;ulink linkID="365728" linkType="Reference"&gt;365728&lt;/ulink&gt;]. In early 2004, phase I/II trials were ongoing for headache [&lt;ulink linkID="562127" linkType="Reference"&gt;562127&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In September 2000, at the Headache World 2000 meeting in London, UK, evidence was provided to show that onabotulinumtoxinA was safe for the treatment of chronic daily headache and reduced both frequency and severity compared to placebo [&lt;ulink linkID="382729" linkType="Reference"&gt;382729&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Migraine&lt;/subtitle&gt;&lt;subtitle&gt;Phase III&lt;/subtitle&gt;In May 2015, clinical data were presented from two long-term, multicenter, open-label (COMPEL, NCT01516892) and double-blind (PREEMPT, NCT00156910 and NCT00168428) studies in 1401 patients at the 17th International Headache Society Congress in Valencia, Spain. Patients received onabotulinumtoxinA (155 units, q12w) for 24 weeks. In COMPEL and PREEMPT studies, reductions in headache days (primary endpoint; -7.6 versus -8.4 days, respectively); change in moderate/severe headache days (secondary endpoint; -6.7 versus -7.7 days, respectively) and headache impact test 6 scores (-5.4 versus -4.8 points, respectively) showed improvements at week 24 [&lt;ulink linkID="1682577" linkType="Reference"&gt;1682577&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In July 2010, clinical data from the phase III PREEMPT program were reported. PREEMPT evaluated the safety and efficacy of onabotulinumtoxinA prophylaxis for headache in patients ( n = 1384) with chronic migraine. Data revealed that at week 24 post-double blinded treatment, patients who received onabotulinumtoxinA experienced significantly fewer migraine days (mean: 8.2 days) compared to a mean of 6.2 days for patients treated with placebo. In addition,  at week 24, 47.1 and 35.1% of onabotulinumtoxinA- and placebo-treated patients  had achieved greater than or equal to 50% reduction from baseline in the number of headache days; at week 56, about 70% of onabotulinumtoxinA treated patients experienced greater than or equal to 50% reduction from baseline in migraine days. Significant improvements in patients functioning, vitality, psychological distress, and overall quality of life were also observed for the onabotulinumtoxinA treated patients [&lt;ulink linkID="1115291" linkType="Reference"&gt;1115291&lt;/ulink&gt;]. In May 2019, exploratory pooled analysis data was presented at 71st AAN Annual Meeting in Philadelphia, PA. From baseline to at the week-24 and at the end of the open-label period, mean headache was significantly decreased with onabotulinumtoxinA compared to placebo. One week after the first treatment, headache and migraine was reduced with the treatment of onabotulinumtoxinA versus placebo. Reduction in headache and migraine was persisted from week 3 of the first treatment cycle over 5 treatment cycles [&lt;ulink linkID="2143264" linkType="Reference"&gt;2143264&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In January 2006, two parallel, randomized, placebo controlled phase III trials (&lt;ulink linkID="13938" linkType="Protocol"&gt;NCT00156910&lt;/ulink&gt; in North America  and &lt;ulink linkID="13940" linkType="Protocol"&gt;NCT00168428&lt;/ulink&gt; in the US) were initiated in subjects (expected n = 650 for each) with frequent migraine, experiencing at least 15 headache-days/month. The primary endpoint measure in both studies  was frequency of headache episodes  [&lt;ulink linkID="887174" linkType="Reference"&gt;887174&lt;/ulink&gt;], [&lt;ulink linkID="887198" linkType="Reference"&gt;887198&lt;/ulink&gt;]. Topline data were released in September 2008. In the first trial, both onabotulinumtoxinA and placebo produced a significant improvement in the number of headache episodes from baseline, however, there was no significant difference between the two. OnabotulinumtoxinA did produce a significantly greater decrease in the number of headache days in a 28-day time period preceding the 24 week endpoint than placebo. The primary endpoint in the second study was therefore changed to number of headache days. In the second study, onabotulinumtoxinA demonstrated a significantly greater decrease in both number of headache days and number of headache episodes than placebo [&lt;ulink linkID="942507" linkType="Reference"&gt;942507&lt;/ulink&gt;]. In September 2009, data were due to be presented at the  14th International Headache Congress in Philadelphia, PA later that month  [&lt;ulink linkID="1061831" linkType="Reference"&gt;1061831&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase II&lt;/subtitle&gt;In June 2006, results were reported at the 48th Annual Meeting of the American Headache Society in Los Angeles, CA. In the randomized, placebo-controlled, double-blind study 36 patients who had discontinued or limited their use of acute pain medications during a a 4-week baseline phase received either one treatment of onabotulinumtoxinA or placebo. Migraine days declined by 26.9% in patients treated with onabotulinumtoxinA injections, compared to an increase of 6% in the control group. In addition, 38.8% of patients treated with onabotulinumtoxinA had a 50% or greater reduction in migraine days, compared to 11% for placebo-treated patients. Use of pain medication fell by 25.5% in the onabotulinumtoxinA arm and rose by 0.9% in the placebo arm. OnabotulinumtoxinA was well tolerated [&lt;ulink linkID="675261" linkType="Reference"&gt;675261&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2005, onabotulinumtoxinA failed to meet its primary endpoint of the number of headache-free days in a phase II trial in migraine patients with chronic daily headache. However, the drug did reduce the number of headaches and the frequency of headache-days, especially in patients not taking other prophylactic medications. These patients also reported a decrease in the use of acute headache medication. In the phase II study, 355 patients received three treatments with onabotulinumtoxinA 105 to 260 units, or placebo every 90 days for 9 months. OnabotulinumtoxinA was generally well tolerated, and treatment-related adverse events included muscular weakness, neck pain, headache and blepharoptosis. A total of 2.3% of onabotulinumtoxinA-treated patients discontinued the study [&lt;ulink linkID="594112" linkType="Reference"&gt;594112&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In 1999, a further phase II trial was initiated for the treatment of migraine headache [&lt;ulink linkID="376356" linkType="Reference"&gt;376356&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;Following the filing of an IND with the FDA in December 1997, Allergan initiated a phase II trial with onabotulinumtoxinA for migraine treatment in February 1998 [&lt;ulink linkID="275797" linkType="Reference"&gt;275797&lt;/ulink&gt;]. Results from the 3-month clinical study were presented at the annual meeting of the American Academy of Neurology in April 1999. When migraine sufferers were given 25 U of onabotulinumtoxinA, there was a reduction in frequency of moderate-to-severe migraines during months 2 and 3. This dose was well tolerated with minimal side effects. Further studies were to seek to identify ideal doses and sites of injection [&lt;ulink linkID="322285" linkType="Reference"&gt;322285&lt;/ulink&gt;], [&lt;ulink linkID="325254" linkType="Reference"&gt;325254&lt;/ulink&gt;], [&lt;ulink linkID="424606" linkType="Reference"&gt;424606&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Other Studies&lt;/subtitle&gt;In July 2015, a multicenter, prospective, observational trial (&lt;ulink linkID="235323" linkType="Protocol"&gt;NCT02502123&lt;/ulink&gt;; GMA-CAN-NEU-0336; PREDICT) began in Canada in patients (n = 215) with Migraine Disorders. The trial completed in January 2019 [&lt;ulink linkID="2161202" linkType="Reference"&gt;2161202&lt;/ulink&gt;]. In May 2019, data were presented at the 71st AAN Annual Meeting in Philadelphia, PA. OnabotulinumtoxinA treatment significantly (p &amp;lt; 0.0001) increased Migraine-Specific Quality of Life scores from baseline to post-Tx4 across all role function domains (restrictive: 36.7 versus 59.8; preventive: 51.4 versus 71.3; emotional: 38.0 versus 63.6, respectively). The percentage of patients decreased from baseline to post-Tx2 and post-Tx4 for those who visited an emergency room (17.3, 9.3 versus 6.6%, respectively), who were admitted to the hospital (3.6, 2.9 versus 1.5%, respectively), and who received headache-related diagnostic testing (35.9, 15.9 versus 8.1%, respectively) [&lt;ulink linkID="2143309" linkType="Reference"&gt;2143309&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Raynaud's syndrome&lt;/subtitle&gt;In January 2015, a randomized, double-blinded, placebo-controlled, efficacy, parallel assigned phase III trial (&lt;ulink linkID="197391" linkType="Protocol"&gt;NCT02165111&lt;/ulink&gt;, NA_00087346) was initiated in the US in patients (n= 40)  to assess the therapeutic efficacy of the toxin in treating scleroderma-associated Raynaud's syndrome. At that time, the trial was expected to be completed in December 2016. In September 2015, the trial completed. In December 2016, data were reported.  Changes in digital blood flow from pre- to post-injection were  -36.19 LDI flux units for onabotulinumtoxinA versus -6.10 laser doppler imaging flux units for placebo  [&lt;ulink linkID="1629968" linkType="Reference"&gt;1629968&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Gastrointestinal indications&lt;/subtitle&gt;At Digestive Disease Week in May 2000, several studies were presented indicating onabotulinumtoxinA for potential therapy in a variety of gastrointestinal disorders. It was effective in the treatment of achalasia and had also been investigated for the treatment of diffuse esophageal spasm (DES), a rare disorder with no pharmacological treatment. Symptom improvement was demonstrated in seven out of nine DES patients immediately following onabotulinumtoxinA injection (100 IU), with a further patient showing improvement after 4 weeks. No serious adverse effects were reported [&lt;ulink linkID="370087" linkType="Reference"&gt;370087&lt;/ulink&gt;], [&lt;ulink linkID="369389" linkType="Reference"&gt;369389&lt;/ulink&gt;]. Injection of onabotulinumtoxinA into the sphincter of Oddi may also be of benefit as an alternative to biliary stenting in the treatment of biliary leaks and fistulae [&lt;ulink linkID="366961" linkType="Reference"&gt;366961&lt;/ulink&gt;]. Similarly, injection of onabotulinumtoxinA into the pyloric sphincter may have benefit in the treatment of gastroparesis. Three patients receiving onabotulinumtoxinA reported an improvement in symptoms and the treatment was well tolerated [&lt;ulink linkID="370087" linkType="Reference"&gt;370087&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Thyroid-associated ophthalmopathy&lt;/subtitle&gt;In January 2011, a randomized, single-blind, parallel-group study (&lt;ulink linkID="189757" linkType="Protocol"&gt;NCT01272414&lt;/ulink&gt;; 10-0261-A)  was planned in Canada to assess the efficacy of onabotulinumtoxinA for the treatment of patients with thyroid-associated ophthalmopathy (expected n = 20). The primary endpoint was reduction in upper lid retraction. At that time, the study was expected to begin in January 2011 and complete in January 2012. However, in February 2012, the trial was withdrawn prior to enrollment due to lack of funding   [&lt;ulink linkID="1254956" linkType="Reference"&gt;1254956&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Premature ejaculation&lt;/subtitle&gt;In August 2013, a randomized, double blind, phase II trial (&lt;ulink linkID="149165" linkType="Protocol"&gt;NCT01917006&lt;/ulink&gt;; 191622-133, 2013-001650-94) to assess safety and efficacy of onabotulinumtoxinA in patients (expected n = 60) with premature ejaculation was initiated. The trial was expected to be completed in July 2015 [&lt;ulink linkID="1467285" linkType="Reference"&gt;1467285&lt;/ulink&gt;]. In August 2017, the trial was terminated [&lt;ulink linkID="1467285" linkType="Reference"&gt;1467285&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Neuropathic pain&lt;/subtitle&gt;In July 2013, a randomized, double-blind, parallel assignment, phase II trial (&lt;ulink linkID="148191" linkType="Protocol"&gt;NCT01911377&lt;/ulink&gt;; Botox 2013) was planned in August 2013 in Canada in patients (expected n = 12) with spinal cord injury having allodynic-type neuropathic pain to evaluate the efficacy of onabotulinumtoxinA. At that time, the trial was expected to be completed in January 2015; in December 2013, the trial was initiated, and in April 2015, it was ongoing. However, by October 2015, the trial had been terminated.  A total of 12 patients with spinal cord injury had been recruited to the study, but following negative data from this patient group, it was decided not to expand recruitment ot patients with muliple sclerosis [&lt;ulink linkID="1468290" linkType="Reference"&gt;1468290&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Bilateral masseter muscle hypertrophy&lt;/subtitle&gt;In December 2013, a phase II study (&lt;ulink linkID="163828" linkType="Protocol"&gt;NCT02010775&lt;/ulink&gt;; 191622-130) in subjects (expected n = 20) with bilateral masseter muscle hypertrophy was expected to begin in January 2014. At that time, the trial was expected to complete in September 2016; in January 2014, the trial was initiated in Canada [&lt;ulink linkID="1509907" linkType="Reference"&gt;1509907&lt;/ulink&gt;]. In August 2016, data were expected in 2017 [&lt;ulink linkID="1787352" linkType="Reference"&gt;1787352&lt;/ulink&gt;]. In November 2017, the trial completed  [&lt;ulink linkID="1509907" linkType="Reference"&gt;1509907&lt;/ulink&gt;]. In March 2019, clinical data were presented at the 77th AAD Annual Meeting in Washington DC. At day 90, lower facial volume was significantly reduced for all onabotulinumtoxina (24, 48, 72 or 96 U) dose groups versus placebo (primary endpoint); mean change as measured by VECTRA M3 was -4.40 (p &amp;lt; 0.001 versus placebo), -6.84 (p = 0.006 versus 24 U), -7.41 and -8.20 versus -0.52 cm3, respectively. In placebo and onabotulinumtoxina (24, 48, 72 or 96 U) dose groups, the proportion of responders who achieved Masseter Muscle Prominence Scale (MMPS) grade &amp;lt;/= 3 were 35.1, 66.7, 83.3 (p &amp;lt;/= 0.008 versus placebo), 89.5 and 89.5%, respectively; and &amp;gt;/= 2 grade change in MMPS was 8.1, 47.2 (p &amp;lt; 0.001 versus placebo), 47.2, 73.7 (p &amp;lt; 0.016 versus 48 U) and 65.8%, respectively. Treatment-related serious AEs or deaths were not reported [&lt;ulink linkID="2126230" linkType="Reference"&gt;2126230&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Major depressive disorder&lt;/subtitle&gt;In April 2017, a phase III program for major depressive disorder was planned [&lt;ulink linkID="1915978" linkType="Reference"&gt;1915978&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2014, a phase II, randomized, parallel assignment, double blind, safety and efficacy study (&lt;ulink linkID="182220" linkType="Protocol"&gt;NCT02116361&lt;/ulink&gt;; 191622-135) was initiated in adult females (n = 258) in the US with major depressive disorder [&lt;ulink linkID="1550953" linkType="Reference"&gt;1550953&lt;/ulink&gt;]. In April 2017, topline data were reported. A single 30 U dose showed numerically superior efficacy over placebo in MADRS total score, although the effect was not statistically significant at the primary endpoint time of 6 weeks; LS mean difference was -4.2 at 3 weeks (p=0.005), -3.7 at week 6 (p=0.053) and -3.6 at week 9 (p=0.049). Superior efficacy was not demonstrated by the 50 U dose. Both doses were well tolerated [&lt;ulink linkID="1915978" linkType="Reference"&gt;1915978&lt;/ulink&gt;]. In December 2017, further data were presented at the 56th Annual Meeting of the ACNP in Palm Springs, CA. At every study visit through week 24, patients achieved consistently numerically greater decrease on Global Impression-Severity (-0.5) and Hamilton Rating Scale for Depression 17-item Version (&amp;gt;/= -1.6). Treatment-emergent adverse events (TEAEs) were reported by approximately 52% of patients which included 54.6 and 48.8% of patients in onabotulinumtoxinA and placebo group, respectively. TEAEs were mostly local to the injection site and mild or moderate in intensity. Treatment related changes in clinical laboratory values, vital signs, physical examination results, or Columbia-Suicide Severity Rating Scale results were not observed [&lt;ulink linkID="1992729" linkType="Reference"&gt;1992729&lt;/ulink&gt;]. In May 2018, further data were presented at the171st APA Annual Meeting in New York, NY. At week 15, when compared to placebo, a numerically greater MADRS reduction was observed in onabotulinumtoxinA (30 U) group (ranged from -3.3 to -5.1) [&lt;ulink linkID="2061189" linkType="Reference"&gt;2061189&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Miscellaneous studies&lt;/subtitle&gt;In August 2018, pooled analysis results were presented from three phase III trials (NCT00910520, NCT00910845, and NCT01767519) and one phase IV trial (NCT01945489) which evaluated the risk of clean intermittent catheterization (CIC) as well as treatment response and QOL outcomes following reinjection with onabotulinumtoxinA 100 Units in patients with idiopathic overactive bladder were presented at the 48th Annual Meeting of the International Continence Society in Philadelphia, PA. CIC rates in the first 12 weeks following the first treatment were 6.2 and 0.3% with onabotulinumtoxinA and placebo, respectively (median duration was 85 and 10 days, respectively). In the 12 weeks after the second treatment, CIC rates were 5.5% for patients who received onabotulinumtoxinA in both treatments 1 and 2, and 3.1% for patients who received their first onabotulinumtoxinA treatment at treatment 2 (median duration was 37 and 64 days, respectively). Improvements in urinary symptoms and QOL were appeared consistent following initial treatment and retreatment with onabotulinumtoxinA 100U [&lt;ulink linkID="2114960" linkType="Reference"&gt;2114960&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In March 2018, clinical data from a study which evaluated the efficacy of intradetrusor onabotulinumtoxinA (Botox), in subjective autonomic dysreflexia (AD) experiences and urinary incontinence-related quality of life (QoL) for the treatment of neurogenic detrusor overactivity in patients with spinal cord injury (SCI) were presented at the 2018 International EAU Meeting in Copenhagen, Denmark. Patients who had chronic (&amp;gt; 1 year post-injury), traumatic SCI at or above the spinal segment T6 (n = 32) received Botox injections (200 IU; across 20 sites in the detrusor muscle, sparing trigone). According to an assessment pre- and post-treatment using the AD Health-Related QoL questionnaire, there was a reduction in the frequency of AD following treatment with Botox. Also, the severity of AD symptoms was reduced following treatment with Botox. Botox treatment resulted in a significant improvement in urinary incontinence-related QoL [&lt;ulink linkID="2013641" linkType="Reference"&gt;2013641&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2017, pooled data from 15 randomized, double-blind placebo controlled studieswere presented at 69th AAN Annual Meeting in Boston, MA. Patients (n = 1877) were randomized to receive onabotulinumtoxinA (im) with antithrombotic therapy (factor Xa inhibitor, direct thrombin inhibitor, heparin, other antithrombotic agent, platelet aggregation inhibitor, thrombolytic agent, vitamin K antagonist) or without antithrombotic therapy and onabotulinumtoxinA or placebo. Overall, patients experienced incidence of bleeding-related treatment-emergent adverse events (TEAEs) was &amp;lt; 2% and was similar for all the groups [&lt;ulink linkID="1920271" linkType="Reference"&gt;1920271&lt;/ulink&gt;].  &lt;/para&gt;&lt;para&gt;In February 2017, clinical data from a multicenter, randomized, double-blind, placebo-controlled study were presented at the 2017 International Stroke Conference in Houston, TX. Adult patients (n = 56) received onabotulinumtoxinA (300 U (150U: elbow flexors; 150U: shoulder adductors)) or 500 units (250 and 250 U)) or placebo. The mean change from baseline in elbow Modified Ashworth Scale (MAS) scores were - 0.4, - 0.8 and - 1.3 in placebo, onabotulinumtoxinA 300 and 500 units dose groups, respectively. Compared with placebo, at all time points (300 U significant (p &amp;lt; 0.05) at weeks-2, 4 and 8) the proportion of treatment responders (&amp;gt;/= 1 grade reduction in elbow MAS) were numerically greater in onabotulinumtoxinA 500 and 300 U groups.Similar proportion of adverse events was reported in both onabotulinumtoxinA 500 and 300 U arms (29.4 and 27.8%, respectively), and greater proportion was observed in placebo group (50%). The study was terminated early due to administrative reasons [&lt;ulink linkID="1906705" linkType="Reference"&gt;1906705&lt;/ulink&gt;]. In April 2017, further clinical data were presented at the 69th AAN Annual Meeting in Boston, MA.  The mean change from baseline in elbow Modified Ashworth Scale (MAS) scores were - 0.5, - 0.6, - 0.7, - 0.6 and - 0.4 (placebo),  - 1.3 (p &amp;lt; 0.05), - 1.5 (p &amp;lt; 0.05), - 1.5, - 1.2 and - 0.8 (onabotulinumtoxin-A 300 U), and  - 1.7,  - 1.8, - 1.6, - 1.9 and - 1.3 (onabotulinumtoxin-A 500 U, for all p &amp;lt; 0.05) at week-2, 4, 6, 8 and 12, respectively.  The mean change from baseline in shoulder adductor MAS scores were - 0.8, - 1, - 1.4, - 1.3 and -1.1 (placebo), - 1.1, - 1.5, - 1.4, - 1.4 and - 1.2 (onabotulinumtoxin-A 300 U), - 1.6 (p &amp;lt; 0.05), - 2 (p &amp;lt; 0.05), - 1.6, - 1.8 and - 1.2 (onabotulinumtoxin-A 500 U,) at week-2, 4, 6, 8 and 12, respectively. The treatment related adverse events reported were muscular weakness (one patient receiving 500 U), headache (one placebo-recipient) and myalgia (one placebo-recipient). There were no reports of deaths or study discontinuation [&lt;ulink linkID="1920171" linkType="Reference"&gt;1920171&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By February 2017, phase III development was underway in Japan for spasmodic dysphonia [&lt;ulink linkID="1941590" linkType="Reference"&gt;1941590&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In May 2016, month-6 interim analysis data from a prospective, non-interventional, observational, open-label study (REPOSE) performed to evaluate the two-year, real-life use of onabotulinumtoxin A, in patients (n = 336) from seven countries with chronic migraine were presented at the Second EAN Congress in Copenhagen, Denmark. Onabotulinumtoxin A showed significant improvements in migraine specific quality of life questionnaire and EuroQol group-5D scores and significant decreases in headache days (–9 and–10) at both visits compared with baseline. Eyelid ptosis and neck pain were the most commonly reported adverse events [&lt;ulink linkID="1789317" linkType="Reference"&gt;1789317&lt;/ulink&gt;]. In September 2017, similar data were presented at the 18th IHC Congress in Vancouver, Canada [&lt;ulink linkID="1970122" linkType="Reference"&gt;1970122&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In January 2016, a prospective study (&lt;ulink linkID="252513" linkType="Protocol"&gt;NCT02673047&lt;/ulink&gt;; MAF/AGN/NS/OAB/006) was planned to be initiated in France in patients (n = 474) with overactive Bladder or neurogenic detrusor overactivity. The trial was expected to complete in June 2016. In February 2016, the trial was initiated, and was completed in August 2016 [&lt;ulink linkID="1733414" linkType="Reference"&gt;1733414&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2015, A double blinded, randomized controlled phase II trial (&lt;ulink linkID="248059" linkType="Protocol"&gt;NCT02623829&lt;/ulink&gt;; GCO 15-1093) was initiated in the US, to evaluate the efficacy of botulinum toxin in patients (expected n = 40) with post-operative excessive scarring. At that time, the completion of the trial was expected in July 2017 [&lt;ulink linkID="1864147" linkType="Reference"&gt;1864147&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In  October 2015, clinical data from the analysis which assessed the effect of onabotulinumtoxin A on quality of life (QOL) in neurogenic bladder patients (n = 18) with indwelling catheters were presented at the 45th annual meeting of the International Continence Society in Montreal, Canada. Majority of patients (12/18) had improvements in at least one type of incontinence, and 6/11 patients who were incontinent at baseline (33% overall) became 100% dry at some point. Overall, onabotulinumtoxin A improved clinical outcome measures such as incontinence, pain, and QOL and worked relatively quickly with durable responses for at least 3 months post-injection [&lt;ulink linkID="1724109" linkType="Reference"&gt;1724109&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2015, pooled  data were presented  from 18 clinical studies in 1342 patients with upper limb spasticity at the 19th International PDMD Congress in San Diego, CA.									Patients  who received &amp;gt;/=1 onabotulinumtoxinA treatment were divided into four dose groups (&amp;lt; 150 U, 150 to 250 U, 251 to 399 U, &amp;gt;/= 400 U). Across dose groups, reported AE rates were similar, without any consistent increase in incidence of any individual AE/serious AE or possible distant spread of toxin AEs at doses &amp;gt;/= 400U across treatments. Treatment with onabotulinumtoxinA at various doses, including &amp;gt;/= 400 U was well tolerated [&lt;ulink linkID="1677025" linkType="Reference"&gt;1677025&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2015, clinical data were presented from a randomized, controlled study in 273 post-stroke spasticity patients at the 19th International PDMD Congress in San Diego, CA.									Patients were randomized to onabotulinumtoxinA + standard of care (SC) or saline + SC. The proportion of patients with baseline pain intensity &amp;gt;/= 4 achieving &amp;gt;/= 30% improvement was 54 and 29% for onabotulinumtoxinA + SC and saline + SC groups, respectively. At week 12, change in pain score was weakly associated with change in muscle tone among patients with moderate to severe spasticity at baseline [&lt;ulink linkID="1677027" linkType="Reference"&gt;1677027&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2013, data from two placebo-controlled studies were presented at the 65th AAN Annual Meeting in San Diego, CA. Patients (study 2, n = 85; study 3, n = 78) received a median dose of 300 units onabotulinumtoxinA injection at ankle plantar-flexors or placebo. In the onabotulinumtoxinA group, a high proportion of responders (with &amp;gt;/= 1 point reduction from baseline muscle tone ankle score) was seen at weeks 4, 6 and 8 when compared with placebo group. At week 8, a significant difference in AS was observed between onabotulinumtoxinA (300 units) and placebo while no difference was seen with the 200-units dose in study 2. In study 3, OnabotulinumtoxinA demonstrated clinically and statistically significant improvements in functioning as measured by goal attainment scale when compared with placebo [&lt;ulink linkID="1389399" linkType="Reference"&gt;1389399&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In February 2006, phase  II trials in benign prostatic hyperplasia  were underway [&lt;ulink linkID="649262" linkType="Reference"&gt;649262&lt;/ulink&gt;]; the trial was ongoing in March 2008 [&lt;ulink linkID="891422" linkType="Reference"&gt;891422&lt;/ulink&gt;]. In November 2007, the Korean FDA approved a multicenter, double-blind, randomized, placebo-controlled, dose-response study of onabotulinumtoxinA which was to be injected into the prostate gland in men with benign prostatic hyperplasia [&lt;ulink linkID="945056" linkType="Reference"&gt;945056&lt;/ulink&gt;]. In March 2011, clinical data were presented at the 26th EAU Annual Congress in Vienna, Austria. Men with urinary symptoms due to benign prostatic hyperplasia were administered 100  (n = 95), 200  (n = 94) or 300 units (n = 97) of onabotulinumtoxinA, or placebo (n = 94). At week 12, a significant reduction from baseline in international prostate symptom score (IPSS) was observed for drug-treated patients; however, the difference compared with placebo was not significant. For patients previously treated with alpha blockers, a significant reduction in IPSS was observed in men receiving 200 units from weeks 8 to 12, compared with placebo [&lt;ulink linkID="1217782" linkType="Reference"&gt;1217782&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Peyronie's Disease&lt;/subtitle&gt;In June 2009, a phase II efficacy study (&lt;ulink linkID="39182" linkType="Protocol"&gt;NCT00812838&lt;/ulink&gt;; 11-07-40-04) of botulinum toxin type a was initiated in patients (expected n = 20) with Peyronie's disease in the US; in September 2015, the study was ongoing.  In November 2016, the  trial was recruiting particpants and at that time, was expected to complete in January 2018 [&lt;ulink linkID="1697385" linkType="Reference"&gt;1697385&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Cerebral Palsy&lt;/subtitle&gt;In June 2004, a randomized, blinded, parallel assigned trial (&lt;ulink linkID="264345" linkType="Protocol"&gt;ACTRN12605000127606&lt;/ulink&gt;) began in Australia, in children  (expected n = 44)  with hemiplegic cerebral palsy to assess the efficacy of botulinum toxin A. By June 2016, the trial had been completed [&lt;ulink linkID="1777738" linkType="Reference"&gt;1777738&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;In February 2014, the drug was listed as being in preclinical studies for depression [&lt;ulink linkID="1523956" linkType="Reference"&gt;1523956&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By March 2012, an optimized formulation of Botox was under investigation, Botox X,  for the potential treatment of spasticity [&lt;ulink linkID="1725452" linkType="Reference"&gt;1725452&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By February 2006, preclinical studies were taking place in gastric outlet obstruction, obesity and osteoarthritis [&lt;ulink linkID="649262" linkType="Reference"&gt;649262&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 2001, preclinical data on onabotulinumtoxinA were presented at the third Croatian Pharmacology congress in Zagreb, Croatia; OnabotulinumtoxinA reduced inflammatory pain perception in a rat formalin model in doses ranging from 3.5 to 15 U/kg [&lt;ulink linkID="424606" linkType="Reference"&gt;424606&lt;/ulink&gt;]. Similar data were presented in August 2002 at the 10th World Congress on Pain in San Diego, CA. OnabotulinumtoxinA significantly inhibited peripheral sensitization brought about by formalin, which then resulted in an indirect reduction in central sensitization. The inhibition of nociceptive processing at the peripheral site and at the level of the spinal cord suggested the mechanism of onabotulinumtoxinA effect in treating painful conditions was via the peripheral site [&lt;ulink linkID="466112" linkType="Reference"&gt;466112&lt;/ulink&gt;].&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical><AdditionalInformation><displayLabel>Additional Information</displayLabel><value>&lt;AdditionalInformation&gt;&lt;para&gt;In 2011, the FDA and Health Canada approved a fully in vitro, cell-based assay for use in the stability and potency testing of onabotulinumtoxinA. In 2012, a positive opinion for this assay was issued in Europe [&lt;ulink linkID="1530302" linkType="Reference"&gt;1530302&lt;/ulink&gt;].&lt;/para&gt;&lt;/AdditionalInformation&gt;</value></AdditionalInformation></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="1088700">Allergan plc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="2225">Hyperhidrosis</Indication><StatusDate>2015-03-17T00:00:00.000Z</StatusDate><Source id="1642310" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1088700">Allergan plc</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="210">Migraine</Indication><StatusDate>2015-03-17T00:00:00.000Z</StatusDate><Source id="1642310" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="28355">GlaxoSmithKline plc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="358">Muscle spasm</Indication><StatusDate>2005-10-03T00:00:00.000Z</StatusDate><Source id="626580" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1088700">Allergan plc</Company><Country id="NZ">New Zealand</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="210">Migraine</Indication><StatusDate>2018-06-06T00:00:00.000Z</StatusDate><Source id="2058447" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="28355">GlaxoSmithKline plc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="564">Cervical dystonia</Indication><StatusDate>2005-10-03T00:00:00.000Z</StatusDate><Source id="626580" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1088700">Allergan plc</Company><Country id="BH">Bahrain</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="210">Migraine</Indication><StatusDate>2015-03-17T00:00:00.000Z</StatusDate><Source id="1642310" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1088700">Allergan plc</Company><Country id="BR">Brazil</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="210">Migraine</Indication><StatusDate>2015-03-17T00:00:00.000Z</StatusDate><Source id="1642310" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1088700">Allergan plc</Company><Country id="AU">Australia</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="210">Migraine</Indication><StatusDate>2015-03-17T00:00:00.000Z</StatusDate><Source id="1642310" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1088700">Allergan plc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="210">Migraine</Indication><StatusDate>2015-03-17T00:00:00.000Z</StatusDate><Source id="1642310" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1088700">Allergan plc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="913">Muscle hypertonia</Indication><StatusDate>2015-03-17T00:00:00.000Z</StatusDate><Source id="1642310" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1088700">Allergan plc</Company><Country id="EC">Ecuador</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="2376">Overactive bladder</Indication><StatusDate>2015-03-17T00:00:00.000Z</StatusDate><Source id="1642310" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1088700">Allergan plc</Company><Country id="CL">Chile</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="2376">Overactive bladder</Indication><StatusDate>2015-03-17T00:00:00.000Z</StatusDate><Source id="1642310" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1088700">Allergan plc</Company><Country id="RU">Russian Federation</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="2376">Overactive bladder</Indication><StatusDate>2015-03-17T00:00:00.000Z</StatusDate><Source id="1642310" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1088700">Allergan plc</Company><Country id="CR">Costa Rica</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="210">Migraine</Indication><StatusDate>2015-03-17T00:00:00.000Z</StatusDate><Source id="1642310" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1088700">Allergan plc</Company><Country id="IN">India</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="2376">Overactive bladder</Indication><StatusDate>2015-03-17T00:00:00.000Z</StatusDate><Source id="1642310" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1088700">Allergan plc</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="564">Cervical dystonia</Indication><StatusDate>2015-03-17T00:00:00.000Z</StatusDate><Source id="1642310" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1088700">Allergan plc</Company><Country id="EU">EU</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="2225">Hyperhidrosis</Indication><StatusDate>2015-03-17T00:00:00.000Z</StatusDate><Source id="1642310" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1088700">Allergan plc</Company><Country id="AR">Argentina</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="2376">Overactive bladder</Indication><StatusDate>2015-03-17T00:00:00.000Z</StatusDate><Source id="1642310" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1088700">Allergan plc</Company><Country id="RU">Russian Federation</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="210">Migraine</Indication><StatusDate>2015-03-17T00:00:00.000Z</StatusDate><Source id="1642310" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1088700">Allergan plc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="913">Muscle hypertonia</Indication><StatusDate>2015-03-17T00:00:00.000Z</StatusDate><Source id="1642310" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1088700">Allergan plc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="2376">Overactive bladder</Indication><StatusDate>2015-03-17T00:00:00.000Z</StatusDate><Source id="1642310" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1088700">Allergan plc</Company><Country id="SG">Singapore</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="2376">Overactive bladder</Indication><StatusDate>2015-03-17T00:00:00.000Z</StatusDate><Source id="1642310" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1088700">Allergan plc</Company><Country id="AU">Australia</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="913">Muscle hypertonia</Indication><StatusDate>2015-03-17T00:00:00.000Z</StatusDate><Source id="1642310" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1088700">Allergan plc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="564">Cervical dystonia</Indication><StatusDate>2015-03-17T00:00:00.000Z</StatusDate><Source id="1642310" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1088700">Allergan plc</Company><Country id="SA">Saudi Arabia</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="2376">Overactive bladder</Indication><StatusDate>2015-03-17T00:00:00.000Z</StatusDate><Source id="1642310" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1088700">Allergan plc</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="2225">Hyperhidrosis</Indication><StatusDate>2015-03-17T00:00:00.000Z</StatusDate><Source id="1642310" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1088700">Allergan plc</Company><Country id="IL">Israel</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="2376">Overactive bladder</Indication><StatusDate>2015-03-17T00:00:00.000Z</StatusDate><Source id="1642310" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="28355">GlaxoSmithKline plc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="913">Muscle hypertonia</Indication><StatusDate>2010-10-31T00:00:00.000Z</StatusDate><Source id="1146735" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1088700">Allergan plc</Company><Country id="FR">France</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="2481">Strabismus</Indication><StatusDate>2015-03-17T00:00:00.000Z</StatusDate><Source id="1642310" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1088700">Allergan plc</Company><Country id="AU">Australia</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="2376">Overactive bladder</Indication><StatusDate>2015-03-17T00:00:00.000Z</StatusDate><Source id="1642310" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1088700">Allergan plc</Company><Country id="OM">Oman</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="2376">Overactive bladder</Indication><StatusDate>2015-03-17T00:00:00.000Z</StatusDate><Source id="1642310" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1088700">Allergan plc</Company><Country id="EU">EU</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="2239">Blepharospasm</Indication><StatusDate>2015-03-17T00:00:00.000Z</StatusDate><Source id="1642310" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1088700">Allergan plc</Company><Country id="PA">Panama</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="2376">Overactive bladder</Indication><StatusDate>2015-03-17T00:00:00.000Z</StatusDate><Source id="1642310" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1088700">Allergan plc</Company><Country id="CL">Chile</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="210">Migraine</Indication><StatusDate>2015-03-17T00:00:00.000Z</StatusDate><Source id="1642310" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1088700">Allergan plc</Company><Country id="EU">EU</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="210">Migraine</Indication><StatusDate>2015-03-17T00:00:00.000Z</StatusDate><Source id="1642310" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1088700">Allergan plc</Company><Country id="NZ">New Zealand</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="2225">Hyperhidrosis</Indication><StatusDate>2015-03-17T00:00:00.000Z</StatusDate><Source id="1642310" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1088700">Allergan plc</Company><Country id="EU">EU</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="564">Cervical dystonia</Indication><StatusDate>2015-03-17T00:00:00.000Z</StatusDate><Source id="1642310" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1088700">Allergan plc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="2376">Overactive bladder</Indication><StatusDate>2015-03-17T00:00:00.000Z</StatusDate><Source id="1642310" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1088700">Allergan plc</Company><Country id="MX">Mexico</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="2376">Overactive bladder</Indication><StatusDate>2015-03-17T00:00:00.000Z</StatusDate><Source id="1642310" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="28355">GlaxoSmithKline plc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="2225">Hyperhidrosis</Indication><StatusDate>2013-01-09T00:00:00.000Z</StatusDate><Source id="1357361" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="28355">GlaxoSmithKline plc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="2239">Blepharospasm</Indication><StatusDate>2005-10-03T00:00:00.000Z</StatusDate><Source id="626580" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="28355">GlaxoSmithKline plc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="2481">Strabismus</Indication><StatusDate>2015-06-16T00:00:00.000Z</StatusDate><Source id="1677140" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1088700">Allergan plc</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="2376">Overactive bladder</Indication><StatusDate>2015-03-17T00:00:00.000Z</StatusDate><Source id="1642310" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1088700">Allergan plc</Company><Country id="MA">Morocco</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="2376">Overactive bladder</Indication><StatusDate>2015-03-17T00:00:00.000Z</StatusDate><Source id="1642310" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1088700">Allergan plc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="2239">Blepharospasm</Indication><StatusDate>2015-03-17T00:00:00.000Z</StatusDate><Source id="1642310" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1088700">Allergan plc</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="913">Muscle hypertonia</Indication><StatusDate>2015-05-17T00:00:00.000Z</StatusDate><Source id="1642310" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1088700">Allergan plc</Company><Country id="AU">Australia</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="2225">Hyperhidrosis</Indication><StatusDate>2015-03-17T00:00:00.000Z</StatusDate><Source id="1642310" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="28355">GlaxoSmithKline plc</Company><Country id="CN">China</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="358">Muscle spasm</Indication><StatusDate>2006-10-20T00:00:00.000Z</StatusDate><Source id="1290656" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="28355">GlaxoSmithKline plc</Company><Country id="CN">China</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="2239">Blepharospasm</Indication><StatusDate>2006-10-20T00:00:00.000Z</StatusDate><Source id="1290656" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1088700">Allergan plc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="2481">Strabismus</Indication><StatusDate>2015-03-17T00:00:00.000Z</StatusDate><Source id="1642310" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1088700">Allergan plc</Company><Country id="IN">India</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="210">Migraine</Indication><StatusDate>2015-03-17T00:00:00.000Z</StatusDate><Source id="1642310" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1088700">Allergan plc</Company><Country id="BR">Brazil</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="2376">Overactive bladder</Indication><StatusDate>2015-03-17T00:00:00.000Z</StatusDate><Source id="1642310" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1088700">Allergan plc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="2225">Hyperhidrosis</Indication><StatusDate>2015-03-17T00:00:00.000Z</StatusDate><Source id="1642310" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1088700">Allergan plc</Company><Country id="AU">Australia</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="2696">Dysphonia</Indication><StatusDate>2018-05-25T00:00:00.000Z</StatusDate><Source id="2037706" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1088700">Allergan plc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="210">Migraine</Indication><StatusDate>2015-03-17T00:00:00.000Z</StatusDate><Source id="1642310" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1088700">Allergan plc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="564">Cervical dystonia</Indication><StatusDate>2015-03-17T00:00:00.000Z</StatusDate><Source id="1642310" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1088700">Allergan plc</Company><Country id="EG">Egypt</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="2376">Overactive bladder</Indication><StatusDate>2015-03-17T00:00:00.000Z</StatusDate><Source id="1642310" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1088700">Allergan plc</Company><Country id="KW">Kuwait</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="210">Migraine</Indication><StatusDate>2015-03-17T00:00:00.000Z</StatusDate><Source id="1642310" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1088700">Allergan plc</Company><Country id="HK">Hong Kong</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="210">Migraine</Indication><StatusDate>2015-03-17T00:00:00.000Z</StatusDate><Source id="1642310" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1088700">Allergan plc</Company><Country id="QA">Qatar</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="2376">Overactive bladder</Indication><StatusDate>2015-03-17T00:00:00.000Z</StatusDate><Source id="1642310" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1088700">Allergan plc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="2481">Strabismus</Indication><StatusDate>2015-03-17T00:00:00.000Z</StatusDate><Source id="1642310" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1088700">Allergan plc</Company><Country id="JO">Jordan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="210">Migraine</Indication><StatusDate>2015-03-17T00:00:00.000Z</StatusDate><Source id="1642310" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="28355">GlaxoSmithKline plc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="2696">Dysphonia</Indication><StatusDate>2018-05-25T00:00:00.000Z</StatusDate><Source id="2037706" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1088700">Allergan plc</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="2376">Overactive bladder</Indication><StatusDate>2015-03-17T00:00:00.000Z</StatusDate><Source id="1642310" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1088700">Allergan plc</Company><Country id="JO">Jordan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="2376">Overactive bladder</Indication><StatusDate>2015-03-17T00:00:00.000Z</StatusDate><Source id="1642310" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1088700">Allergan plc</Company><Country id="AU">Australia</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="2481">Strabismus</Indication><StatusDate>2015-03-17T00:00:00.000Z</StatusDate><Source id="1642310" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1088700">Allergan plc</Company><Country id="NZ">New Zealand</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="2376">Overactive bladder</Indication><StatusDate>2015-03-17T00:00:00.000Z</StatusDate><Source id="1642310" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1088700">Allergan plc</Company><Country id="KW">Kuwait</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="2376">Overactive bladder</Indication><StatusDate>2015-03-17T00:00:00.000Z</StatusDate><Source id="1642310" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1088700">Allergan plc</Company><Country id="PH">Philippines</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="2376">Overactive bladder</Indication><StatusDate>2015-03-17T00:00:00.000Z</StatusDate><Source id="1642310" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1088700">Allergan plc</Company><Country id="EU">EU</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="2376">Overactive bladder</Indication><StatusDate>2015-03-17T00:00:00.000Z</StatusDate><Source id="1642310" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1088700">Allergan plc</Company><Country id="EU">EU</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="913">Muscle hypertonia</Indication><StatusDate>2015-03-17T00:00:00.000Z</StatusDate><Source id="1642310" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="28355">GlaxoSmithKline plc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="2376">Overactive bladder</Indication><StatusDate>2016-05-23T00:00:00.000Z</StatusDate><Source id="1765575" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1088700">Allergan plc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="2521">Hypertrophy</Indication><StatusDate>2015-03-17T00:00:00.000Z</StatusDate><Source id="1642310" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14042">Allergan Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1790">Penile induration</Indication><StatusDate>2009-06-16T00:00:00.000Z</StatusDate><Source id="1697385" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14042">Allergan Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1542">Atrial fibrillation</Indication><StatusDate>2019-03-01T00:00:00.000Z</StatusDate><Source id="2106734" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1088700">Allergan plc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="4898">Major depressive disorder</Indication><StatusDate>2015-03-17T00:00:00.000Z</StatusDate><Source id="1642310" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1088700">Allergan plc</Company><Country id="CN">China</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="20">Pain</Indication><StatusDate>2019-03-04T00:00:00.000Z</StatusDate><Source id="2124883" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14042">Allergan Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="20">Pain</Indication><StatusDate>2017-07-11T00:00:00.000Z</StatusDate><Source id="1956040" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1088700">Allergan plc</Company><Country id="IE">Ireland</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1107">Allergic rhinitis</Indication><StatusDate>2018-08-08T00:00:00.000Z</StatusDate><Source id="2061434" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14042">Allergan Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="2934">Temporomandibular joint syndrome</Indication><StatusDate>2017-07-11T00:00:00.000Z</StatusDate><Source id="1956040" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14042">Allergan Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="1241">Prostate hyperplasia</Indication><StatusDate>2013-03-06T00:00:00.000Z</StatusDate><Source id="1391329" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23191">Oculinum</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="5">Other</DiscontinuedReason><Indication id="589">Dystonia</Indication><StatusDate>1989-12-31T00:00:00.000Z</StatusDate><Source id="1201421" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14042">Allergan Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="5">Other</DiscontinuedReason><Indication id="2967">Thyroid associated ophthalmopathy</Indication><StatusDate>2012-02-29T00:00:00.000Z</StatusDate><Source id="1254956" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15587">Daewoong Pharmaceutical Co Ltd</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="913">Muscle hypertonia</Indication><StatusDate>2009-01-01T00:00:00.000Z</StatusDate><Source id="996519" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15587">Daewoong Pharmaceutical Co Ltd</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="2225">Hyperhidrosis</Indication><StatusDate>2009-01-01T00:00:00.000Z</StatusDate><Source id="996519" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1088700">Allergan plc</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="1274">Premature ejaculation</Indication><StatusDate>2017-03-30T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14042">Allergan Inc</Company><Country id="DE">Germany</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="689">Esophageal function disorder</Indication><StatusDate>2009-03-05T00:00:00.000Z</StatusDate><Source id="365728" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1088700">Allergan plc</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="478">Raynauds disease</Indication><StatusDate>2018-06-30T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1088700">Allergan plc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="1295">Neuropathic pain</Indication><StatusDate>2017-04-30T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14042">Allergan Inc</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="2231">Vagina disease</Indication><StatusDate>2014-06-30T00:00:00.000Z</StatusDate><Source id="365728" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1088700">Allergan plc</Company><Country id="IN">India</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="564">Cervical dystonia</Indication><StatusDate>2010-06-30T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14042">Allergan Inc</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="245">Osteoarthritis</Indication><StatusDate>2016-09-17T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14042">Allergan Inc</Company><Country id="X5">Europe</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="20">Pain</Indication><StatusDate>2004-01-31T00:00:00.000Z</StatusDate><Source id="365728" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14042">Allergan Inc</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="217">Paralysis</Indication><StatusDate>2009-03-05T00:00:00.000Z</StatusDate><Source id="365728" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14042">Allergan Inc</Company><Country id="AF">Afghanistan</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="376">Gastric motility disorder</Indication><StatusDate>2009-03-05T00:00:00.000Z</StatusDate><Source id="365728" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14042">Allergan Inc</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="148">Headache</Indication><StatusDate>2005-08-06T00:00:00.000Z</StatusDate><Source id="562127" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14042">Allergan Inc</Company><Country id="DK">Denmark</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="245">Osteoarthritis</Indication><StatusDate>2016-09-17T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14042">Allergan Inc</Company><Country id="CZ">Czech Republic</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="245">Osteoarthritis</Indication><StatusDate>2016-09-17T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14042">Allergan Inc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="358">Muscle spasm</Indication><StatusDate>2005-10-03T00:00:00.000Z</StatusDate><Source id="626580" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14042">Allergan Inc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="2239">Blepharospasm</Indication><StatusDate>2005-10-03T00:00:00.000Z</StatusDate><Source id="626580" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14042">Allergan Inc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="564">Cervical dystonia</Indication><StatusDate>2005-10-03T00:00:00.000Z</StatusDate><Source id="626580" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="14042">Allergan Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="210">Migraine</Indication><StatusDate>2010-02-04T00:00:00.000Z</StatusDate><Source id="1073300" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28355">GlaxoSmithKline plc</Company><Country id="CN">China</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="358">Muscle spasm</Indication><StatusDate>2005-10-03T00:00:00.000Z</StatusDate><Source id="626580" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14042">Allergan Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1241">Prostate hyperplasia</Indication><StatusDate>2006-02-06T00:00:00.000Z</StatusDate><Source id="649262" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14042">Allergan Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1295">Neuropathic pain</Indication><StatusDate>2013-07-25T00:00:00.000Z</StatusDate><Source id="1468290" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14042">Allergan Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="2521">Hypertrophy</Indication><StatusDate>2013-12-10T00:00:00.000Z</StatusDate><Source id="1509907" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14042">Allergan Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="4898">Major depressive disorder</Indication><StatusDate>2014-02-12T00:00:00.000Z</StatusDate><Source id="1523956" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14042">Allergan Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1295">Neuropathic pain</Indication><StatusDate>2013-12-02T00:00:00.000Z</StatusDate><Source id="1468290" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14042">Allergan Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="4898">Major depressive disorder</Indication><StatusDate>2014-04-15T00:00:00.000Z</StatusDate><Source id="1550953" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14042">Allergan Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="2521">Hypertrophy</Indication><StatusDate>2014-01-28T00:00:00.000Z</StatusDate><Source id="1509907" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14042">Allergan Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1274">Premature ejaculation</Indication><StatusDate>2013-08-20T00:00:00.000Z</StatusDate><Source id="1467285" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14042">Allergan Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="478">Raynauds disease</Indication><StatusDate>2015-01-12T00:00:00.000Z</StatusDate></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14042">Allergan Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="2967">Thyroid associated ophthalmopathy</Indication><StatusDate>2011-01-06T00:00:00.000Z</StatusDate><Source id="1254956" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14042">Allergan Inc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="2239">Blepharospasm</Indication><StatusDate>1997-12-31T00:00:00.000Z</StatusDate><Source id="372009" type="SERIAL"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14042">Allergan Inc</Company><Country id="EU">EU</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="210">Migraine</Indication><StatusDate>2009-12-31T00:00:00.000Z</StatusDate><Source id="1073300" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14042">Allergan Inc</Company><Country id="NZ">New Zealand</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="210">Migraine</Indication><StatusDate>2010-11-01T00:00:00.000Z</StatusDate><Source id="1146735" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14042">Allergan Inc</Company><Country id="EC">Ecuador</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="2376">Overactive bladder</Indication><StatusDate>2014-07-21T00:00:00.000Z</StatusDate><Source id="1579469" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14042">Allergan Inc</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="2376">Overactive bladder</Indication><StatusDate>2013-10-29T00:00:00.000Z</StatusDate><Source id="1494584" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14042">Allergan Inc</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="2376">Overactive bladder</Indication><StatusDate>2013-10-29T00:00:00.000Z</StatusDate><Source id="1494584" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14042">Allergan Inc</Company><Country id="QA">Qatar</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="2376">Overactive bladder</Indication><StatusDate>2013-10-29T00:00:00.000Z</StatusDate><Source id="1494584" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14042">Allergan Inc</Company><Country id="IL">Israel</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="2376">Overactive bladder</Indication><StatusDate>2013-12-31T00:00:00.000Z</StatusDate><Source id="1530302" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14042">Allergan Inc</Company><Country id="US">US</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="913">Muscle hypertonia</Indication><StatusDate>2010-03-09T00:00:00.000Z</StatusDate><Source id="1080788" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14042">Allergan Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="564">Cervical dystonia</Indication><StatusDate>1999-12-31T00:00:00.000Z</StatusDate><Source id="365728" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15587">Daewoong Pharmaceutical Co Ltd</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="913">Muscle hypertonia</Indication><StatusDate>2008-06-30T00:00:00.000Z</StatusDate><Source id="996519" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15587">Daewoong Pharmaceutical Co Ltd</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="2225">Hyperhidrosis</Indication><StatusDate>2008-06-30T00:00:00.000Z</StatusDate><Source id="996519" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14042">Allergan Inc</Company><Country id="BR">Brazil</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="2376">Overactive bladder</Indication><StatusDate>2009-02-04T00:00:00.000Z</StatusDate><Source id="869019" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14042">Allergan Inc</Company><Country id="MX">Mexico</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="2376">Overactive bladder</Indication><StatusDate>2009-02-04T00:00:00.000Z</StatusDate><Source id="869019" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14042">Allergan Inc</Company><Country id="EU">EU</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="210">Migraine</Indication><StatusDate>2010-07-09T00:00:00.000Z</StatusDate><Source id="1115291" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14042">Allergan Inc</Company><Country id="US">US</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="2481">Strabismus</Indication><StatusDate>1989-12-31T00:00:00.000Z</StatusDate><Source id="989200" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14042">Allergan Inc</Company><Country id="US">US</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="2239">Blepharospasm</Indication><StatusDate>1989-12-31T00:00:00.000Z</StatusDate><Source id="989200" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14042">Allergan Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="913">Muscle hypertonia</Indication><StatusDate>1999-12-31T00:00:00.000Z</StatusDate><Source id="365728" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14042">Allergan Inc</Company><Country id="US">US</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="2376">Overactive bladder</Indication><StatusDate>2011-08-24T00:00:00.000Z</StatusDate><Source id="1217387" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14042">Allergan Inc</Company><Country id="AU">Australia</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="210">Migraine</Indication><StatusDate>2011-03-31T00:00:00.000Z</StatusDate><Source id="1197962" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14042">Allergan Inc</Company><Country id="BR">Brazil</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="210">Migraine</Indication><StatusDate>2011-03-31T00:00:00.000Z</StatusDate><Source id="1197962" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14042">Allergan Inc</Company><Country id="HK">Hong Kong</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="210">Migraine</Indication><StatusDate>2011-03-31T00:00:00.000Z</StatusDate><Source id="1197962" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14042">Allergan Inc</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="210">Migraine</Indication><StatusDate>2011-03-31T00:00:00.000Z</StatusDate><Source id="1197962" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14042">Allergan Inc</Company><Country id="IN">India</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="210">Migraine</Indication><StatusDate>2011-08-11T00:00:00.000Z</StatusDate><Source id="1214548" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14042">Allergan Inc</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="2225">Hyperhidrosis</Indication><StatusDate>2000-01-01T00:00:00.000Z</StatusDate><Source id="365347" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14042">Allergan Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="210">Migraine</Indication><StatusDate>2011-11-14T00:00:00.000Z</StatusDate><Source id="1259743" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14042">Allergan Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="2376">Overactive bladder</Indication><StatusDate>2011-12-21T00:00:00.000Z</StatusDate><Source id="1259743" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14042">Allergan Inc</Company><Country id="CL">Chile</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="210">Migraine</Indication><StatusDate>2011-03-31T00:00:00.000Z</StatusDate><Source id="1197962" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14042">Allergan Inc</Company><Country id="RU">Russian Federation</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="210">Migraine</Indication><StatusDate>2013-02-05T00:00:00.000Z</StatusDate><Source id="1366306" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14042">Allergan Inc</Company><Country id="RU">Russian Federation</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="2376">Overactive bladder</Indication><StatusDate>2013-02-05T00:00:00.000Z</StatusDate><Source id="1366306" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14042">Allergan Inc</Company><Country id="SA">Saudi Arabia</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="2376">Overactive bladder</Indication><StatusDate>2013-02-05T00:00:00.000Z</StatusDate><Source id="1366306" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14042">Allergan Inc</Company><Country id="KW">Kuwait</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="2376">Overactive bladder</Indication><StatusDate>2013-02-05T00:00:00.000Z</StatusDate><Source id="1366306" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14042">Allergan Inc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="913">Muscle hypertonia</Indication><StatusDate>2000-01-01T00:00:00.000Z</StatusDate><Source id="365347" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14042">Allergan Inc</Company><Country id="AR">Argentina</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="2376">Overactive bladder</Indication><StatusDate>2013-02-05T00:00:00.000Z</StatusDate><Source id="1366306" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14042">Allergan Inc</Company><Country id="CR">Costa Rica</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="210">Migraine</Indication><StatusDate>2012-08-01T00:00:00.000Z</StatusDate><Source id="1313331" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14042">Allergan Inc</Company><Country id="BH">Bahrain</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="210">Migraine</Indication><StatusDate>2012-08-01T00:00:00.000Z</StatusDate><Source id="1313331" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14042">Allergan Inc</Company><Country id="KW">Kuwait</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="210">Migraine</Indication><StatusDate>2012-08-01T00:00:00.000Z</StatusDate><Source id="1313331" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14042">Allergan Inc</Company><Country id="JO">Jordan</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="210">Migraine</Indication><StatusDate>2012-08-01T00:00:00.000Z</StatusDate><Source id="1313331" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14042">Allergan Inc</Company><Country id="PA">Panama</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="2376">Overactive bladder</Indication><StatusDate>2012-08-01T00:00:00.000Z</StatusDate><Source id="1313331" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14042">Allergan Inc</Company><Country id="EG">Egypt</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="2376">Overactive bladder</Indication><StatusDate>2012-08-01T00:00:00.000Z</StatusDate><Source id="1313331" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14042">Allergan Inc</Company><Country id="JO">Jordan</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="2376">Overactive bladder</Indication><StatusDate>2012-08-01T00:00:00.000Z</StatusDate><Source id="1313331" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14042">Allergan Inc</Company><Country id="PH">Philippines</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="2376">Overactive bladder</Indication><StatusDate>2012-08-01T00:00:00.000Z</StatusDate><Source id="1313331" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14042">Allergan Inc</Company><Country id="SG">Singapore</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="2376">Overactive bladder</Indication><StatusDate>2013-07-31T00:00:00.000Z</StatusDate><Source id="1461069" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14042">Allergan Inc</Company><Country id="MA">Morocco</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="2376">Overactive bladder</Indication><StatusDate>2013-07-31T00:00:00.000Z</StatusDate><Source id="1461069" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14042">Allergan Inc</Company><Country id="AU">Australia</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="2376">Overactive bladder</Indication><StatusDate>2013-07-31T00:00:00.000Z</StatusDate><Source id="1461069" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14042">Allergan Inc</Company><Country id="NZ">New Zealand</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="2376">Overactive bladder</Indication><StatusDate>2013-07-31T00:00:00.000Z</StatusDate><Source id="1461069" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14042">Allergan Inc</Company><Country id="IN">India</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="2376">Overactive bladder</Indication><StatusDate>2013-07-31T00:00:00.000Z</StatusDate><Source id="1461069" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14042">Allergan Inc</Company><Country id="OM">Oman</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="2376">Overactive bladder</Indication><StatusDate>2013-07-31T00:00:00.000Z</StatusDate><Source id="1461069" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14042">Allergan Inc</Company><Country id="CL">Chile</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="2376">Overactive bladder</Indication><StatusDate>2013-07-31T00:00:00.000Z</StatusDate><Source id="1461069" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14042">Allergan Inc</Company><Country id="US">US</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="564">Cervical dystonia</Indication><StatusDate>1999-12-31T00:00:00.000Z</StatusDate><Source id="365728" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14042">Allergan Inc</Company><Country id="EU">EU</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="913">Muscle hypertonia</Indication><StatusDate>2002-04-10T00:00:00.000Z</StatusDate><Source id="457501" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14042">Allergan Inc</Company><Country id="EU">EU</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="2239">Blepharospasm</Indication><StatusDate>1992-12-31T00:00:00.000Z</StatusDate><Source id="1085385" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14042">Allergan Inc</Company><Country id="EU">EU</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="2239">Blepharospasm</Indication><StatusDate>1992-12-31T00:00:00.000Z</StatusDate><Source id="1085385" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14042">Allergan Inc</Company><Country id="EU">EU</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="564">Cervical dystonia</Indication><StatusDate>1993-07-14T00:00:00.000Z</StatusDate><Source id="1445020" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14042">Allergan Inc</Company><Country id="EU">EU</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="564">Cervical dystonia</Indication><StatusDate>1993-07-14T00:00:00.000Z</StatusDate><Source id="1445020" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14042">Allergan Inc</Company><Country id="EU">EU</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="913">Muscle hypertonia</Indication><StatusDate>2002-04-10T00:00:00.000Z</StatusDate><Source id="457501" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14042">Allergan Inc</Company><Country id="GB">UK</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="2225">Hyperhidrosis</Indication><StatusDate>2001-09-13T00:00:00.000Z</StatusDate><Source id="422204" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14042">Allergan Inc</Company><Country id="GB">UK</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="2225">Hyperhidrosis</Indication><StatusDate>2001-09-13T00:00:00.000Z</StatusDate><Source id="422204" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14042">Allergan Inc</Company><Country id="EU">EU</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="2225">Hyperhidrosis</Indication><StatusDate>2003-06-30T00:00:00.000Z</StatusDate><Source id="498678" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14042">Allergan Inc</Company><Country id="EU">EU</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="2225">Hyperhidrosis</Indication><StatusDate>2003-06-30T00:00:00.000Z</StatusDate><Source id="498678" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14042">Allergan Inc</Company><Country id="EU">EU</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="210">Migraine</Indication><StatusDate>2010-07-09T00:00:00.000Z</StatusDate><Source id="1115291" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14042">Allergan Inc</Company><Country id="EU">EU</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="2376">Overactive bladder</Indication><StatusDate>2011-06-17T00:00:00.000Z</StatusDate><Source id="1212203" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14042">Allergan Inc</Company><Country id="EU">EU</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="2376">Overactive bladder</Indication><StatusDate>2012-02-28T00:00:00.000Z</StatusDate><Source id="1267857" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14042">Allergan Inc</Company><Country id="EU">EU</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="2376">Overactive bladder</Indication><StatusDate>2012-02-28T00:00:00.000Z</StatusDate><Source id="1267857" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14042">Allergan Inc</Company><Country id="AU">Australia</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="2481">Strabismus</Indication><StatusDate>2014-05-31T00:00:00.000Z</StatusDate><Source id="1649035" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14042">Allergan Inc</Company><Country id="FR">France</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="2481">Strabismus</Indication><StatusDate>2014-05-31T00:00:00.000Z</StatusDate><Source id="1649035" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14042">Allergan Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="2481">Strabismus</Indication><StatusDate>2014-05-31T00:00:00.000Z</StatusDate><Source id="1649035" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14042">Allergan Inc</Company><Country id="FR">France</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="2481">Strabismus</Indication><StatusDate>2014-05-31T00:00:00.000Z</StatusDate><Source id="1649035" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14042">Allergan Inc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="2481">Strabismus</Indication><StatusDate>1989-12-31T00:00:00.000Z</StatusDate><Source id="989200" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14042">Allergan Inc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="2239">Blepharospasm</Indication><StatusDate>1989-12-31T00:00:00.000Z</StatusDate><Source id="989200" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14042">Allergan Inc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="2225">Hyperhidrosis</Indication><StatusDate>2004-07-20T00:00:00.000Z</StatusDate><Source id="549794" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14042">Allergan Inc</Company><Country id="US">US</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="564">Cervical dystonia</Indication><StatusDate>2000-12-27T00:00:00.000Z</StatusDate><Source id="394727" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14042">Allergan Inc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="564">Cervical dystonia</Indication><StatusDate>2000-12-27T00:00:00.000Z</StatusDate><Source id="394727" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14042">Allergan Inc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="913">Muscle hypertonia</Indication><StatusDate>2010-03-09T00:00:00.000Z</StatusDate><Source id="1080788" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14042">Allergan Inc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="2376">Overactive bladder</Indication><StatusDate>2011-08-24T00:00:00.000Z</StatusDate><Source id="1217387" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14042">Allergan Inc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="210">Migraine</Indication><StatusDate>2010-10-15T00:00:00.000Z</StatusDate><Source id="1140062" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14042">Allergan Inc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="2239">Blepharospasm</Indication><StatusDate>1997-12-31T00:00:00.000Z</StatusDate><Source id="372009" type="SERIAL"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14042">Allergan Inc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="358">Muscle spasm</Indication><StatusDate>2000-06-26T00:00:00.000Z</StatusDate><Source id="372009" type="SERIAL"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14042">Allergan Inc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="358">Muscle spasm</Indication><StatusDate>2000-06-26T00:00:00.000Z</StatusDate><Source id="372009" type="SERIAL"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14042">Allergan Inc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="564">Cervical dystonia</Indication><StatusDate>2001-12-31T00:00:00.000Z</StatusDate><Source id="457501" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28355">GlaxoSmithKline plc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="913">Muscle hypertonia</Indication><StatusDate>2010-10-31T00:00:00.000Z</StatusDate><Source id="1146735" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28355">GlaxoSmithKline plc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="2225">Hyperhidrosis</Indication><StatusDate>2011-12-19T00:00:00.000Z</StatusDate><Source id="1253898" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28355">GlaxoSmithKline plc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="2225">Hyperhidrosis</Indication><StatusDate>2012-11-21T00:00:00.000Z</StatusDate><Source id="1342871" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28355">GlaxoSmithKline plc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="2481">Strabismus</Indication><StatusDate>2014-07-25T00:00:00.000Z</StatusDate><Source id="1649035" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28355">GlaxoSmithKline plc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="2481">Strabismus</Indication><StatusDate>2015-06-16T00:00:00.000Z</StatusDate><Source id="1677140" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28355">GlaxoSmithKline plc</Company><Country id="CN">China</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="2239">Blepharospasm</Indication><StatusDate>2005-10-03T00:00:00.000Z</StatusDate><Source id="626580" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14042">Allergan Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="564">Cervical dystonia</Indication><StatusDate>1999-12-31T00:00:00.000Z</StatusDate><Source id="365728" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14042">Allergan Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="913">Muscle hypertonia</Indication><StatusDate>1999-12-31T00:00:00.000Z</StatusDate><Source id="365728" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14042">Allergan Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="2225">Hyperhidrosis</Indication><StatusDate>2001-10-30T00:00:00.000Z</StatusDate><Source id="426726" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14042">Allergan Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="2376">Overactive bladder</Indication><StatusDate>2011-12-21T00:00:00.000Z</StatusDate><Source id="1259743" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14042">Allergan Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="210">Migraine</Indication><StatusDate>2011-11-14T00:00:00.000Z</StatusDate><Source id="1259743" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14042">Allergan Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="2481">Strabismus</Indication><StatusDate>2014-05-31T00:00:00.000Z</StatusDate><Source id="1649035" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14042">Allergan Inc</Company><Country id="CL">Chile</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="210">Migraine</Indication><StatusDate>2011-03-31T00:00:00.000Z</StatusDate><Source id="1197962" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14042">Allergan Inc</Company><Country id="RU">Russian Federation</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="210">Migraine</Indication><StatusDate>2013-02-05T00:00:00.000Z</StatusDate><Source id="1366306" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14042">Allergan Inc</Company><Country id="RU">Russian Federation</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="2376">Overactive bladder</Indication><StatusDate>2013-02-05T00:00:00.000Z</StatusDate><Source id="1366306" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14042">Allergan Inc</Company><Country id="SA">Saudi Arabia</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="2376">Overactive bladder</Indication><StatusDate>2013-02-05T00:00:00.000Z</StatusDate><Source id="1366306" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14042">Allergan Inc</Company><Country id="KW">Kuwait</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="2376">Overactive bladder</Indication><StatusDate>2013-02-05T00:00:00.000Z</StatusDate><Source id="1366306" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14042">Allergan Inc</Company><Country id="AR">Argentina</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="2376">Overactive bladder</Indication><StatusDate>2013-02-05T00:00:00.000Z</StatusDate><Source id="1366306" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14042">Allergan Inc</Company><Country id="CR">Costa Rica</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="210">Migraine</Indication><StatusDate>2012-08-01T00:00:00.000Z</StatusDate><Source id="1313331" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14042">Allergan Inc</Company><Country id="BH">Bahrain</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="210">Migraine</Indication><StatusDate>2012-08-01T00:00:00.000Z</StatusDate><Source id="1313331" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14042">Allergan Inc</Company><Country id="KW">Kuwait</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="210">Migraine</Indication><StatusDate>2012-08-01T00:00:00.000Z</StatusDate><Source id="1313331" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14042">Allergan Inc</Company><Country id="JO">Jordan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="210">Migraine</Indication><StatusDate>2012-08-01T00:00:00.000Z</StatusDate><Source id="1313331" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14042">Allergan Inc</Company><Country id="PA">Panama</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="2376">Overactive bladder</Indication><StatusDate>2012-08-01T00:00:00.000Z</StatusDate><Source id="1313331" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14042">Allergan Inc</Company><Country id="EG">Egypt</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="2376">Overactive bladder</Indication><StatusDate>2012-08-01T00:00:00.000Z</StatusDate><Source id="1313331" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14042">Allergan Inc</Company><Country id="JO">Jordan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="2376">Overactive bladder</Indication><StatusDate>2012-08-01T00:00:00.000Z</StatusDate><Source id="1313331" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14042">Allergan Inc</Company><Country id="MA">Morocco</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="2376">Overactive bladder</Indication><StatusDate>2013-07-31T00:00:00.000Z</StatusDate><Source id="1461069" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14042">Allergan Inc</Company><Country id="OM">Oman</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="2376">Overactive bladder</Indication><StatusDate>2013-07-31T00:00:00.000Z</StatusDate><Source id="1461069" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14042">Allergan Inc</Company><Country id="CL">Chile</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="2376">Overactive bladder</Indication><StatusDate>2013-07-31T00:00:00.000Z</StatusDate><Source id="1461069" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14042">Allergan Inc</Company><Country id="EC">Ecuador</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="2376">Overactive bladder</Indication><StatusDate>2014-07-21T00:00:00.000Z</StatusDate><Source id="1579469" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14042">Allergan Inc</Company><Country id="QA">Qatar</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="2376">Overactive bladder</Indication><StatusDate>2013-10-29T00:00:00.000Z</StatusDate><Source id="1494584" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14042">Allergan Inc</Company><Country id="IL">Israel</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="2376">Overactive bladder</Indication><StatusDate>2013-12-31T00:00:00.000Z</StatusDate><Source id="1530302" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14042">Allergan Inc</Company><Country id="BR">Brazil</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="2376">Overactive bladder</Indication><StatusDate>2009-02-04T00:00:00.000Z</StatusDate><Source id="869019" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14042">Allergan Inc</Company><Country id="MX">Mexico</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="2376">Overactive bladder</Indication><StatusDate>2009-02-04T00:00:00.000Z</StatusDate><Source id="869019" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14042">Allergan Inc</Company><Country id="BR">Brazil</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="210">Migraine</Indication><StatusDate>2011-03-31T00:00:00.000Z</StatusDate><Source id="1197962" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14042">Allergan Inc</Company><Country id="AU">Australia</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="2481">Strabismus</Indication><StatusDate>2014-05-31T00:00:00.000Z</StatusDate><Source id="1649035" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14042">Allergan Inc</Company><Country id="AU">Australia</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="913">Muscle hypertonia</Indication><StatusDate>1998-12-31T00:00:00.000Z</StatusDate><Source id="929710" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14042">Allergan Inc</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="564">Cervical dystonia</Indication><StatusDate>2009-01-01T00:00:00.000Z</StatusDate><Source id="982627" type="SERIAL"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14042">Allergan Inc</Company><Country id="AU">Australia</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="2225">Hyperhidrosis</Indication><StatusDate>2001-12-30T00:00:00.000Z</StatusDate><Source id="457501" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14042">Allergan Inc</Company><Country id="HK">Hong Kong</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="210">Migraine</Indication><StatusDate>2011-03-31T00:00:00.000Z</StatusDate><Source id="1197962" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14042">Allergan Inc</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="210">Migraine</Indication><StatusDate>2011-03-31T00:00:00.000Z</StatusDate><Source id="1197962" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14042">Allergan Inc</Company><Country id="IN">India</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="210">Migraine</Indication><StatusDate>2011-08-11T00:00:00.000Z</StatusDate><Source id="1214548" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14042">Allergan Inc</Company><Country id="PH">Philippines</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="2376">Overactive bladder</Indication><StatusDate>2012-08-01T00:00:00.000Z</StatusDate><Source id="1313331" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14042">Allergan Inc</Company><Country id="SG">Singapore</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="2376">Overactive bladder</Indication><StatusDate>2013-07-31T00:00:00.000Z</StatusDate><Source id="1461069" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14042">Allergan Inc</Company><Country id="AU">Australia</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="2376">Overactive bladder</Indication><StatusDate>2013-07-31T00:00:00.000Z</StatusDate><Source id="1461069" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14042">Allergan Inc</Company><Country id="NZ">New Zealand</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="2376">Overactive bladder</Indication><StatusDate>2013-07-31T00:00:00.000Z</StatusDate><Source id="1461069" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14042">Allergan Inc</Company><Country id="IN">India</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="2376">Overactive bladder</Indication><StatusDate>2013-07-31T00:00:00.000Z</StatusDate><Source id="1461069" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14042">Allergan Inc</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="2376">Overactive bladder</Indication><StatusDate>2013-10-29T00:00:00.000Z</StatusDate><Source id="1494584" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14042">Allergan Inc</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="2376">Overactive bladder</Indication><StatusDate>2013-10-29T00:00:00.000Z</StatusDate><Source id="1494584" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14042">Allergan Inc</Company><Country id="AU">Australia</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="210">Migraine</Indication><StatusDate>2011-03-31T00:00:00.000Z</StatusDate><Source id="1197962" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14042">Allergan Inc</Company><Country id="NZ">New Zealand</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="2225">Hyperhidrosis</Indication><StatusDate>2001-12-30T00:00:00.000Z</StatusDate><Source id="457501" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14042">Allergan Inc</Company><Country id="AU">Australia</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="913">Muscle hypertonia</Indication><StatusDate>1998-12-31T00:00:00.000Z</StatusDate><Source id="929710" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14042">Allergan Inc</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="913">Muscle hypertonia</Indication><StatusDate>2009-01-01T00:00:00.000Z</StatusDate><Source id="982627" type="SERIAL"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14042">Allergan Inc</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="2225">Hyperhidrosis</Indication><StatusDate>2009-01-01T00:00:00.000Z</StatusDate><Source id="982627" type="SERIAL"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14042">Allergan Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="2231">Vagina disease</Indication><StatusDate>2010-08-31T00:00:00.000Z</StatusDate><Source id="1201025" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14042">Allergan Inc</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="20">Pain</Indication><StatusDate>1999-12-31T00:00:00.000Z</StatusDate><Source id="365728" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14042">Allergan Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="20">Pain</Indication><StatusDate>1999-12-31T00:00:00.000Z</StatusDate><Source id="365728" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1088700">Allergan plc</Company><Country id="DK">Denmark</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="245">Osteoarthritis</Indication><StatusDate>2012-01-24T00:00:00.000Z</StatusDate><Source id="1552552" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1088700">Allergan plc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="245">Osteoarthritis</Indication><StatusDate>2014-09-30T00:00:00.000Z</StatusDate></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1088700">Allergan plc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1274">Premature ejaculation</Indication><StatusDate>2015-03-17T00:00:00.000Z</StatusDate><Source id="1642310" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28355">GlaxoSmithKline plc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="2696">Dysphonia</Indication><StatusDate>2017-02-15T00:00:00.000Z</StatusDate></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28355">GlaxoSmithKline plc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="2696">Dysphonia</Indication><StatusDate>2017-06-23T00:00:00.000Z</StatusDate></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28355">GlaxoSmithKline plc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="2696">Dysphonia</Indication><StatusDate>2018-05-25T00:00:00.000Z</StatusDate><Source id="2037706" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1088700">Allergan plc</Company><Country id="AU">Australia</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="2696">Dysphonia</Indication><StatusDate>2018-05-25T00:00:00.000Z</StatusDate><Source id="2037706" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1088700">Allergan plc</Company><Country id="AU">Australia</Country><DevelopmentStatus id="CU" sortOrder="9">Clinical</DevelopmentStatus><Indication id="2696">Dysphonia</Indication><StatusDate>2004-06-01T00:00:00.000Z</StatusDate><Source id="1777738" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1088700">Allergan plc</Company><Country id="XH">Far East</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="564">Cervical dystonia</Indication><StatusDate>2008-07-03T00:00:00.000Z</StatusDate><Source id="1727125" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1088700">Allergan plc</Company><Country id="IN">India</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="564">Cervical dystonia</Indication><Source id="1727125" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14042">Allergan Inc</Company><Country id="DK">Denmark</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="245">Osteoarthritis</Indication><StatusDate>2012-01-31T00:00:00.000Z</StatusDate><Source id="1642310" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14042">Allergan Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="245">Osteoarthritis</Indication><StatusDate>2015-03-17T00:00:00.000Z</StatusDate><Source id="1642310" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14042">Allergan Inc</Company><Country id="CZ">Czech Republic</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="245">Osteoarthritis</Indication><StatusDate>2015-03-17T00:00:00.000Z</StatusDate><Source id="1642310" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1088700">Allergan plc</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="478">Raynauds disease</Indication><StatusDate>2015-01-31T00:00:00.000Z</StatusDate><Source id="1642310" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1088700">Allergan plc</Company><Country id="NZ">New Zealand</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="210">Migraine</Indication><StatusDate>2015-03-17T00:00:00.000Z</StatusDate><Source id="1642310" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1088700">Allergan plc</Company><Country id="NZ">New Zealand</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="210">Migraine</Indication><StatusDate>2018-06-06T00:00:00.000Z</StatusDate><Source id="2058447" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14042">Allergan Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1542">Atrial fibrillation</Indication><StatusDate>2018-12-19T00:00:00.000Z</StatusDate><Source id="2106734" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23191">Oculinum</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="589">Dystonia</Indication><Source id="343345" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14042">Allergan Inc</Company><Country id="US">US</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="2225">Hyperhidrosis</Indication><StatusDate>2003-07-23T00:00:00.000Z</StatusDate><Source id="498678" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14042">Allergan Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="148">Headache</Indication><Source id="322285" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14042">Allergan Inc</Company><Country id="ZA">South Africa</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="210">Migraine</Indication><StatusDate>1999-04-22T00:00:00.000Z</StatusDate><Source id="322285" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14042">Allergan Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="2376">Overactive bladder</Indication><StatusDate>2004-02-06T00:00:00.000Z</StatusDate><Source id="562127" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14042">Allergan Inc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="913">Muscle hypertonia</Indication><StatusDate>2002-04-01T00:00:00.000Z</StatusDate><Source id="457501" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14042">Allergan Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="210">Migraine</Indication><StatusDate>1998-01-29T00:00:00.000Z</StatusDate><Source id="275797" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14042">Allergan Inc</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="913">Muscle hypertonia</Indication><StatusDate>2001-02-02T00:00:00.000Z</StatusDate><Source id="365728" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14042">Allergan Inc</Company><Country id="NZ">New Zealand</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="2225">Hyperhidrosis</Indication><StatusDate>2001-12-30T00:00:00.000Z</StatusDate><Source id="457501" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14042">Allergan Inc</Company><Country id="AU">Australia</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="2225">Hyperhidrosis</Indication><StatusDate>2001-12-30T00:00:00.000Z</StatusDate><Source id="457501" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14042">Allergan Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="2225">Hyperhidrosis</Indication><StatusDate>2001-10-30T00:00:00.000Z</StatusDate><Source id="426726" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14042">Allergan Inc</Company><Country id="US">US</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="2225">Hyperhidrosis</Indication><StatusDate>2004-07-20T00:00:00.000Z</StatusDate><Source id="549794" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14042">Allergan Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="913">Muscle hypertonia</Indication><StatusDate>1998-10-14T00:00:00.000Z</StatusDate><Source id="301312" type="SERIAL"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14042">Allergan Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="217">Paralysis</Indication><Source id="175740" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14042">Allergan Inc</Company><Country id="DE">Germany</Country><DevelopmentStatus id="CU" sortOrder="9">Clinical</DevelopmentStatus><Indication id="689">Esophageal function disorder</Indication><StatusDate>2000-06-05T00:00:00.000Z</StatusDate><Source id="369389" type="SERIAL"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14042">Allergan Inc</Company><Country id="US">US</Country><DevelopmentStatus id="CU" sortOrder="9">Clinical</DevelopmentStatus><Indication id="376">Gastric motility disorder</Indication><StatusDate>2000-06-07T00:00:00.000Z</StatusDate><Source id="370087" type="SERIAL"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14042">Allergan Inc</Company><Country id="ZA">South Africa</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="210">Migraine</Indication><StatusDate>2004-10-11T00:00:00.000Z</StatusDate></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14042">Allergan Inc</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="913">Muscle hypertonia</Indication><StatusDate>2005-12-31T00:00:00.000Z</StatusDate><Source id="678813" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14042">Allergan Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="210">Migraine</Indication><StatusDate>2006-10-10T00:00:00.000Z</StatusDate><Source id="757311" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14042">Allergan Inc</Company><Country id="US">US</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="913">Muscle hypertonia</Indication><StatusDate>2008-10-29T00:00:00.000Z</StatusDate><Source id="996519" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14042">Allergan Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="148">Headache</Indication><StatusDate>2004-02-06T00:00:00.000Z</StatusDate><Source id="562127" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14042">Allergan Inc</Company><Country id="US">US</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="210">Migraine</Indication><StatusDate>2009-09-30T00:00:00.000Z</StatusDate><Source id="1052917" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14042">Allergan Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="2376">Overactive bladder</Indication><StatusDate>2006-04-04T00:00:00.000Z</StatusDate><Source id="869019" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14042">Allergan Inc</Company><Country id="AU">Australia</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="210">Migraine</Indication><StatusDate>2010-11-01T00:00:00.000Z</StatusDate><Source id="1146735" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14042">Allergan Inc</Company><Country id="US">US</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="210">Migraine</Indication><StatusDate>2010-10-15T00:00:00.000Z</StatusDate><Source id="1140062" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14042">Allergan Inc</Company><Country id="US">US</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="2376">Overactive bladder</Indication><StatusDate>2010-09-30T00:00:00.000Z</StatusDate><Source id="1143621" type="PR"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><RegulatoryDesignationStatus><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="14042">Allergan Inc</OwnerCompany><Country id="US">US</Country><Indication id="2620">Cerebral palsy</Indication><AwardedIndication>Treatment of dynamic muscle contracture in pediatric cerebral palsy patients.</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>1991-12-06T00:00:00.000Z</MileStoneDate></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="14042">Allergan Inc</OwnerCompany><Country id="US">US</Country><Indication id="564">Cervical dystonia</Indication><AwardedIndication>Treatment of cervical dystonia.</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>1986-08-20T00:00:00.000Z</MileStoneDate><Source id="366468" type="CORPORATE"/></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="14042">Allergan Inc</OwnerCompany><Country id="US">US</Country><Indication id="2481">Strabismus</Indication><AwardedIndication>Treatment of strabismus and blepharospasms</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>1984-03-22T00:00:00.000Z</MileStoneDate></Row><Row><RegulatoryDesignation id="11">Priority Review</RegulatoryDesignation><OwnerCompany id="14042">Allergan Inc</OwnerCompany><Country id="US">US</Country><Indication id="913">Muscle hypertonia</Indication><AwardedIndication>Treatment of pediatric patients 2 years of age and older with upper limb spasticity</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2019-03-07T00:00:00.000Z</MileStoneDate><Source id="2126949" type="PR"/></Row></RegulatoryDesignationStatus><Targets><Target id="PTGT-00042"><Name>Acetylcholine receptor</Name><SwissprotNumbers/></Target><Target id="PTGT-09910"><Name>p130Cas associated protein</Name><SwissprotNumbers><Swissprot>Q9C0H9</Swissprot><Swissprot>Q9QWI6</Swissprot><Swissprot>Q9QXY2</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate><ReasonForUpdate><Reason>Reference Added</Reason><Description>3 references added [&lt;ulink url="utility.reference?i_reference_id=2142996" linkType="reference" linkID="2142996"&gt;2142996&lt;/ulink&gt;, &lt;ulink url="utility.reference?i_reference_id=798617" linkType="reference" linkID="798617"&gt;798617&lt;/ulink&gt;, &lt;ulink url="utility.reference?i_reference_id=2166888" linkType="reference" linkID="2166888"&gt;2166888&lt;/ulink&gt;]							</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="1088700">Allergan plc</Company><CountAsPrincipalActive>2</CountAsPrincipalActive><CountAsPrincipalInactive>1</CountAsPrincipalInactive><CountAsPartnerActive>2</CountAsPartnerActive><CountAsPartnerInactive>1</CountAsPartnerInactive><CountTotal>6</CountTotal></Company><Company><Company id="14042">Allergan Inc</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>1</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="15587">Daewoong Pharmaceutical Co Ltd</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>1</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="17058">Bausch Health Companies Inc</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="20614">University of Manitoba</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="28355">GlaxoSmithKline plc</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="29618">WhanIn Pharmaceutical Co Ltd</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="4">Drug - Development/Commercialization License</Type><CountActive>2</CountActive><CountInactive>0</CountInactive><CountTotal>2</CountTotal></Type><Type><Type sortOrder="5">Drug - Commercialization License</Type><CountActive>1</CountActive><CountInactive>2</CountInactive><CountTotal>3</CountTotal></Type><Type><Type sortOrder="6">Drug - Manufacturing/Supply</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type></CountsByTypes><Deals><Deal id="114558" title="Valeant to distribute Allergan's Botox in Hungary and Poland"/><Deal id="114561" title="GSK to develop Allergan's Botox in Japan, China and Allergan to copromote GSK's triptans in the US "/><Deal id="120485" title="Daewoong to market Allergan's BOTOX in Korea"/><Deal id="135355" title="Allergan to distribute Oculinum's BOTOX"/><Deal id="146449" title="Allergan and University of Manitoba to develop Botox against Allodynic-type neuropathic pain  "/><Deal id="152321" title="WhanIn Pharmaceutical to distribute and promote Allergan's botox injection and juvederm   "/></Deals><PatentFamilies><PatentFamily id="1006744" number="WO-2007143410" title="Methods for treating a urethral stricture with a botulinum toxin"/><PatentFamily id="1013315" number="WO-2010078242" title="Injectable botulinum toxin formulations"/><PatentFamily id="1028134" number="WO-2004078201" title="Treatment of sinusitis related chronic facial pain and headache with botulinum toxin"/><PatentFamily id="1045438" number="WO-2011028371" title="Methods of treating chronic neurogenic inflammation using a modified clostridial toxin"/><PatentFamily id="105471" number="WO-2005084705" title="Botulinum toxin treatments of neurological and neuropsychiatric disorders"/><PatentFamily id="1056285" number="WO-09305800" title="Method and compositions for the treatment of cerebral palsy."/><PatentFamily id="1067779" number="WO-2005065754" title="Botulinum toxin injection guide"/><PatentFamily id="1087423" number="WO-03094808" title="Methods for therapeutic treatment of carpal tunnel syndrome"/><PatentFamily id="1113373" number="WO-2010096134" title="Extended length botulinum toxin formulation for human or mammalian use"/><PatentFamily id="1117915" number="WO-2012103035" title="Nanoparticle compositions"/><PatentFamily id="1121185" number="WO-2010138392" title="Methods of treating chronic neurogenic inflammation using neurotrophin retargeted endopepidases"/><PatentFamily id="1131902" number="WO-09735604" title="Pharmaceutical compositions of botulinum toxin or botulinum neurotoxin and methods of preparation."/><PatentFamily id="1139620" number="WO-00234286" title="Methods for treating endocrine disorders"/><PatentFamily id="1142177" number="WO-2005121354" title="Peptide substrates recognisable by a botulinum toxin A, BoNT/A and the use thereof"/><PatentFamily id="1162788" number="WO-00207759" title="Clostridial toxin derivatives and methods for treating pain"/><PatentFamily id="1166231" number="WO-09611699" title="Pharmaceutical Composition Of Botulinum Neurotoxin And Method Of Preparation"/><PatentFamily id="1219694" number="US-20080063732" title="Method of increasing the efficacy of neurotoxin"/><PatentFamily id="1234216" number="WO-00154711" title="Methods for treating diabetes"/><PatentFamily id="1234925" number="WO-2007078997" title="Methods and apparatus for pulsed electric field neuromodulation via an intra-to-extravascular approach"/><PatentFamily id="1241109" number="US-07906124" title="Inactivation of smooth muscle tissue"/><PatentFamily id="1242186" number="WO-03094955" title="Intracranial treatment of neuropsychiatric disorders by clostridial neurotoxins such as botulinum toxin"/><PatentFamily id="1269355" number="WO-2010138384" title="Methods of treating urogenital-neurological disorders using interleukin retargeted endopeptidases"/><PatentFamily id="1291565" number="WO-2006116302" title="High-potency botulinum toxin formulations"/><PatentFamily id="1307261" number="US-20100086567" title="Botulinum toxin therapy for prevention of anastamotic thrombosis in free tissue transfer"/><PatentFamily id="1309991" number="WO-2004112830" title="Methods and compositions for treating eye disorders"/><PatentFamily id="1335994" number="WO-2010017100" title="Treatment of excess cerumen secretion"/><PatentFamily id="1343488" number="WO-2010138387" title="Methods of treating chronic neurogenic inflammation using interleukin retargeted endopepidases"/><PatentFamily id="1352628" number="WO-09428923" title="Multiple botulinum toxins for treating neuromuscular disorders and conditions."/><PatentFamily id="1363783" number="WO-2005072433" title="Toxin induced sympathectomy"/><PatentFamily id="1367527" number="WO-2008030638" title="Use of dmso and botulinum toxin therapy for urinary incontinence and related disorders"/><PatentFamily id="1367794" number="WO-2008070538" title="Amphiphilic entity nanoparticles"/><PatentFamily id="1384004" number="WO-2006036202" title="Stabilized biodegradable neurotoxin implants"/><PatentFamily id="1384994" number="WO-03082315" title="Remedy for hypermyotonia"/><PatentFamily id="1393190" number="WO-2007024672" title="Use of a botulinum toxin to improve gastric emptying and/or to treat GERD"/><PatentFamily id="1398489" number="WO-2004078199" title="Treatment of chronic chalazion and hordeolum with botulinum toxin"/><PatentFamily id="1417346" number="WO-2010138395" title="Methods of treating chronic neurogenic inflammation using glucagon like hormone retargeted endopepidases"/><PatentFamily id="1435967" number="WO-00162270" title="Method for treating hashimoto's thyroiditis"/><PatentFamily id="1436838" number="WO-2004002502" title="Botulinum toxins for treating priapism"/><PatentFamily id="144919" number="WO-2011011513" title="Inhibition of pathological bone formation"/><PatentFamily id="1456456" number="WO-2005053733" title="Botulinum toxin treatment of spastic bladder"/><PatentFamily id="1456901" number="WO-09639167" title="Improved Compositions And Methods For Chemodenervation Using Neurotoxins"/><PatentFamily id="1461325" number="WO-00228425" title="Methods for treating miscle injuries"/><PatentFamily id="1511506" number="WO-2005030119" title="Botulinum toxin a peptides and methods of predicting and reducing immunoresistance to botulinum toxin therapy"/><PatentFamily id="1511775" number="WO-2005067961" title="Methods for treating vascular disorders"/><PatentFamily id="1516515" number="WO-2009014854" title="Methods of activiting clostridial toxins"/><PatentFamily id="1530567" number="WO-2006127642" title="Methods for treating peritoneal adhesions"/><PatentFamily id="1533665" number="WO-2005079828" title="Treatment of abnormalities of the first metatarsophalangeal joint of the foot"/><PatentFamily id="1540994" number="WO-00160396" title="Method For Treating Thyroid Disorders"/><PatentFamily id="1549378" number="US-07255865" title="Methods of administering botulinum toxin"/><PatentFamily id="1552827" number="WO-2008105901" title="Modified clostridial toxins with enhanced translocation capability and enhanced targeting activity."/><PatentFamily id="1553209" number="WO-2011112713" title="Microneedle nasal delivery device"/><PatentFamily id="155408" number="US-08791072" title="Modulating neuromuscular junction density changes in botulinum-toxin treated tissue"/><PatentFamily id="1583970" number="WO-02053177" title="Agents and methods for treating pain"/><PatentFamily id="1586904" number="WO-2006029287" title="Use of a botulinum toxin for treating a buttock deformity"/><PatentFamily id="158891" number="WO-2010138382" title="Methods of treating chronic neurogenic inflammation using a modified clostridial toxin"/><PatentFamily id="1590631" number="WO-2009008595" title="Pharmaceutical liquid composition of botulinum toxin with improved stability"/><PatentFamily id="1604216" number="WO-00126736" title="Methods for treating pain"/><PatentFamily id="1614187" number="WO-2005091891" title="Compositions and methods for preventing and treating skin and hair conditions"/><PatentFamily id="1634536" number="WO-2011084507" title="Treatment of nasal and sinus disorders"/><PatentFamily id="1649049" number="EP-00593176" title="Pharmaceutical compositions containing botulinum toxin and method of preparation."/><PatentFamily id="1657451" number="WO-00193827" title="Neurotoxin implant"/><PatentFamily id="1657725" number="WO-02074327" title="Compositions and methods for treating gonadotrophin related illnesses"/><PatentFamily id="1663637" number="WO-2008039245" title="Assessment of the effects of topical administration of chemodenervating pharmaceuticals"/><PatentFamily id="1733752" number="WO-2005009450" title="Use of botulinum toxin for producing drug for preventing or treating final phase of lung troubles"/><PatentFamily id="1734854" number="WO-2006022965" title="Needleless microprotrusion elastoplast system"/><PatentFamily id="1734981" number="WO-2006028724" title="Stretch mark treatment with botulinum toxic"/><PatentFamily id="1737237" number="WO-2007089454" title="Methods for enhancing skin treatments"/><PatentFamily id="1765468" number="WO-2010135538" title="Botulinum toxin screening assays"/><PatentFamily id="178141" number="WO-03063898" title="Method of treating pain"/><PatentFamily id="1781568" number="WO-2011141907" title="Low volume accurate injector"/><PatentFamily id="178188" number="WO-03070920" title="Vaccination and vaccine and drug delivery by topical application of vectors and vector extracts recombinant vectors, and noninvasive genetic immunization, expression products therefrom,and uses thereof"/><PatentFamily id="178489" number="WO-2004010934" title="Methods for the use of neurotoxin in the treatment of urologic disorders"/><PatentFamily id="179438" number="US-20050096629" title="Techniques for transurethral delivery of a denervating agent to the prostate gland"/><PatentFamily id="1807164" number="WO-2004098714" title="Methods for treating sinus headache"/><PatentFamily id="1810939" number="WO-2007085728" title="Composition containing several botulic toxins"/><PatentFamily id="1810987" number="WO-2007092929" title="Apparatus and methods for delivering fluid and material to a subject"/><PatentFamily id="1830279" number="WO-2006025976" title="Methods for treating cancer"/><PatentFamily id="1830344" number="WO-2008112018" title="Apparatus and method for treating obesity using neurotoxins in conjuction with bariatric procedures"/><PatentFamily id="1832325" number="WO-09517904" title="Botulinum toxins for treating various disorders and associated pain."/><PatentFamily id="1841669" number="US-20040228872" title="Tyrosine kinase inhibitors as an adjunctive therapy to botulinum toxin treatment"/><PatentFamily id="1914910" number="WO-2006017749" title="Optimizing expression of active Botulinum toxin type A"/><PatentFamily id="1923395" number="US-20080113051" title="Methods for alleviating tattoo pain"/><PatentFamily id="192385" number="WO-09903483" title="Use of neurotoxin therapy for treatment of urologic and related disorders."/><PatentFamily id="1954911" number="WO-2004071525" title="Methods for treating mammary gland disorders"/><PatentFamily id="1976868" number="WO-2006138059" title="Treatment of autoimmune disorders with a neurotoxin"/><PatentFamily id="1976979" number="WO-2005084361" title="Multi-component biological transport systems"/><PatentFamily id="198148" number="WO-09528171" title="Treatment of automatic nerve dysfunction with botulinum toxin"/><PatentFamily id="2002885" number="WO-2011123456" title="Botulinum toxin dosage regimen for chronic migraine prophylaxis"/><PatentFamily id="2009486" number="WO-2010138389" title="Methods of treating urogenital-neurological disorders using neurotrophin retargeted endopepidases"/><PatentFamily id="2009487" number="WO-2010138393" title="Methods of treating urogenital-neurological disorders using glucagon like hormone retargeted endopepidases"/><PatentFamily id="2020325" number="EP-00845267" title="Neurotoxins for treating cutaneous disorders in mammals"/><PatentFamily id="2029840" number="US-07270287" title="Botulinum toxin treatment for kinesia"/><PatentFamily id="2033401" number="WO-2007143294" title="Use of botulinum toxin for alleviating testicular pain"/><PatentFamily id="2048912" number="WO-2006011966" title="Optimizing expression of active Botulinum toxin type E"/><PatentFamily id="2062082" number="WO-00110458" title="Use of neurotoxin for treating cardiac muscle disorders"/><PatentFamily id="2083395" number="WO-2010138379" title="Methods of treating chronic neurogenic inflammation using galanin retargeted endopeptidases"/><PatentFamily id="209501" number="WO-2010114828" title="Methods and compositions for treating skin conditions associated with vascular hyper-reactivity"/><PatentFamily id="2123422" number="WO-2009142352" title="Method of producing &lt;i&gt;Clostridium botulinum&lt;/i&gt; toxin using media containing plant-derived components and flexible closed container"/><PatentFamily id="2124952" number="WO-2007024631" title="Botulinum toxin in treatment of clubfoot"/><PatentFamily id="2137468" number="WO-2004060384" title="Improved pharmaceutical botulinum toxin compositions"/><PatentFamily id="216115" number="WO-2007024630" title="Botulinum toxin in treatment of clubfoot relapse"/><PatentFamily id="2170148" number="US-06063768" title="Application of botulinum toxin to the management of neurogenic inflammatory disorders."/><PatentFamily id="2177352" number="WO-2005000343" title="Use of a clostridial toxin to reduce appetite"/><PatentFamily id="2178154" number="WO-2005110525" title="Multi-site injection system"/><PatentFamily id="2178823" number="US-07897147" title="Treatment of premenstrual disorders"/><PatentFamily id="2181375" number="US-20080021437" title="Enhancement of the efficacy of a clenching reduction device by augmenting with botulinum toxin type A"/><PatentFamily id="2199999" number="WO-2009035680" title="Skin treatment system and method"/><PatentFamily id="2211722" number="WO-2005048949" title="Rescue agents for treating botulinum toxin intoxications"/><PatentFamily id="2213237" number="WO-2010059436" title="Early treatment and prevention of increased muscle tonicity"/><PatentFamily id="2216934" number="WO-2010090677" title="Clostridial toxin pharmaceutical compositions"/><PatentFamily id="2249540" number="WO-00178760" title="Method for treating pain by peripheral administration of a neurotoxin"/><PatentFamily id="2256343" number="WO-2008101098" title="Botulinum toxin compositions and methods"/><PatentFamily id="2274573" number="WO-2006025902" title="Botox(r) needle injector"/><PatentFamily id="230706" number="WO-2012103038" title="Nanoparticle compositions, formulations thereof, and uses therefor"/><PatentFamily id="2327313" number="WO-2006099590" title="Modified clostridial toxins with altered targeting capabilities for clostridial toxin target cells"/><PatentFamily id="23382" number="WO-09530431" title="Method for reduction of headache pain"/><PatentFamily id="2344669" number="WO-2004096183" title="Compositions, targets, methods and devices for the therapy of ocular and periocular disorders"/><PatentFamily id="2379583" number="WO-2010138366" title="Methods of treating urogenital-neurological disorders using galanin retargeted endopepidases"/><PatentFamily id="2395497" number="US-08697090" title="Method of treating persistent genital arousal disorder with a neurotoxin"/><PatentFamily id="2428747" number="WO-2012174123" title="Treatment of psychological trauma"/><PatentFamily id="2440424" number="WO-2013002531" title="Pharmaceutical composition for treating scars on the skin, and method for treating scars on the skin using same"/><PatentFamily id="2455293" number="WO-2013009625" title="Method for treatment of autonomic nervous system disorders"/><PatentFamily id="2455481" number="WO-2013010100" title="Methods for treatment of incontinence associated with sexual activity"/><PatentFamily id="2458243" number="WO-2013012457" title="Method of treating and confirming diagnosis of exertional compartment syndrome"/><PatentFamily id="2458262" number="WO-2013013042" title="Botulinum toxins for use in a method for treatment of adipose deposits"/><PatentFamily id="2482960" number="WO-00141790" title="Botulinum toxin for reducing catecholamine secretion"/><PatentFamily id="2496013" number="WO-2007086965" title="Methods and apparatus for intravascularly-induced neuromodulation"/><PatentFamily id="2496015" number="US-20110208173" title="Methods for treating sleep apnea via renal denervation"/><PatentFamily id="2496018" number="WO-2006041881" title="Methods and apparatus for renal neuromodulation"/><PatentFamily id="2496875" number="WO-2007103879" title="Methods and apparatus for bilateral renal neuromodulation"/><PatentFamily id="2517978" number="JP-2014158930" title="Kidney nerve blocking method and apparatus"/><PatentFamily id="254076" number="US-08530410" title="Method for treating a keloid with a botulinum toxin"/><PatentFamily id="2543342" number="WO-2011115602" title="A built-in non-verbal instructional device integratable to applicators"/><PatentFamily id="2563061" number="WO-2013106860" title="Cryogenic probe filtration system"/><PatentFamily id="2563526" number="WO-2013106857" title="Skin protection for subdermal cryogenic remodeling for cosmetic and other treatments"/><PatentFamily id="2573971" number="WO-2005084410" title="Compositions and methods for topical application and transdermal delivery of botulinum toxins"/><PatentFamily id="257564" number="US-09061025" title="Methods for selecting headache patients responsive to botulinum toxin therapy"/><PatentFamily id="2587304" number="US-08568741" title="Botulinum toxin for smoking cessation"/><PatentFamily id="2587954" number="WO-2013130529" title="Perineum overlay device"/><PatentFamily id="2593419" number="US-20130245227" title="Methods of activating clostridial toxins"/><PatentFamily id="2687974" number="WO-2014031809" title="A neurotoxin for treating premature ejaculation"/><PatentFamily id="272589" number="US-07507419" title="Topically applied clostridium botulinum toxin compositions and treatment methods"/><PatentFamily id="2739869" number="WO-2014078724" title="Treatment of post-traumatic stress disorder using botulinum toxin A"/><PatentFamily id="2757140" number="WO-2014100019" title="Prophylactic treatment of herpes recurrence"/><PatentFamily id="2796533" number="WO-2014138663" title="Methods of detecting neurotoxin using synaptic activity"/><PatentFamily id="2823793" number="US-09492513" title="Methods for treatment of hip and groin pain associated with femoroacetabular impingement (fai)"/><PatentFamily id="2834302" number="WO-2014190224" title="Syringe extrusion accessory"/><PatentFamily id="2834558" number="WO-2014190222" title="Mechanical syringe accessory"/><PatentFamily id="2857785" number="WO-2015003128" title="Reducing adverse side effects of a compound by a neurotoxin"/><PatentFamily id="2858504" number="EP-02821089" title="Syringe with alternatively selectable graduations"/><PatentFamily id="2911753" number="WO-2015047243" title="Methods for modifying progression of osteoarthritis"/><PatentFamily id="2911754" number="WO-2006138127" title="Botulinum toxin and the treatment of primary disorders of mood and affect"/><PatentFamily id="2914310" number="US-09566387" title="Syringe with alternatively selectable graduations"/><PatentFamily id="2916551" number="KR-01506204" title="The drug composition in which the botox function including the lipid analysis function is reinforced."/><PatentFamily id="2923301" number="WO-2015057696" title="Systems and methods for treating cancer and/or augmenting organ function"/><PatentFamily id="2936006" number="WO-2015073441" title="Treatment of social anxiety disorder, obsessive compulsive disorder and panic disorder using botulinum toxin"/><PatentFamily id="3009771" number="WO-2015129940" title="Device and method for injecting drug"/><PatentFamily id="3079220" number="WO-2015183923" title="Methods for reducing the occurrence or preventing formation of bladder calculi"/><PatentFamily id="3104021" number="US-20150374805" title="Use of botulinum toxin therapy for treatment of urological neurological conditions"/><PatentFamily id="3116444" number="US-09901627" title="Topical ocular preparation of botulinum toxin for use in ocular surface disease"/><PatentFamily id="3135445" number="WO-2016028744" title="Cholinergic antagonism as an adjunct to cancer therapy"/><PatentFamily id="3146370" number="WO-2016040932" title="Longevity enhancement induced by repetitive injections of botulinum toxin (centurion effect)"/><PatentFamily id="3153551" number="US-09302008" title="Pharmaceutical compositions containing botulinum toxin"/><PatentFamily id="31706" number="WO-2006020208" title="Therapeutic composition whit a botulinum neurotoxin"/><PatentFamily id="3196157" number="US-20160144125" title="Syringe extrusion accessory"/><PatentFamily id="3202150" number="WO-2016090143" title="Systems and methods for treating cancer and/or augmenting organ function"/><PatentFamily id="3204489" number="WO-2016092365" title="Carrier molecule compositions and related methods"/><PatentFamily id="3236817" number="WO-2016112361" title="Systems and methods for inhibiting heterotopic ossification"/><PatentFamily id="325727" number="WO-00162269" title="Method for treating parathyroid disorders"/><PatentFamily id="328043" number="WO-2005056050" title="Botulinum toxin therapy for skin disorders"/><PatentFamily id="330930" number="WO-2007041664" title="Non-protein stabilized clostridial toxin pharmaceutical compositions"/><PatentFamily id="330937" number="WO-2007041435" title="Methods for treating pain and hyperhidrosis"/><PatentFamily id="3341160" number="US-20170361130" title="Stabilized and solubilized drug formulation for topical application and transdermal efficacy for cosmetic improvement and methods of formulation"/><PatentFamily id="3372308" number="WO-2016149092" title="Improved injection paradigm for administration of botulinum toxins"/><PatentFamily id="3427492" number="WO-2016170501" title="A new therapeutic use of the botulinum neurotoxin serotype A"/><PatentFamily id="3444478" number="WO-2016180924" title="Attachment for or on a device for injecting a fluid into or under the skin"/><PatentFamily id="34478" number="US-07563875" title="Recombinant chimeric human anti-botulinum antibodies"/><PatentFamily id="3449231" number="WO-2016187078" title="Syringes and methods of using them to treat overactive bladder"/><PatentFamily id="3611945" number="WO-2016040039" title="Methods for treating osteoarthritis pain"/><PatentFamily id="361791" number="WO-2005082339" title="Medicaments and methods for treating headache"/><PatentFamily id="3654342" number="WO-2017209551" title="Injection system capable of botox&lt;sup&gt;®&lt;/sup&gt; precision injection and simulation"/><PatentFamily id="3668981" number="WO-2017087677" title="Botulinum toxin administration for treatment of neurogenic detrusor overactivity associated urinary incontinence"/><PatentFamily id="372258" number="WO-2010101968" title="Clostridial toxin to improve ejaculate"/><PatentFamily id="3738185" number="WO-2017127840" title="Delivery of botulinum with microneedle arrays"/><PatentFamily id="374244" number="WO-2012029082" title="Device for adjusting the penetration depth of a syringe needle"/><PatentFamily id="3774204" number="WO-2017147170" title="Improved bladder injection paradigm for administration of botulinum toxins"/><PatentFamily id="3821746" number="WO-2017184599" title="Handheld medical substance dispensing system, apparatus and methods"/><PatentFamily id="3828219" number="WO-2017164743" title="Syringe"/><PatentFamily id="3848591" number="US-20170327811" title="Process and system for obtaining botulinum neurotoxin"/><PatentFamily id="3855223" number="US-20150258183" title="Botulinum toxin and the treatment of primary disorders of mood and affect"/><PatentFamily id="3907109" number="WO-2018005494" title="Kits and methods of using ascorbates to modify polysaccharide fillers and delivery systems"/><PatentFamily id="3980001" number="WO-2018053004" title="Non-protein clostridial toxin compositions"/><PatentFamily id="400531" number="WO-03084567" title="Use of botulinum toxin for treating cardiovasular diseases"/><PatentFamily id="4012328" number="WO-2015168471" title="Formulations of biologics for intravesical instillation"/><PatentFamily id="413394" number="WO-2009055610" title="Syringe system for controlled delivery or removal of material"/><PatentFamily id="4135451" number="WO-2018135722" title="Stable liquid composition comprising botulinum toxin"/><PatentFamily id="4156922" number="WO-2018146550" title="Methods and systems for preventing, correcting, transforming, and modifying facial, aesthetics, and consulting patients regarding the same"/><PatentFamily id="4167211" number="WO-2018151832" title="Microneedle array with active ingredient"/><PatentFamily id="4206231" number="WO-2006022790" title="Methods and devices for renal nerve blocking"/><PatentFamily id="422590" number="WO-2007065421" title="Treatment of trichodynia and superficial temporal artery swelling"/><PatentFamily id="428049" number="WO-03077954" title="Method for determining effect of a clostridial toxin upon a muscle"/><PatentFamily id="4286488" number="WO-2018216974" title="Pharmaceutical composition for treating foot pain disease including botulinum toxin and hyaluronic acid, and foot pain disease treatment method using same"/><PatentFamily id="428875" number="WO-2005082096" title="Botulinum toxin screening assays"/><PatentFamily id="4292576" number="WO-2018220232" title="Pharmaceutical combination product comprising botulinum toxin for the treatment of erectile dysfunction"/><PatentFamily id="429551" number="WO-00209742" title="Method for treating a pancreatic disorder with a neurotoxin"/><PatentFamily id="4420062" number="WO-2019046311" title="Transmucosal botulinum toxin compositions, kits, and methods for treating bladder disorders"/><PatentFamily id="4420489" number="WO-2019051315" title="Incremental syringe"/><PatentFamily id="4434846" number="US-20190083588" title="Method for treating axons with botulinum toxin"/><PatentFamily id="4456143" number="US-20190099198" title="Anti-microbial medical injection assemblies for onabotulinumtoxina delivery and methods of use thereof"/><PatentFamily id="4542735" number="WO-2019113044" title="Topical compositions and methods of use thereof"/><PatentFamily id="479082" number="WO-2007087154" title="Methods for enhancing therapeutic effects of a neurotoxin"/><PatentFamily id="509373" number="WO-2006083455" title="Targeted delivery of botulinum toxin for the treatment and prevention of trigeminal autonomiccephalgias, migraine and vascular conditions"/><PatentFamily id="513731" number="EP-01807698" title="Assay for determining clostridial toxin activity combining fret and fluorescence polarization"/><PatentFamily id="547051" number="WO-00209743" title="Method for treating a neoplasm"/><PatentFamily id="54751" number="WO-00158472" title="Botulinum toxin pharmaceutical compositions"/><PatentFamily id="547527" number="WO-00195924" title="Method for treating a movement disorder"/><PatentFamily id="550138" number="WO-2006033843" title="Lanthanide-based substrates and methods for determining clostridial toxin activity"/><PatentFamily id="567224" number="WO-00126674" title="Method for treating otic disorders"/><PatentFamily id="574787" number="WO-00182961" title="Methods for treating bone tumors"/><PatentFamily id="583583" number="WO-2005077416" title="Lipid rafts and clostridial toxins"/><PatentFamily id="59817" number="WO-2009105369" title="Sustained release poloxamer containing pharmaceutical compositions"/><PatentFamily id="622532" number="US-07459164" title="Composition for therapeutic and cosmetic botulinum toxin"/><PatentFamily id="623615" number="WO-2005067967" title="Methods of using botulinum toxin for the treatment of hypervolemic lip deformity (lip ectropion)"/><PatentFamily id="652913" number="WO-2006129171" title="Method and medical package for repairing tendons by surgery"/><PatentFamily id="65894" number="WO-2004078202" title="Clostridial neurotoxins for treating uterine disorders"/><PatentFamily id="672725" number="WO-2012094163" title="Methods and kits for topical application, removal, and inactivation of therapeutic or cosmetic toxin compositions"/><PatentFamily id="672837" number="WO-2011038015" title="Method of treating osteoporosis with a neurotoxin"/><PatentFamily id="696429" number="WO-2004043430" title="Botulinum toxin formulations for oral administration"/><PatentFamily id="770168" number="WO-2004016763" title="Treatment of holocrine gland dysfunction with clostridia neurotoxins"/><PatentFamily id="773982" number="WO-2007038282" title="Stabilization of &lt;i&gt;Clostridium botulinum&lt;/i&gt; neurotoxin complex"/><PatentFamily id="774982" number="WO-2008036060" title="Clostridial toxin activity assays"/><PatentFamily id="79043" number="WO-2011146704" title="Degradable clostridial toxins"/><PatentFamily id="798118" number="WO-2004006954" title="Transdermal botulinum toxin compositions"/><PatentFamily id="822036" number="WO-2012103415" title="Dosage regimen for the treatment of multiple disorders with botulinum toxins"/><PatentFamily id="833956" number="WO-09428922" title="Treatment of neuromuscular disorders and conditions with different botulinum serotype."/><PatentFamily id="875218" number="WO-2004031773" title="Fret protease assays for clostridial toxins"/><PatentFamily id="887958" number="WO-09505842" title="Method and device for treating gastrointestinal muscle disorders and other smooth muscle dysfunction."/><PatentFamily id="888797" number="WO-2012064910" title="Piperidinone carboxamide azaindane CGRP receptor antagonists"/><PatentFamily id="920203" number="WO-2006034404" title="Treating neoplasms with neurotoxin"/><PatentFamily id="938779" number="WO-2007087418" title="Composition and method for neuromuscular blockade"/><PatentFamily id="939424" number="US-06623742" title="Methods for treating fibromyalgia"/><PatentFamily id="943001" number="WO-2007098057" title="Method and system for delivery of neurotoxins"/><PatentFamily id="947205" number="WO-2009021926" title="Use of a neurotoxin"/><PatentFamily id="968995" number="US-20060057165" title="Clostridium botulinum toxin formulation and method for reducing weight"/><PatentFamily id="970383" number="US-08740872" title="Magnetically-targeted treatment for cardiac disorders"/><PatentFamily id="996561" number="WO-2007106727" title="Methods for facilitating weight loss"/></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="1">Analyte</Type><Count>7</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="10">Process</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="12">Product</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="3">Component of Combination</Type><Count>7</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="4">Delivery device</Type><Count>11</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="5">Formulation</Type><Count>18</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="8">General interest</Type><Count>6</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="9">New use</Type><Count>80</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Universite De Versailles-St Quentin En Yvelines" id="1020773"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Kbby Llc" id="1022358"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="US WorldMeds LLC" id="1040227"/><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Swedish Medical Center (Colorado)" id="1041987"/><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Carilion Clinic" id="1043360"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="NeuroSigma Inc" id="1050043"/><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Swedish Medical Center (Seattle)" id="1065436"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Virginia Tech Carilion School of Medicine and Research Institute" id="1069079"/><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Allergan plc" id="1088700"/><CountAsOwner>108</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>108</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Perrigo Co plc" id="1091305"/><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Accunit Llc" id="1116619"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Advanced Aesthetic Technologies Inc" id="1130551"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Uro-1 Inc" id="1182380"/><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Allergan Inc" id="14042"/><CountAsOwner>31</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>31</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Daewoong Pharmaceutical Co Ltd" id="15587"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Ipsen" id="17259"/><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Merz &amp; Co GmbH" id="18187"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Baylor College of Medicine" id="20534"/><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Columbia University" id="20559"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Mayo Clinic Foundation" id="21111"/><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Individual" id="21144"/><CountAsOwner>9</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>9</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Dublin City University" id="23762"/><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Assistance Publique Hopitaux de Paris" id="23948"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="University of Wurzburg" id="24121"/><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="GlaxoSmithKline plc" id="28355"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Norwegian University of Science and Technology (NTNU)" id="28980"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>Y</hasSWOTs></Drug></drugRecordsOutput>